










Determining the contribution of Mx1 in the 







Thesis submitted in partial fulfillment of the requirements for the degree of 





Promoter: Prof. Dr. Xavier Saelens 
Co-promoter: Dr. Kenny Roose 
Academic year: 2017-2018 
Faculty of Sciences, Ghent University 
Department of Biomedical Molecular Biology 


































Jan Spitaels was supported by a personal PhD fellowship at IWT-Vlaanderen (project 
number 131507). 
 
No part of this thesis may be reproduced or used in any way without prior written 
permission of the author. 
 
© Jan Spitaels 2017 
 
 




Molecular Virology Unit 
VIB-Center for Medical Biotechnology 
UGent Faculty of Sciences – Department of Biomedical Molecular Biology 
Technologiepark 927 
9052 Zwijnaarde (Ghent) 
Belgium 
 




Chairman:   Prof. Dr. Rudi Beyaert1,2 
Secretary:   Dr. Emma Job1,3 
Promoters:   Prof. Dr. Xavier Saelens1,3 
    Dr. Kenny Roose1,3 
Reading committee  Prof. Dr. Georg Kochs4 
    Prof. Dr. Herman Favoreel5 
    Prof. Dr. Andy Wullaert2,6 






1UGent Faculty of Sciences, Department of Biomedical Molecular Biology, Ghent, Belgium 
2VIB-UGent Center for Inflammation Research, VIB, Ghent, Belgium 
3VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium 
4Institute of Virology – Universitätsklinikum Freiburg, Freiburg, Germany 
5UGent Faculty of Veterinary Medicine, Department of Virology, Parasitology & 
Immunology, Merelbeke, Belgium 
6UGent Faculty of Medicine and Health Sciences, Department of Internal Medicine, Ghent, 
Belgium 








Influenza or the flu, which is caused by infection with an influenza virus, is characterized by 
symptoms such as fever, cough, headache, muscle and joint pain, severe malaise, a sore 
throat and a runny nose. Most people recover within one week after onset of symptoms. 
However, influenza viruses cause three to five million severe cases of illness and 
approximately 250 000 to 500 000 fatalities worldwide every year, particularly in children, 
elderly and people with underlying malignancies or other infections1. Influenza virus is 
easily transmitted by both direct contact and through the air. The latter is particularly of 
importance in crowded areas, as sneezing or coughing produces small virus-containing 
droplets which spread easily to nearby persons who breathe in these droplets. In the 
respiratory tract, influenza viruses infect airway epithelial cells. After entry in these cells, 
the viral genetic material, in the form of viral ribonucleoproteins (vRNPs), is released into 
the cytoplasm and subsequently enters the nucleus. In the nucleus, transcription and 
replication occurs. The former leads to production of viral mRNA, which is transported to 
the cytosol for translation into viral proteins. Some of these newly produced proteins 
shuttle back to the nucleus where they initiate the replication of the viral genome. The 
newly produced viral RNA molecules form new vRNPs which leave the nucleus and 
associate with structural viral proteins to form new virus particles. After budding, released 
viruses can infect neighboring cells and the cycle starts over again2. 
 
More than 50 years ago Lindenmann et al. discovered a gene which conferred resistance 
against influenza A virus (FLUAV) infection in mice, and which is now known as Mx13-5. The 
term Mx signifies myxovirus-resistance, because mice that can express a functional form of 
this protein are resistant to infection with influenza A virus and other myxoviruses4,5. Quite 
some years later, a human ortholog of murine Mx1 was isolated and named MxA6. Hitherto, 
several Mx orthologs have been described in practically all vertebrates, and they confer 
resistance against a whole array of viruses such as Orthomyxoviridae, Rhabdoviridae, and 
Bunyaviridae (reviewed by Verhelst et al.7). The exact mechanism by which murine Mx1 
exerts viral inhibition is largely unknown. Our lab has contributed to the elucidation of the 
influenza-specific antiviral mechanism by showing that Mx1 interacts with the 
nucleoprotein (NP) and polymerase basic 2 (PB2) protein of influenza A viruses and, that in 
the presence of mouse Mx1 the interaction between the NP and PB2 molecules is 
abolished8. We also found evidence that Mx1 might actively disrupt existing influenza A 
vRNPs9. Being a type I interferon-inducible protein, Mx1 is thought to primarily exert an 
innate antiviral effect by reducing FLUAV early after infection, and preventing viral spread 
through the airways. It is not known whether Mx1 could also fulfill a role in the antiviral 




antiviral state in antigen presenting cells and in memory T cells has been reported to 
directly affect the immune response against a primary and secondary influenza virus 
infection, respectively10,11. In addition, human DCs rapidly upregulate MxA and thus, at least 
in vitro, become resistant to the virus and can sustain antigen presentation12. Most in vivo 
studies which examine the FLUAV-induced immune response are performed using mouse 
strains which do not possess a functional Mx1 locus13. Based on such models, it has been 
reported that certain immune cell types, i.e. CD103+ dendritic cells and lung resident 
memory CD8+ T cells, are protected against FLUAV infection due to an interferon-induced 
antiviral state10,11. This was the reason for us to hypothesize that Mx1 could also play a role 
in the formation of this antiviral state. 
 
To address this question, we set up an infection model wherein we made use of bone 
marrow chimeric mice. Since most immune cell types have a hematopoietic origin, bone 
marrow transfer from mice with a functional Mx1 locus (B6.A2G Mx1+/+) to mice without a 
functional Mx1 locus (B6.A2G Mx1-/-), and vice versa, allowed us to study the possible 
function of Mx1 in bone marrow-derived cell types. The bone marrow chimeric mice were 
infected with a high dose of FLUAV. Multiple parameters were examined (body weight, lung 
viral titers, viral mRNA and protein levels), and it was apparent that Mx1 expression in 
bone marrow-derived cell types was not the main factor determining resistance against 
FLUAV infection. The driving force in resistance against FLUAV infection was whether or 
not Mx1 is expressed in stromal cells. This difference between Mx1-/- and Mx1+/+ recipient 
mice was also noticeable in the evolution of the levels of eosinophils, monocyte-derived 
dendritic cells, and alveolar macrophages in the lung. 
 
Results obtained with the FLUAV infection model were not conclusive to address the 
hypothesis that Mx1 could play a role in bone marrow-derived cell types after viral 
infection. Therefore, we tried a second Orthomyxovirus infection model. Thogoto virus 
(THOV) is a tick-borne virus which, like FLUAV, belongs to the family of Orthomyxoviruses. 
Importantly, small rodents are natural hosts for this virus, and THOV is also sensitive to 
inhibition by Mx114,15. Bone marrow chimeric mice were infected with a high dose of THOV. 
Again, multiple parameters were examined (body weight, liver viral titers, viral protein 
levels, liver pathology). Like in the FLUAV infection model, the main determinant for 
resistance against infection is Mx1 expression in the stromal cells. However, irradiated Mx1-
/- recipient mice that had received Mx1+/+ bone marrow cells, displayed reduced morbidity 
from the THOV infection compared with Mx1-/- recipients which received Mx1-/- bone 
marrow cells as evidenced by the reduced weight loss and liver pathology which was 




role in immune cell types after viral infection, although the importance of this role is largely 
dependent on the infecting virus. 
 
We also addressed the possible contribution of Mx1 in context of a vectored influenza A NP 
vaccine antigen. Recently, Altenburg et al. examined whether recombinant modified 
vaccinia Ankara (rMVA) vaccines which expressed mutated forms of NP would elicit a 
stronger antigen-specific immune response than rMVA vaccines expressing the wild type 
(WT) form of NP (rMVA NPwt). The introduced mutations were intended to enhance 
cytosolic retention or degradation of the NP molecules. For this, they either mutated the 
nuclear localization signal (NLS) (rMVA-NPmut), deleted the NLS (rMVA-NPΔNLS) or fused 
ubiquitin to NP (rMVA-UbqNP). In vitro, these mutated NP constructs outperformed rMVA-
NPwt in activating NP-specific T cells. However, immunization of C57BL/6 mice with the 
mutant rMVA-NP constructs did not result in significantly higher NP-specific CD8+ T cell 
responses or protection against influenza A virus challenge than the rMVA-NPwt 
construct16. We reasoned that this might be because the required threshold of processed NP 
antigen for a robust CD8+ T cell response may be readily reached by the WT NP and thus 
difficult to improve further by NP variant constructs. Therefore, we speculated that mice 
which do express a functional Mx1 protein, as opposed to C57BL/6 mice, would be a better 
suited model to test these different rMVA-NP constructs. Mx1, which has been shown to 
interact with NP8, could be the additional restriction factor needed to demonstrate the 
advantage of these mutated NP constructs. 
 
We vaccinated B6.A2G Mx1-/- and B6.A2G Mx1+/+ mice with the different rMVA-NP 
constructs. One week after the second immunization the NP-specific CD8+ T cell response 
was examined by intracellular cytokine staining (ICS) and enzyme-linked immunospot 
(ELISPOT) assay using blood and spleen. Both ICS and ELISPOT data showed no significant 
differences between the mutated and the WT NP constructs in B6.A2G Mx1+/+ mice. 
However, ELISPOT data showed a trend that rMVA-NPmut and rMVA-NPΔNLS constructs 
elicit a stronger CD8+ T cell response than the rMVA-NPwt construct. To further 
substantiate the theory that Mx1 might act as a determinant for the induction of NP-specific 
cellular responses, additional experiments will have to be performed. 
 
The results obtained with the THOV infection model show clearly that Mx1 plays a role of 
significance in immune cells upon viral infection. Consequently, we could draw two major 
conclusions from this thesis. First, when studying an infection model it is imperative to use 
a well suited combination of host and virus. Since THOV is a natural pathogen of small 
rodents, it is ideal to use in a mouse model. Second, additional to the choice of a suitable 




importance. When investigating the antiviral role of a protein in a certain cell type, it is 
essential that the chosen virus infects this cell type. THOV infects myeloid CD11b+ cells17, 





Influenza of de griep is een ziekte die wordt veroorzaakt door een infectie met het influenza 
virus en ze wordt gekenmerkt door symptomen als koorts, hoesten, hoofdpijn, pijnlijke 
spieren en gewrichten, algehele malaise, keelpijn en een loopneus. Meestal is men binnen 
een week na de eerste symptomen hersteld. Toch veroorzaken influenza virussen jaarlijks 
drie tot vijf miljoen ernstige gevallen van ziekte en leiden ze tot ongeveer 250 000 tot 
500 000 sterfgevallen wereldwijd. Vooral kinderen, ouderen, en personen met 
onderliggende aandoeningen of andere infecties zijn zeer gevoelig voor infecties met het 
influenza virus1. Het influenza virus wordt makkelijk overgedragen van mens tot mens, 
zowel via rechtstreeks contact als via de lucht. Dit laatste is vooral belangrijk in drukke 
omgevingen, want door niezen en hoesten worden er kleine druppeltjes gevormd die het 
virus bevatten. Deze druppeltjes worden makkelijk verspreid naar personen in de nabije 
omgeving, die deze dan op hun beurt inademen. Hierna kunnen de influenza virussen 
epitheelcellen infecteren in de luchtwegen. Wanneer het virus de cellen is 
binnengedrongen, zal het zijn genetisch materiaal vrijstellen in het cytoplasma onder de 
vorm van virale ribonucleoproteïnen (vRNP’s) die vervolgens de celkern binnengaan. In de 
celkern vindt de transcriptie en de replicatie plaats. Transcriptie leidt tot de productie van 
mRNA en dit mRNA wordt vervolgens naar het cytosol gebracht waar het vertaald wordt tot 
virale eiwitten. Sommige van deze virale eiwitten gaan naar de celkern waar ze de replicatie 
van het virale genoom opstarten. Replicatie leidt tot de productie van nieuwe virale RNA 
moleculen die aanleiding geven tot de vorming van nieuwe vRNP’s. Deze vRNP’s verlaten 
vervolgens de celkern en vormen nieuwe viruspartikels samen met structurele virale 
eiwitten. De nieuwe virussen komen vrij uit de geïnfecteerde cel en kunnen de naburige 
cellen infecteren, waardoor de hele cyclus van voor af aan begint2. 
 
Meer dan 50 jaar geleden ontdekten Lindenmann et al. een gen dat ervoor zorgt dat muizen 
resistent zijn tegen infectie door het influenza A virus (FLUAV). Dit gen werd Mx1 
genoemd3-5, wat staat voor myxovirus resistance 1. Deze naam werd gegeven omdat muizen 
die een functionele vorm van het eiwit aanmaken resistent zijn tegen infecties door FLUAV 
en andere myxovirussen4,5. Een tijd later werd een humane ortholoog van muis Mx1 
geïsoleerd, en dit gen werd MxA genoemd6. Tot nu toe zijn er verschillende Mx orthologen 
beschreven in zo goed als alle vertebraten. Deze orthologen verlenen resistentie tegen een 
hele resem aan virussen zoals Orthomyxoviridae, Rhabdoviridae, en Bunyaviridae7. Het 
exacte mechanisme waarmee muis Mx1 virussen onderdrukt, is nog steeds grotendeels 
onbekend. Onze onderzoeksgroep heeft bijgedragen aan de ontrafeling van het specifieke 
anti-influenza mechanisme door aan te tonen dat Mx1 een interactie aangaat met het 




aanwezigheid van muis Mx1 de interactie tussen deze twee eiwitten wordt verhinderd8. We 
hebben ook bewijzen gevonden dat het Mx1 eiwit reeds gevormde influenza A vRNP’s actief 
zou kunnen verbreken9. Aangezien Mx1 een type I interferon-induceerbaar eiwit is, 
vermoedt men dat het voornamelijk vroeg na de infectie FLUAV onderdrukt en het virus op 
deze manier verhindert zich in de luchtwegen te verspreiden. Het is niet bekend of Mx1 een 
rol kan spelen in het immuun cel compartiment na een infectie door FLUAV. De inductie van 
een antivirale status, door type I interferon, in antigenpresenterende cellen of geheugen T 
cellen heeft een direct effect op het immuunsysteem tegen respectievelijk primaire of 
secundaire influenza virus infecties10,11. Daarenboven kunnen humane dendritische cellen 
MxA snel opreguleren en waardoor ze, tenminste in vitro, resistent worden tegen het virus 
en de antigenpresentatie in stand kunnen houden12. De meeste studies die het 
immuunantwoord opgewekt door FLUAV bestuderen maken gebruik van muisstammen die 
geen functionele vorm van Mx1 kunnen produceren13. Op basis van deze studies wordt 
beweerd dat bepaalde types immuuncellen zoals CD103+ dendritische cellen en long 
residente geheugen CD8+ T cellen, beschermd zijn tegen FLUAV infecties doordat ze een 
interferon-geïnduceerde antivirale status aannemen10,11. Hierdoor is de hypothese ontstaan 
dat Mx1 ook een rol zou kunnen spelen in het vormen van de antivirale status in deze 
cellen. 
 
Om deze hypothese te onderzoeken, hebben we een infectiemodel opgezet waarin we 
gebruik maakten van beenmergchimeren. Aangezien de meerderheid van de 
immuunceltypes voortkomen uit het beenmerg, zal een beenmergtransplantatie van 
muizen met een functioneel Mx1 gen (B6.A2G Mx1+/+) naar muizen zonder een functioneel 
Mx1 gen (B6.A2G Mx1-/-) en vice versa, ons toelaten om de eventuele functie van Mx1 te 
bestuderen in celtypes die afkomstig zijn uit het beenmerg. De chimere muizen werden 
geïnfecteerd met een hoge dosis FLUAV en meerdere parameters werden onderzocht 
(lichaamsgewicht, virale titers in de long, virale mRNA- en eiwitniveaus in de long). Hieruit 
konden we afleiden dat Mx1-expressie in celtypes afkomstig uit het beenmerg niet de 
voornaamste factor was die de resistentie tegen een FLUAV infectie bepaalde. De drijvende 
kracht achter de resistentie tegen FLUAV infecties was de aanwezigheid van Mx1 in 
stromale cellen. Dit verschil tussen Mx1-/- en Mx1+/+ recipiënt muizen was ook merkbaar bij 
de verandering van de hoeveelheden eosinofielen, monocytafgeleide dendritische cellen en 
alveolaire macrofagen in de long. 
 
De reeds bekomen resultaten boden echter geen sluitend bewijs om onze hypothese te 
bevestigen. Daarom hebben we een tweede infectiemodel opgezet met het Thogoto virus 
(THOV), een virus dat wordt overgedragen door teken. THOV is, net als FLUAV, een lid van 




ratten de natuurlijke gastheren van dit virus en is THOV ook gevoelig voor inhibitie door 
Mx114,15. Chimere muizen werden geïnfecteerd met een hoge dosis THOV en wederom 
werden meerdere parameters onderzocht (lichaamsgewicht, virale titers in de lever, virale 
eiwitniveaus in de lever, leverpathologie). Net als bij het FLUAV infectiemodel is Mx1-
expressie in de stromale cellen de belangrijkste determinant voor resistentie tegen infectie. 
Toch vertoonden bestraalde Mx1-/- recipiënt muizen die Mx1+/+ beenmergcellen ontvingen 
een gereduceerde morbiditeit na THOV infectie in vergelijking met Mx1-/- recipiënt muizen 
die Mx1-/- beenmergcellen ontvingen. Dit uitte zich in minder verlies van lichaamsgewicht 
en minder ernstige leverpathologie bij deze groep muizen. Deze observatie toont aan dat 
Mx1 een belangrijke rol kan spelen in immuunceltypes na een virale infectie, hoewel het 
belang van deze rol sterk afhankelijk is van het infecterende virus. 
 
Als tweede luik van deze thesis hebben we onderzocht wat de bijdrage van Mx1 kan zijn in 
de context van een vaccinatie met een influenza A NP antigen dat door middel van een 
virale vector wordt toegediend. Altenburg et al. hebben recentelijk onderzocht of 
recombinante gemodificeerde vaccinia Ankara (rMVA) vaccins die gemuteerde vormen van 
het FLUAV NP eiwit aanmaken, een sterkere antigenspecifieke immuunrespons zouden 
opwekken dan rMVA vaccins die de wild type (WT) vorm van NP aanmaken (rMVA-NPwt). 
De aangebrachte mutaties waren bedoeld om de NP moleculen in het cytosol te houden of 
om hun afbraak tot peptiden te verbeteren. Hiervoor werd het nucleair lokalisatiesignaal 
(NLS) van NP gemuteerd (rMVA-NPmut) of volledig verwijderd (rMVA-NPΔNLS), of werd 
ubiquitine aan NP gekoppeld (rMVA-UbqNP). De gemuteerde NP constructen konden in 
vitro NP-specifieke T cellen beter activeren dan het rMVA-NPwt construct. Dit effect kon 
echter niet doorgetrokken worden naar een in vivo situatie, want vaccinatie van C57BL/6 
muizen met de verschillende rMVA-NP constructen leidde niet tot een significant verhoogde 
NP-specifieke CD8+ T cel respons of een betere bescherming tegen een FLUAV infectie dan 
het geval was voor het rMVA-NPwt construct16. Dit resultaat komt waarschijnlijk voort uit 
het feit dat het rMVA-NPwt construct gemakkelijk de vereiste drempelwaarde voor NP-
antigen kan bereiken en dus moeilijk verbeterd kan worden door deze variante NP 
constructen. Deze drempelwaarde voor NP-antigen moet bereikt worden om een robuuste 
CD8+ T cel respons te kunnen ontwikkelen. Daarom vermoedden wij dat muizen die een 
functioneel Mx1 eiwit aanmaken een beter model zouden zijn dan C57BL/6 muizen, die 
geen functioneel Mx1 eiwit aanmaken13, om deze verschillende rMVA-NP constructen te 
testen. Mx1, waarvan is aangetoond dat het een interactie aangaat met NP8, kan optreden 
als de extra restrictiefactor die nodig is om het voordeel van de gemuteerde NP constructen 





Daarom werden B6.A2G Mx1-/- en B6.A2G Mx1+/+ muizen gevaccineerd met de 
verschillende rMVA-NP constructen. Een week na de tweede vaccinatie werd de NP-
specifieke CD8+ T cel respons onderzocht in bloed en milt door middel van intracellular 
cytokine staining (ICS) en enzyme-linked immunospot assay (ELISPOT). Zowel de resultaten 
bekomen met ICS als met ELISPOT vertoonden geen significante verschillen tussen de 
gemuteerde constructen en het WT NP construct in B6.A2G Mx1+/+ muizen. Desalniettemin 
vertoonden de ELISPOT resultaten wel de trend dat rMVA-NPmut en rMVA-NPΔNLS 
constructen een sterkere CD8+ T cel respons opwekken dan het rMVA-NPwt construct. 
Maar om de theorie dat Mx1 een belangrijke factor zou kunnen zijn in de inductie van een 
NP-specifieke cellulaire respons na vaccinatie met gemuteerde NP constructen zijn er 
bijkomende experimenten nodig. 
 
De resultaten die we bekomen hebben met het THOV infectiemodel tonen duidelijk aan dat 
Mx1 na virale infectie een belangrijke rol speelt in immuuncellen. Bijgevolg konden we twee 
grote conclusies trekken uit deze thesis. Ten eerste is het bij het bestuderen van een 
infectiemodel is het van groot belang om een gepaste combinatie van gastheer en virus te 
gebruiken. Aangezien THOV een natuurlijke pathogeen is voor kleine knaagdieren, is dit 
virus ideaal om te gebruiken in een muismodel. Ten tweede is het tropisme van het 
geselecteerde virus is ook zeer belangrijk. Bij het onderzoeken van de antivirale rol van een 
eiwit in een bepaald celtype is het essentieel dat het gebruikte virus dit celtype ook effectief 
kan infecteren. THOV infecteert myeloïde CD11b+ cellen17, en bleek dus uitermate geschikt 
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Empty your mind. Be formless, shapeless, like water. 
If you put water into a cup, it becomes the cup. You  
put water into a bottle and it becomes the bottle. You  
put it in a teapot, it becomes the teapot. Now, water can  
flow or it can crash. Be water, my friend. 

















































Everything must be made as simple as possible, but not simpler. 
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1.1 Classification, nomenclature and clinical impact 
Members of the Orthomyxoviridae family are characterized by their negative-stranded, 
segmented ribonucleic acid (RNA) genome. Hitherto, this family contains seven different 
genera: Influenza A, B, C and D, Thogotovirus, Quaranjavirus and Isavirus1-3. However, novel 
sequencing techniques and analysis methods suggest the existence of additional viruses 
that belong to the Orthomyxoviridae family, although these viruses have not yet been 
isolated4. The Thogotovirus genus can be further divided into seven species: Thogoto, Dhori, 
Araguari, Upolu, Aransas Bay, Jos and Bourbon virus1,5-8. Influenza strains are 
conventionally named according to genus (A, B, C or D), the animal species – if not human – 
from which the virus was isolated, followed by the location, number and year of isolation. In 
the case of influenza A viruses, the hemagglutinin (HA; 1-18) and neuraminidase (NA; 1-11) 
subtype are also mentioned9. For instance, the commonly used lab strain influenza 
A/Puerto Rico/8/34 (H1N1) is the eighth isolate of a human influenza A virus isolated in 
Puerto Rico in the year 1934, and it has an HA subtype 1 and an NA subtype 1. 
1.1.1 Influenza virus 
Every year, seasonal influenza causes an estimated three to five million cases of severe 
illness, and 250 000 to 500 000 lethal cases worldwide10. Next to seasonal influenza, the 
burden of this disease is also determined by the much feared for and unpredictable 
pandemic outbreaks of influenza A viruses that carry an HA (sometimes also an NA) that is 
antigenically very distinct from that of the circulating human influenza viruses. A pandemic 
can be described as an outbreak which impacts a large geographic area and large 
proportions of the population in a short period of time. In the past 100 years there were 
four documented influenza pandemics, namely the Spanish flu (H1N1, 1918), Asian flu 
(H2N2, 1957), Hong Kong flu (H3N2, 1968) and Mexican flu (H1N1, 2009). The Spanish flu 
pandemic was by far the most severe of all, killing 25 million people in the first 25 weeks 
after its outbreak. The most recently declared human influenza pandemic emerged in 2009 
and was caused by a swine origin H1N1 virus11. It is estimated that globally over 200 000 
people succumbed to this virus within the first year after its outbreak in the spring of 
200912. 
1.1.2 Thogoto virus 
Thogoto virus (THOV) was first isolated in 1960 from ticks which were themselves isolated 
from cattle in the Thogoto forest near Nairobi (Kenya)13,14. Antibodies against this virus are 
found in an array of vertebrates such as rats, sheep, cattle, buffaloes, donkeys, camels and 
humans. In sheep, Thogoto virus has been shown to be a causative agent of febrile illness 
and abortion15. THOV infections in humans are rare, although there is one case where the 
virus was isolated from the cerebral fluid of a patient with bilateral optic neuritis and in 
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another case from the blood of a patient with meningitis. However, a causative relationship 
between the virus and the disease has never been proven16. Dhori virus, another tick-borne 
virus which belongs to the Thogotovirus genus, has been shown to cause febrile illness and 
encephalitis after accidental human lab infections17. Bourbon virus, the latest identified 
member of the Thogotovirus genus, recently took its fifth human victim since its discovery18. 
This person was admitted to the hospital suffering from severe headache, pain, a light-red 
rash, and a low white blood cell count. This was shortly after she removed two ticks from 
her body. 
1.2 Virion and genome structure 
Orthomyxoviruses are enveloped viruses whose virions can adopt either a spherical or a 
filamentous form. Their genome comprises six to eight segments, with some segments 
coding for more than one protein. Viral RNA sequences of influenza and Thogoto viruses 
contain conserved sequences at their 3’ and 5’ ends which are partially complementary19,20. 
1.2.1 Influenza A virus 
The outer layer of an influenza A virion consists of a lipid membrane derived from the host 
cell from which the virion originated. This membrane is studded with viral membrane-
spanning proteins i.e. HA, NA and a small amount of matrix protein 2 ion channels (M2) 
(Figure 1.1). HA proteins are essential for the viral attachment to glycans with terminal 
sialic acids, e.g. on host cell glycoproteins, and for the membrane fusion process with the 
host cell. NA is a sialidase, which is important for cleavage of sialic acids present on virus 
receptors on the cell surface and on neighboring virions that are budding from an infected 
cell. NA activity thus ensures efficient release of newly produced virions from the host cell. 
Furthermore, there is evidence that NA also facilitates the passage of virions through the 
sialic acid-rich mucosal layer that lines the respiratory mucosa in humans21. M2 proteins 
form tetrameric ion channels in the membrane of the virion and the host cell. The HA:M2 
ratio (101-102 to 1) is much bigger than the HA:NA ratio (4 to 1) due to the small amount of 
M2 proteins in the virion membrane22-25. Just beneath the membrane envelope there is a 
layer composed of matrix 1 (M1) proteins. This peripheral membrane protein is one of the 
most abundant proteins in the virion. The M1 protein binds to the lipid envelope and by this 
maintains the shape of the virion. This shape can be either spherical/elliptical or 
filamentous26. The core of the influenza virion is made up of eight viral ribonucleoproteins 
(vRNPs), which consist of viral RNA (vRNA) complexed with nucleoprotein (NP) molecules, 
and a single heterotrimeric RNA polymerase complex comprising the polymerase basic 1 
(PB1) and 2 (PB2) and polymerase acidic (PA) proteins. These proteins have their own 
distinct functions within the viral polymerase, i.e. PB1 contains the RNA-dependent RNA 
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domain of PA functions as an endonuclease29,30. Recently, the structures of the influenza A, 
B and C polymerase complexes were published in a remarkably short period of time31-33. 
Another protein in the virion is the nuclear export protein (NEP), a.k.a. nonstructural 
protein 2 (NS2), but the exact location of this protein in the virion is not yet known34-36. 
Recently, Hutchinson et al. also detected the nonstructural protein 1 (NS1) protein in the 
virion, albeit at very low levels25. 
 
The genome of influenza A viruses (FLUAVs) consists of eight segments which code for 13 
different proteins. The PB2, PB1, PA, HA, NP, NA, M and NS proteins are encoded by 
segments 1 to 8 respectively. Spliced and unspliced mRNA transcripts of segments 7 and 8 
give rise to different proteins, i.e. M1 and M2 for segment 7, and NS1 and NEP (NS2) for 
segment 8. The NS1 protein interferes with the induction of an adequate interferon 
response by interacting with different host factors, involved in interferon induction or 
conveying antiviral action37-43. More recently, it has been shown that segment 2 and 3 also 
code for other proteins next to PB1 and PA respectively. Segment 2 encodes the accessory 
protein PB1-F2 in a +1 alternate reading frame. This protein has pro-apoptotic activity, 
regulates host interferon response, and modulates the susceptibility to bacterial infection of 
the host44-46. In addition to PB1 and PB1-F2, segment 2 also codes for a product that is 
translated starting from an in-frame (relative to PB1) downstream initiation site, producing 
an N-terminally truncated version of PB1 with no known function, called N4047. Segment 3 
produces, next to the PA protein, the product of a + 1 ribosomal frameshift i.e. PA-X which is 
Figure 1.1 Schematic representation of the influenza A virion. 
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involved in modulation of the host immune response to influenza A virus infection48. PB1-
F2, N40 and PA-X are not present in the virion of influenza A viruses. 
1.2.2 Thogoto virus 
Thogoto viruses resemble influenza A viruses structurally and genetically. The outer layer 
of the virion is also a host cell-derived lipid membrane studded with glycoproteins (Figure 
1.2). The Thogoto virus genome consists of six segments. The three largest segments, 
similar to influenza A viruses, code for the three RNA polymerase subunits PB2, PB1 and 
PA. The coding sequences for these polymerase subunits show distant similarity to 
corresponding sequences of influenza A virus49,50. The fourth segment encodes the single 
glycoprotein (GP) in the THOV envelope. The GP is probably responsible for the virus 
attachment to and fusion with the host cell. This protein is not related to the influenza A 
glycoproteins, but there is sequence identity to the baculovirus glycoprotein gp6451. 
Adaptation to the arthropod host is the most plausible explanation for this resemblance. 
Segment 5 codes for the nucleoprotein (NP), which shows similarity to the corresponding 
protein of influenza A viruses52,53. The smallest segment (segment 6) of the THOV genome 
codes for two different proteins i.e. the matrix (M) and the matrix long (ML) proteins. The M 
protein is produced from a spliced mRNA54, like it is also the case for influenza C viruses55. 
This protein has an inhibitory effect on the viral RNA-dependent RNA polymerase and is 
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essential for the formation of virus-like particles56. The ML protein has an extended C-
terminus (38 amino acids) in comparison to the M protein, and is translated from the 
unspliced transcript of segment 6. This protein has been shown to be a potent inhibitor of 
the interferon β (IFNβ) response, so it fulfills a similar role as the influenza A NS1 protein57. 
Like NS1, the ML protein is also packaged into the virion56. The fact that NS1 and ML are 
structural proteins is in accordance with an interferon antagonizing strategy used by some 
other viruses: e.g. the pp65 protein of human cytomegalovirus and the VP35 protein of 
Ebola virus counteract the host antiviral response early after infection and are also present 
in the virion58,59. THOV ML suppresses the IFN response in a different way than influenza 
NS1. FLUAV NS1 prevents IFN induction by retaining the interferon regulatory factor 3 
(IRF3) protein into the cytoplasm, by which it cannot reach the nucleus where it would 
activate the IFNβ promoter38. THOV ML, on the other hand, was shown to interact with RNA 
polymerase II transcription factor IIB. This interaction has a strong negative effect for IRF3-
regulated promoters60. 
1.3 Virus replication cycle 
1.3.1 Influenza A virus 
A schematic overview of the influenza A virus replication cycle is shown in Figure 1.3. 
Influenza A viruses attach to their host cell by binding to sialic acids on the cell surface. 
These are commonly found at the termini of many glycoconjugates. Influenza HA 
glycoproteins on the virion preferentially recognize α2,3-linked and α2,6-linked sialic acids. 
This means that the carbon-2 of sialic acid is bound either with carbon-3 or -6 of the 
subsequent galactose molecule, which causes unique steric conformations of this sialic acid. 
On epithelial cells of the human trachea α2,6-linked sialic acid is the most abundant. 
However, α2,3-linked sialic acids are also present in the human airways; the highest 
prevalence of α2,3-linked sialic acids can be found in the lower respiratory tract61. On avian 
gut epithelium cells the most prevalent sialic acids are α2,3-linked. Avian and human 
influenza strains apparently have evolved to have a preference for either the α2,3- or the 
α2,6-linked sialic acids respectively62. Attachment to the target cell is followed by receptor 
mediated endocytosis, whereby the virion is engulfed by the target cell and is consequently 
situated in an endosome. 
 
Following endocytosis, the virus has to release its genetic material into the cytosol. For this, 
the acidity of the endosome is crucial, since a low pH triggers a conformational change in 
the HA protein – exposing the fusion peptide – which leads to fusion of the viral and 
endosomal membrane63. The pH of the endosome is also crucial for the acidification of the 
virion itself. This disrupts the protein-protein interactions between vRNPs and the matrix 
(M1) proteins, which allows the vRNPs to be released into the host cell cytoplasm. The 
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acidification of the virion is achieved by the passive transfer of protons into the virus 
particle through the M2 ion channel. The disruption of vRNP-M1 interactions and the 
disintegration of the virion matrix layer is a consequence of extensive conformational 
changes in the M1 structure. A symmetrical dimer conformation is changed into an 
asymmetrical dimer conformation at low pH64,65. The combination of the fusion process and 
the dissociation of the vRNPs from the M1 matrix proteins allows the release of the vRNPs 
in the vicinity of the nuclear pores. 
 
Next, the vRNPs traffick into the nucleus by means of their nuclear localization signals 
(NLSs). All vRNP subunits carry an NLS in their sequence. However, the NP protein was 
shown to be required and sufficient for import of vRNPs into the nucleus66,67. More specific, 
the unconventional NLS at the amino-terminal end of the NP protein is crucial. Possibly 
because it is much more accessible than the NLSs of the other subunits of the vRNP 
complex68,69. The NLSs are recognized by importin α proteins which, in turn, are recognized 
by importin β proteins. The formed complexes are imported into the nucleus by the small 
GTPase Ran, which shuttles between the nucleus and the cytoplasm70. 
 
In the nucleus, the viral RNA-dependent RNA polymerase uses the negative sense viral RNA 
(vRNA) as a template for the production of messenger RNA (mRNA) (viral transcription) 
and complementary RNA (cRNA) (viral replication). Viral transcription results in the 
production of positive-stranded mRNA which contains a cap structure at its 5’ end, and a 
poly-adenosine (poly(A)) tail at its 3’ end. In this way, the viral mRNA strongly resembles 
cellular mRNA. The 5’ cap is obtained through a process called cap-snatching. The viral 
polymerase complex ‘steals’ the cap from cellular pre-mRNA molecules. The cap structure 
on these pre-mRNAs is recognized and bound by the cap-binding domain of the polymerase 
PB2 subunit, and subsequently cleaved off – at 10 to 13 bases 3’ from the cap structure – by 
the endonuclease activity of the amino-terminal domain of the PA subunit28-30. The cleaved 
RNA-fragment functions as a primer for initiating the viral transcription by the viral 
polymerase complex, which synthesizes the viral mRNA as it proceeds over the vRNA 
template. When the polymerase reaches the 5’ end of the vRNA, it forms the poly(A) tail to 
the 3’ end of the viral mRNA by repetitive copying (stuttering) of a stretch of five to seven 
uracil residues in the vRNA71-73. 
 
Viral replication is a two-step process wherein firstly the vRNA is copied into a positive-
stranded complementary RNA (cRNA), and subsequently this cRNA functions as a template 
for the production of full-length progeny vRNAs. The initiation of cRNA synthesis occurs de 
novo, and the resulting cRNA does not contain a poly(A) tail. The newly produced cRNA and 
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cRNP and vRNP complexes74. Therefore, viral replication will only start when a vast amount 
of free NP molecules are produced. In this way the cRNA is protected from degradation by 
cellular nucleases75,76. 
 
Viral mRNAs are transported out of the nucleus similarly to the host mRNA molecules. The 
two main mRNA nuclear export processes are mediated by the nuclear RNA export factor 1 
(NXF1) or by the chromosome region maintenance 1 (CRM1) protein. Which pathway is 
utilized by influenza viruses is still heavily discussed, but evidence for the NXF1 pathway is 
growing77-80. The NXF1 pathway was shown to be necessary for the optimal nuclear export 
of influenza mRNA, however the export of PA, PB1 and PB2 mRNA seems to be independent 
of NXF1 and CRM181. Recently, it was revealed that a member of the DExD-box (DDX) 
helicases – DDX19 – associates with intronless, unspliced and spliced influenza A mRNAs, 
and to be involved in their nuclear export82. This illustrates the poor understanding about 
this particular part of the influenza virus life cycle. 
 
After nuclear export, mRNAs are translated to proteins. This is mediated by the eukaryotic 
translation initiation factor 4 F (eIF4F) complex. This complex consists of three subunits: 
the cap-binding protein eIF4E, an RNA helicase eIF4A, and a scaffold protein eIF4G83. 
Translation of viral mRNA is reliant on this host cell translation machinery, although some 
reports suggest that only two out of three subunits are required for this. The eIF4E 
subunit’s cap-binding function is taken over by the viral polymerase PB2 subunit. The 
eIF4A and eIF4G subunits on the other hand are indispensable for the viral mRNA 
translation84,85. However, based on immune-precipitation experiments, Bier et al. proposed 
that eIF4E (and not the viral RNA polymerase) is involved in cap-binding of influenza A 
virus mRNA86. 
 
Envelope proteins are synthesized on endoplasmic reticulum-associated ribosomes and 
thereby targeted for secretion. In the ER these proteins are folded and N-glycosylated in the 
case of HA and NA and trafficked to the Golgi apparatus for further post-translational 
modifications. Eventually, HA, NA and M2 reach the plasma membrane for virion assembly. 
Newly translated PB1, PB2, PA and NP molecules are imported back into the nucleus where 
vRNA is encapsidated into vRNPs87. The NP protein is transported back into the nucleus by 
recognition of its unconventional NLS69. The polymerase subunits need some extra help to 
reach the nucleus. The PB2 protein can be assisted by the host cell heat shock protein 90 
(Hsp90)88. The PB1 and PA polymerase subunits are imported into the nucleus as a 
heterodimer, helped by the Ran binding protein 5 (RanBP5)89. Once arrived in the nucleus, 
PA, PB1 and PB2 form the polymerase complex. Next to the polymerase subunits and NP 
proteins, viral NEP and M1 proteins are also transported into the nucleus. The newly 
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produced vRNPs are exported out of the nucleus and transported to the host cell membrane 
with the help of M1 and NEP proteins90. Since there are no nuclear export signals (NESs) 
found in RNP proteins, vRNPs need assistance of other viral proteins for nuclear export. M1 
proteins bind to the vRNPs and prevent re-entry into the nucleus91. M1 subsequently 
interacts with the NEP protein which does contain an NES. NEP, in turn, interacts with the 
CRM1 protein that facilitates the nuclear vRNP export90. 
Accumulation of HA and NA molecules in lipid rafts (cholesterol and sphingo-lipid enriched 
areas) in the cell membrane induces virion budding92. The cytoplasmic tails of HA and NA 
proteins function as docking sites for M1 proteins. Here the eight different vRNPs assemble 
in a unique 7+1 pattern through inter-vRNP and vRNP-M1 interactions93-95. Each genomic 
segment contains specific packaging signals, which facilitate this 7+1 packaging pattern96. 
Subsequent accumulation of M2 in the plasma membrane at the edge of the HA- and NA-
containing lipid-rich region, can complete budding by inducing membrane curvature97,98. 
After budding, HA molecules interact with sialic acids on the host cell membrane which 
would cause them to accumulate on the host cell membrane. To prevent this, NA uses its 
sialidase activity to cut sialic acids from the host cell glycoconjugates. It also removes the 
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sialic acids from the virion glycoproteins to prevent aggregation99. The newly produced 
virions are now ready to infect neighboring cells, and start the replication cycle all over. 
1.3.2 Thogoto virus 
The THOV replication is not as elaborately studied as the influenza A virus replication, but it 
has been shown that their replication cycles are quite similar. The THOV glycoprotein (GP) 
functions as a hemagglutinin and as a fusion protein. Fusion is pH dependent, indicating 
that entry occurs via the endocytic pathway as for FLUAVs100. The acidification of the virion 
also triggers a conformational change in the matrix protein, which supports the process of 
viral uncoating101. After fusion, it has been shown that the THOV replication cycle has a 
nuclear phase, which suggests that transcription and replication occur in the nucleus100,102. 
Further evidence is provided by the fact that the murine Mx1 protein, which is only active in 
the cell nucleus, inhibits THOV multiplication103. The human MxA protein also inhibits 
THOV multiplication by preventing the THOV vRNPs from entering the nucleus. MxA 
inhibits THOV by interaction with the NP molecules of the vRNPs104,105. These data suggest 
that the NP protein plays a major role in the vRNP import. The THOV vRNPs are similar to 
the ones from FLUAV in the sense that they were shown to be able to transcribe and 
replicate model vRNA106. Like FLUAV, THOV transcription is dependent on the activity of 
cellular DNA-dependent RNA polymerase II14,102. Cap snatching in the FLUAV transcription 
involves ‘stealing’ the cap structure of host pre-mRNA with an additional 10 to 13 
nucleotides28-30. THOV does this slightly differently: the cap structures are still ‘stolen’ from 
host pre-mRNA molecules, but there is only one extra nucleotide taken along (preferentially 
an adenosine residue)52,107. Although the THOV and FLUAV polymerase complexes are 
structurally homologous, their cap-snatching mechanisms probably differ a lot more than 
previously thought. Guilligay et al. showed that the putative PA endonuclease and PB2 cap-
binding domains are degenerated and that they have lost their biochemical activities in 
vitro108. How cap-snatching is done by THOV remains unclear. The protein synthesis and 
vRNP formation are not studied extensively for THOV, but are most likely similar to FLUAV 
considering the similarity between the vRNP-comprising proteins of the two viruses. 
Budding of the virions is shown to be dependent on GP and M proteins56,109, as is the case 
for FLUAV where HA, NA and M proteins are necessary for virion budding. 
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And don't spend your time looking around 
For something you want that can't be found 
When you find out you can live without it 
And go along not thinking about it 
I'll tell you something true 
The bare necessities of life will come to you 
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2.1 History and phylogeny of Mx proteins 
The recorded history of Mx proteins starts in the early 1960s when Jean Lindenmann 
started investigating the accidental observation of increased resistance against a 
neurotropic influenza A virus in a line of the mouse A2G strain1. Further research showed 
that these A2G mice are also resistant to other myxoviruses2. This feature was passed on to 
the offspring as a dominant autosomal trait, and the responsible allele was called Mx, short 
for myxovirus resistance3. Another landmark experiment was performed by Dr. Otto Haller, 
who showed that treating A2G mice with an interferon (IFN)-neutralizing antiserum from 
sheep rendered these mice susceptible to influenza A virus (FLUAV) infection, showing that 
this resistance associated with the Mx allele is interferon-dependent4. Building on this, the 
murine Mx1 protein could be identified as a protein that was only detectable after type I 
IFN induction of A2G mouse-derived cells5,6. Shortly thereafter, a protein – later called MxA 
– was isolated from human peripheral blood lymphocytes and fibroblasts by 
immunoprecipitation with a monoclonal antibody (2C12) that had been raised against 
murine Mx1. This protein was, like murine Mx1, only induced by type I IFN, and not by type 
II IFN. Unlike Mx1, this protein (MxA) was mainly detected in the cytoplasm7. Since then, Mx 
genes have been identified in almost all vertebrates, and all of these Mx genes are induced 
by type I IFN. Notably, an extra Mx gene has been identified both in mice and humans, and 
this gene codes for the Mx2 (mouse) and the MxB (human) proteins respectively8,9. More 
recently, expression of mouse Mx1 and human MxA proteins has been shown to be induced 
not only by type I, but also by type III IFN10. 
 
Mx genes are observed in nearly all chordate genomes with few exceptions such as the 
opossum genome. Mx genes can be divided into three phylogenetic classes i.e. fish, 
mammals, and the collective group of amphibians, reptiles and birds11. The number of Mx 
genes in fish can vary from one to as many as nine, which is most likely the result of gene 
duplications. Birds, reptiles and amphibians have only one Mx gene, and most mammals 
have two Mx genes (Mx1 and Mx2). From amphibians to mammals the Mx alleles are flanked 
by the same two genes i.e. TMPRSS2 and FAM3B11. TMPRSS2 encodes a serin protease which 
can process the influenza A HA to a fusion-competent form12. FAM3B codes for a pancreatic 
secreted cytokine13. 
 
The two Mx genes in the rodent genome are both closely linked to the Mx1 genes of other 
mammals. The Mx2 gene in rodents is probably derived from the ancestral Mx1 gene after 
gene duplication11. Most commonly used inbred mouse strains however fail to synthesize a 
functional Mx1 protein. This is the result of either a deletion of exons 9 to 11, resulting in a 
frame shift and premature termination of the Mx1 protein (e.g. BALB/c and C57BL/6J 
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strains), or because of a point mutation, which introduces a premature stop codon (e.g. 
CBA/J strain)14. Similar gene erosion is seen in the Mx genes of toothed whales 
(Odontocetes), which lead to the lack of functional Mx proteins in this phylogenetic group15. 
Next to a defective Mx1 gene, most mouse inbred strains (including the A2G strain) also 
carry a defective Mx2 gene due to a single nucleotide insertion resulting in a frame shift8. 
Markedly, the presence of a functional full-length Mx1 protein does not necessarily convey a 
strong resistance against FLUAV for a specific mouse strain. The Mus spretus Mx1 protein 
for instance, differing at 25 positions from the Mus musculus A2G Mx1 protein, is less potent 
than A2G Mx1 in inhibiting FLUAV. This difference in potency could be attributed to a single 
amino acid16. The CAST/EiJ mouse strain (derived from Mus musculus castaneus) on the 
other hand, only differs at two positions from the A2G Mx1 protein, but is highly susceptible 
to FLUAV infection17,18. This susceptibility could again be attributed to a single amino acid 
change19. In addition, it has been shown that expression of the A2G Mx1 gene in a different 
murine genetic background (DBA/2J) does not result in FLUAV resistance like seen for A2G 
Mx1 in the A2G or C57BL/6J background20. This can be explained by the highly FLUAV-
susceptible phenotype, which is polygenetic, of DBA/2J mice21. Furthermore, it was shown 
that not only the genetic background matters for the protective effect of A2G Mx1 to be 
displayed, but also the virulence of the virus and the kinetics of Mx1 induction play a major 
role20,22,23. 
2.2 Structure of Mx proteins 
Mx proteins belong to the dynamin superfamily, a subcategory of the large guanosine 
triphosphate (GTP)-hydrolyzing enzymes (GTPases). All dynamins and dynamin-like 
proteins consist of at least three domains: a GTPase domain, a middle domain (MD) and a 
carboxy-terminal GTPase effector domain (GED). Dynamin also contains a pleckstrin 
homology (PH) domain that facilitates binding to the plasma membrane, and a proline-rich 
domain (PRD) which can bind other proteins24. Mx proteins, however, do not have these 
PRD and PH domains. The Mx GTPase domain contains a GTP-binding motif and a so-called 
dynamin signature which is required for GTPase activity25. The middle domain of Mx 
proteins is important for oligomerization and target recognition, and the GED contains an 
intramolecular GTP-activating domain26,27 (Figure 2.1). 
 
The three-dimensional (3D) protein structure of MxA was determined in 2011 by Gao et al., 
and it appeared to strongly resemble the structure of dynamin28,29. The 3D structure of MxA 
can also be divided into three major domains, albeit that these domains differ from the ones 
recognized in the primary structure. The globular GTPase domain is made up of a central β-
sheet surrounded by α-helices. The GTPase domain is connected to the stalk domain, which 
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domain and the stalk is formed by the third domain called the bundle signaling element 
(BSE). The BSE comprises three α-helices, each from a different part of the primary 
structure, and is formed by backfolding of the carboxy-terminal leucin-zipper to the amino-
terminal GTPase domain30. 
2.3 Oligomerization of Mx proteins 
One of the shared features between dynamin and Mx proteins is their ability to oligomerize 
and form ring or helical filament structures that surround their target structure (reviewed 
by Faelber et al.31). The MxA protein stalk acts as an oligomerization ‘hub’, with three 
interfaces and one loop which are responsible for the major interactions between 
neighboring MxA molecules (Figure 2.2a). First, MxA dimers are formed through a highly 
conserved interface (interface 2) in the stalk that mediates the dimerization (Figure 2.2b). 
Further oligomerization results in the formation of a crisscross pattern of MxA molecules by 
the formation of interactions between the stalk domains of different MxA molecules26 
(Figure 2.3). Additional stabilizing interactions between MxA molecules are mediated by 
two other interfaces (interfaces 1 and 3) and one loop (L4) located in the stalk region26,28. 
Oligomerized MxA proteins form ring-like structures with the stalks pointed inwards, which 
is critical for target recognition, and the GTPase domains located at the periphery of the 
ring32,33 (Figure 2.4). At the tip of the stalk there is a flexible, unstructured loop (L4) which 
Figure 2.1 Structure of human MxA protein. Ribbon type 
representation of a human MxA molecule with indication of the three 
structural domains. BSE = bundle signaling element, G-domain = GTPase 
domain. Human MxA structure with Protein Data Bank accession code 
3SZR. Figure generated using PyMOL software. 
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is surface exposed, and which has been shown to be responsible for lipid binding and 
recognition of certain viral structures16,34-36. Ring formation of dynamins has the purpose to 
facilitate membrane fission. For MxA, this feature is thought to be associated with its 
antiviral activity28,37. A model for dynamin activity was proposed by Faelber et al. and 
Morlot and Roux38,39, and this model was recently supported with structural, enzymatic and 
biophysical data gathered from MxA proteins by Rennie et al. and Chen et al.40,41. In this 
model, MxA’s conformation changes drastically upon GTP binding, leading to constriction of 
the ring or helix, which changes back to the ‘resting state’ after hydrolysis and release of 
GDP. This kind of ‘power stroke’ in a ring formation is essential for dynamin to facilitate 
Figure 2.2 Human MxA interaction interfaces and dimerization. (a) Space-filling representation of human 
MxA with indication of the three interaction interfaces. (b) Space-filling representation of a human MxA 
dimer. BSE = bundle signaling element, G-domain = GTPase domain. Human MxA structure with Protein Data 
Bank accession code 3SZR. Figure generated using PyMOL software. Figure based on Gao et al., 2010, Nature 
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scission of membranes (Figure 2.5). However, for MxA-mediated inhibition of Thogoto virus 
and Vesicular Stomatitis virus (VSV) GTP binding has been shown to be sufficient, so 
GTPase activity was not necessary42,43. This suggests that MxA, at least for some viruses, 
does not require a mechanical or enzymatic step in its antiviral mechanism. 
2.4 Antiviral activity of Mx proteins against Orthomyxoviruses 
The antiviral activity of Mx proteins against different members of the Orthomyxoviruses 
has some common traits. Inhibition of Orthomyxoviruses by Mx proteins requires an intact 
GTP-binding domain44. GTP binding by MxA is thought to facilitate assembly of newly 
synthesized MxA into stable dimers or tetramers associated with the ER membranes. After 
interferon induction, and consequently MxA synthesis, the ER membrane acts as a kind of 
depot for MxA molecules32,45. GTP hydrolysis then promotes dynamic redistribution from 
cellular membranes to viral target structures46. Mutations in the GTPase domain can render 
Mx proteins antivirally inactive against FLUAV44,47. However, Janzen et al. described an MxA 
protein carrying a single point mutation (L612K) which caused failure to oligomerize and 
Figure 2.3 Structure of an MxA oligomer. Ribbon type representation of an oligomer formed by six different 
human MxA monomers. G-domain = GTPase domain. Human MxA structure with Protein Data Bank accession 
code 3SZR. Figure generated using PyMOL software. Figure based on Gao et al., 2011, Immunity. 
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lack of GTPase activity. Surprisingly, this protein was still able to inhibit THOV and VSV 
infection43. Possibly, this protein could still bind to, but not hydrolyze GTP. Interestingly, 
GTP binding might not be necessary for recognition of viral targets, but rather stabilizes the 
complex between MxA and its viral target46. However, there is controversy around the 
notion that monomeric MxA has antiviral activity. The group of Pavlovic reported that 
overexpressed monomeric MxA can suppress Thogoto virus replication, whereas Chen et al. 
concluded that the monomeric mutant MxA(M527D) does not display antiviral activity41,48. 
Another communal trait of Mx proteins in their inhibition of Orthomyxoviruses is the 
comparable way of recognizing the virus. This was demonstrated by the fact that the 
antiviral activity of several Mx proteins (murine Mx1, human MxA, and rat Mx1) can be 
neutralized with the monoclonal 2C12 antibody which has been raised against murine 
Mx127,49,50. This antibody targets a conserved epitope in the carboxy-terminal region of Mx 
proteins51. Probably the most important common trait is the importance of the 
unstructured loop L4, located at the tip of the stalk of Mx molecules. This loop is essential 
for the specificity and antiviral activity of Mx proteins against Orthomyxoviruses16,34. 
Figure 2.4 Model of ring formed by MxA molecules. Space-filling representation of a ring-like MxA 
oligomer. BSE = bundle signaling element, G-domain = GTPase domain. Human MxA structure with Protein 
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2.4.1 Influenza A virus 
Murine Mx1 has a strong inhibitory effect on influenza A viruses, but how this inhibition 
works exactly remains an enigma. Since mouse Mx1 resides in the nucleus52, it presumably 
has no effect on viral attachment and entrance, uncoating of the virus, or transport of vRNPs 
to the nucleus6,53,54. Instead, the mouse Mx1 activity specifically targets primary viral 
transcription. Murine Mx1 has been shown to differentially inhibit the transcription of 
diverse influenza genomic segments55. Mainly the larger segments, such as PB2, PB1 and 
PA, are affected. The effect on the HA and NP segments is less pronounced, and is almost 
nonexistent for the smallest segments i.e. M and NS. This indicates that murine Mx1 
primarily interferes with transcriptional elongation instead of initiation55. The main targets 
of Mx1 are the NP and the PB2 proteins. Both are components of the influenza vRNPs, and 
together with PB1 and PA, essential for influenza transcription. Overexpression of the PB2 
protein can outcompete Mx1 activity56,57, and NP has been shown to determine the 
sensitivity of influenza A viruses for Mx1 and MxA activity37,47,58. The latter is the reason 
why human influenza A viruses are more resistant to murine Mx1 or human MxA activity 
than avian influenza A viruses. This reduced sensitivity can be attributed to only three 
exposed residues in the body domain of NP which are accessible for Mx proteins59,60. 
Introducing this ‘Mx escape cluster’ into the NP of otherwise Mx-susceptible viruses 
drastically reduces viral fitness of these viruses59, suggesting that escape from human Mx 
activity and maintaining viral fitness proves to be challenging for influenza viruses. Because 
of this, Mx proteins are considered a powerful barrier against zoonotic transmission of 
avian influenza viruses. The newly emerging H7N9 FLUAV however overcomes this 
restriction with an NP that is less sensitive to the activity of Mx61. Interestingly, Hanke et al. 
recently described an NP-specific single-domain antibody fragment (VHH) that binds a 
region on the body domain of NP, and this region overlaps with the cluster of residues 
which are decisive for Mx1 and MxA sensitivity. Based on a reporter assay, wherein the 
VHH and murine Mx1 differentially affected the expression of long and short transcripts, 
the authors concluded that this VHH displayed similar inhibitory effects on the influenza 
virus transcriptional elongation as seen for murine Mx162. This indicates that mere binding 
to NP molecules can be sufficient to interfere with their role in transcription elongation. Our 
lab demonstrated that Mx1 can interact with PB2 and NP, and moreover, that Mx1 inhibits 
the interaction between PB2 and NP molecules37. Not only can Mx1 inhibit the PB2-NP 
interaction, it might actively disrupt this interaction in already formed vRNPs. Our lab 
concluded this based on experiments with a synthetic murine Mx1 construct which could be 
conditionally activated. Activation of the Mx1 construct after formation of FLUAV vRNPs 
still resulted in disruption of the PB2-NP interaction, and consequently resulted in the 
inhibition of FLUAV replication63. 
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Unlike mouse Mx1, human MxA is located in the cytoplasm, thus it can inhibit both viruses 
that replicate in the cytoplasm and those that replicate in the nucleus (antiviral profile of 
MxA reviewed by Verhelst et al. and Haller et al.11,64). Inhibition of influenza A virus 
infection by MxA was initially thought to occur after primary viral transcription, but before 
viral proteins are expressed55,65. However, Xiao et al. showed in in vitro studies that MxA – 
in cooperation with interferon-induced transmembrane 3 (IFITM3) protein – retains viral 
genomic RNA in the cytoplasm near the late endosome66. If only MxA is present, which was 
accomplished by the use of a stably transformed cell line that constitutively expresses MxA, 
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genome is not replicated66. So it is tempting to hypothesize that human MxA only prevents 
nuclear import of newly synthesized vRNP components, but until today this has not been 
confirmed. Interestingly, fusion of MxA with an NLS showed that the working mechanism of 
MxA is similar to that of murine Mx1 in the nucleus52,67. Here, it was also postulated that 
MxA interacts with PB2 and NP, like murine Mx1. This was concluded based on two 
findings, first, overexpression of PB2 or NP could counteract the inhibition by nuclear MxA. 
Second, NP co-immunoprecipitates with nuclear MxA and wild type MxA, albeit after the 
used cell lysates were treated with a reversible cross-linking reagent prior to 
immunoprecipitation67. Considering this, another hypothesis can come to mind wherein 
human MxA can inhibit influenza A virus by recognizing the incoming vRNPs and form 
oligomeric rings around them at the cytoplasmic side of the nuclear membrane, and mouse 
Mx1 could do the same at the nuclear side of the membrane. This would mean that Mx 
proteins in influenza A virus infected cells act as some kind of gatekeepers to the nucleus11. 
2.4.2 Thogoto virus 
Thogoto virus is very sensitive to Mx1 and MxA activity68,69. The exact mechanism of THOV 
inhibition by mouse Mx1 has not been studied in detail. However, fusion of an NLS to 
human MxA blocks the THOV polymerase activity in the nucleus by interacting with the 
assembled vRNPs70. Given the fact that mouse Mx1 and the nuclear form of MxA show a 
similar working mechanism for the inhibition of FLUAV, and that FLUAV and THOV show a 
lot of similarities in their replication cycles, it is conceivable that mouse Mx1 inhibits the 
primary transcription of THOV in the same way it does for FLUAV. 
 
MxA can block the transport of THOV vRNPs to the nucleus by interacting with the NP 
components of the vRNPs, and so covering the NLSs of the vRNPs71. The region of MxA that 
interacts with NP is located at the carboxy-terminal domain which contains loop L434,71. 
This was demonstrated through preventing the interaction between MxA and NP by adding 
Figure 2.5 Mechanism of polymer constriction by dynamin or MxA rings. (a) Schematic representation of 
the process of shear force output in the GTP hydrolysis cycle. (b) GTPase domains interact randomly, and 
subsequent GTP hydrolysis induces power strokes which drives conformational changes in the MxA/dynamin 
molecule. These conformational changes cause the movement of the MxA/dynamin polymers in the opposite 
direction, hereby constricting the vRNP or the membranes of the budding vesicle respectively. Two 
neighboring rings are represented as two linear oligomers. Opposing molecules from upper and lower 
oligomers are numbered 1-4 and A-D, respectively. (I) GTP-binding shifts the GD from a closed to an open 
conformation. In this conformation, GDs from molecules 4 and A associate with each other. (II) GTP hydrolysis 
induces the GDs of molecules 4 and A to return to the closed conformation. This so-called power stroke 
generates a latitudinal shear force. (III) This shear force promotes the relative moving of the neighboring 
rings in opposite directions. GDs are reloaded with GTP, and again may randomly form contact with GDs from 
the neighboring ring. The whole process is constantly repeated, generating a continuous shear force and 
consequently movement of the neighboring rings. GD = GTPase domain, BSE = bundle signaling element. 
Figure adapted from Chen et al., 2017, Nature Communications. 
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the monoclonal 2C12 antibody who’s epitope is located at the carboxy-terminal end of 
MxA68. Loop L4 is necessary for the interaction between MxA and NP, and by extension for 
the antiviral activity against THOV and FLUAV. Especially the phenylalanine residue at 
position 561 in this loop is essential for the antiviral activity of human MxA against THOV 
and FLUAV34. 
2.5 MxB: The new kid on the block 
Until recently it was thought that the human MxB protein had no antiviral role, and that it 
was solely involved in cell cycle progression72. However, this was refuted concomitantly by 
two research groups. Their work was based on the finding that type I IFN treatment can 
reduce human immunodeficiency virus type 1 (HIV-1) infection in cultured human cells and 
cell lines73,74. Transcriptional profiling of RNA isolated from these treated cells revealed 
several candidate interferon-stimulated genes (ISGs) that suppressed HIV-1 infection. After 
testing these candidate genes in vitro, only the human MxB exhibited a clear antiviral 
phenotype against HIV-1 infection75,76. These results were backed up by studies where the 
antiviral properties of several ISGs were assessed, proving that MxB displayed antiviral 
activity against vesicular stomatitis virus, mouse herpes virus type 68, and HIV-177-79. 
Further research demonstrated that human MxB blocks nuclear uptake of HIV-1 viral 
replication complexes75,76. It most likely does this by inhibiting the uncoating process of 
HIV-1, and hereby ‘trapping’ the proviral DNA in the virus core after reverse transcription 
occurred80. Thereby, chromosomal integration – a key event of the HIV-1 replication cycle – 
is inhibited. Inhibition of the uncoating process is mediated by binding of MxB to the capsid 
protein of HIV-1, which was readily indentified as the specific target and restriction factor 
for the antiviral activity of MxB75,76,79,81. The amino-terminal region of MxB was shown to be 
responsible for binding the capsid protein76,82-86. More precisely, a triple-arginine motif 
within the amino-terminal region (at positions 11 to 13) is essential for HIV-1 capsid-
binding, and by extension for anti-HIV-1 function83,86. This explains why the shorter isoform 
of MxB, which lacks the first 25 residues of the amino-terminal domain (including the 
triple-arginine motif), does not affect HIV-1 infectivity76,84. In addition to the amino-
terminal domain, there is one other factor which is very important to ensure antiviral 
activity of the MxB protein. Oligomerization87, and more specific dimerization, seemed 
indispensable for robust inhibition of HIV-1 infection82,83,88,89. However, Alvarez et al. 
recently studied MxB oligomerization in detail by using cryo-electron microscopy and a 
fusion protein of maltose binding protein and MxB. Their data suggest that nonhelical MxB 
oligomers greater than a dimer are the active anti-HIV-1 species, and that a newly 
discovered oligomerization interface is crucial for MxB oligomerization, and consequently 
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Clinical data were gathered that suggest an important role for the MxB protein in the 
resistance against HIV-1 infections. The human MX2 gene is represented by two different 
haplotypes in Asian and European populations. The G allele of haplotype rs2074560(G/A) is 
enriched in a cohort of individuals who were protected from HIV-1 infection after repeated 
exposure to the virus91. On the other hand, naturally occurring capsid variants can render 
HIV-1 resistant to the effects of MxB. Knowing this, it is quite alarming that these variants 
are most frequently found in clade C of HIV-1, which is the most rapidly expanding clade 
throughout the world92. 
 
Recently, also herpes viruses were shown to be sensitive to MxB activity. This viral 
restriction shows similarities with the anti-HIV-1 activity of MxB in that only the long 
isoform of MxB is able to inhibit herpes viruses, indicating that the amino-terminal domain 
is a key determinant for antiviral activity. Oligomerization is, like in HIV-1 restriction, also 
important for the inhibition of herpes virus infection. In contrast to its anti-HIV-1 activity, 
MxB seemed to require a functional GTPase domain for its anti-herpes virus activity93. 
2.6 Known role for Mx1 protein in the immune cell compartment 
The role of the Mx1 protein in the immune cell compartment is poorly characterized. For a 
start, almost all immunological studies in life science research labs are performed in inbred 
mouse strains that lack a functional Mx1 gene. However, there were some studies on the 
possible role of Mx1 in immune cells for viral resistance. Haller and coworkers showed that 
athymic (nude) mice, carrying a functional Mx1 gene, survived intracerebral infection with a 
neurotropic influenza A virus strain, leading them to conclude that mice that carry a 
functional Mx1 gene do not require a functional T cell system or an orderly development of 
neutralizing antibodies to survive a primary infection with influenza A virus94. Suppression 
of the immune system with either cyclophosphamide, methotrexate, or procarbazine 
showed no effect on the resistance of Mx1-bearing mice against the highly pathogenic 
hepatotropic influenza A virus strain TURH (derived from the avian influenza A virus strain 
A/Turkey/England/63)95. Some years later, the same lab demonstrated that in vivo 
resistance to a macrophage-adapted influenza A virus was largely independent of whether 
or not the mice’s macrophages carried a functional Mx1 gene96. These studies led to the 
assumption that Mx1-expression in immune cells does not play a major role in the 
resistance against influenza virus infection. However, several studies have reported 
different, sometimes contradictory, findings about the ability of influenza viruses to infect 
different immune cell types and the formation of a type I IFN-dependent antiviral state in 
these cells. Moltedo and colleagues state that migratory CD103+ dendritic cells (DCs) can be 
infected and carry infectious virus from lungs to the mediastinal lymph nodes. This is 
possible because of an attenuated interferon α/β receptor (IFNAR)-response97. Another 
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study, however, claims that CD103+ DCs are not productively infected. This study shows 
that CD103+ DCs are resistant to influenza virus infections by acquiring an antiviral state, 
which is induced by type I IFN signalization98. In this respect, Wakim et al. showed that lung 
resident memory CD8+ T cells express elevated levels of the interferon-induced 
transmembrane protein 3 (IFITM3), which also displays antiviral activity. This elevates the 
resistance of these cells against influenza virus infection99. So it seems that interferon 
signaling and interferon-induced proteins play a major role in determining whether certain 
immune cell types are susceptible or resistant to influenza virus infection. However, lung 
macrophages block seasonal influenza virus and do not allow productive replication, but 
this block is supposedly not dependent on interferon-induced proteins such as IFITM3 or 
Mx1 because they affect other steps in the replication cycle than the ones where the 
blockages in macrophages were observed100. Nevertheless, all these studies have been 
performed in mice or cells that do not express a functional form of the Mx1 protein, which is 
a powerful antiviral mediator. So one could argue that completely ignoring a role for Mx1 in 
immune cells, based on these studies, would be putting things too bluntly. 
2.7 Interferon-stimulated genes and their anti-influenza A virus activity 
Next to Mx proteins, the variety of interferon-stimulated gene products with antiviral 
activities is ample. Here, a brief overview is given of the interferon-stimulated genes (ISGs) 
with known anti-influenza activity. 
2.7.1 OAS/RNaseL system 
The oligoadenylate synthetase (OAS)/RNaseL system was discovered in the late 1970s101. 
The activity of RNaseL is dependent on IFN, and it is correlated with the synthesis of 2’-5’ 
oligoadenylates (2-5A) by OAS. This synthesis is triggered by binding of double-stranded 
RNA (dsRNA) to OAS, which then converts ATP to 2-5A. These 2-5A are short 
oligoadenylates linked by 2’, 5’-phosphodiester bonds, and their only function known today 
is the activation of RNaseL102. RNaseL is a latent endoribonuclease which cleaves viral and 
cellular mRNA. RNaseL is activated by forming homodimers, this dimerization is triggered 
by 2-5A. Activated RNaseL cleaves viral and cellular single-stranded RNA (ssRNA), which is 
a threat for RNA viruses such as FLUAV103. However, FLUAV is not strongly affected by the 
RNaseL activity. This is because FLUAV produces the NS1 protein which binds to dsRNA, 
and isolates it from OAS. Therefore, OAS activation and subsequent RNaseL activation is 
prevented104. 
2.7.2 Double-stranded RNA-activated protein kinase 
Double-stranded RNA-activated protein kinase (PKR) (or eukaryotic translation initiation 
factor 2-alpha kinase (IEF2AK2)) is a known inhibitor of cellular and viral mRNA 
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conditions it resides in the cytoplasm as an inactive monomer105. Upon binding of dsRNA it 
forms homodimers and performs autophosphorylation which stabilizes the now active 
dimeric enzyme106,107. Activated PKR catalyzes the phosphorylation of the alpha subunit of 
eukaryotic initiation factor 2 (eIF2α) which, in turn, inhibits mRNA translation. In this way 
it hampers the cellular and viral protein synthesis. As with RNaseL, FLUAV has a way to 
circumvent the inhibitory effects of PKR by means of its NS1 protein. The sequestration of 
dsRNA by NS1 also prevents PKR from getting activated. Additionally, NS1 can form a 
complex with PKR and in this way directly inhibit the enzyme108. 
2.7.3 Cholesterol-25-hydroxylase 
Cholesterol-25-hydroxylase (CH25H) is an enzyme that converts cholesterol into 25-
hydroxycholesterol (25HC), and whose expression is upregulated in response to type I and 
II IFN109-111. 25HC, the product of CH25H-activity, protects cells against viral infection by 
inducing changes in the physical properties of host cell membranes. High 25HC 
concentrations prevent fusion of virus and host membranes, and consequently prevent 
virus entry112. Therefore, it is no surprise that enveloped viruses – including influenza A 
virus – are sensitive to the antiviral activity of 25HC112,113. 
2.7.4 TRIM proteins 
The tripartite motif (TRIM) protein family contains more than 60 members with a wide 
range of activities. The best known TRIM protein probably is TRIM5α, which has an anti-
HIV-1 activity. TRIM5α accelerates the uncoating process of the HIV-1 virion by direct 
binding to the viral capsid proteins, hereby prematurely exposing the HIV-1 nucleoprotein 
complex114. Next to TRIM5α, the TRIM protein family has other members with antiviral 
activities. Of interest is the TRIM22 protein, which also plays a role in the restriction of HIV-
1 virus infection115 and, in addition, inhibits hepatitis B virus116, encephalomyocarditis 
virus117, and influenza A virus infection118. TRIM22 restricts influenza A virus infection by 
targeting the virus nucleoprotein for proteasomal degradation. 
2.7.5 IFITM proteins 
Interferon-induced transmembrane (IFITM) proteins were first described based on their 
expression after IFN treatment of cells119. Humans express four different IFITM proteins, 
IFITM1, -2, -3 and -5, whereas mice express two additional IFITM proteins, IFITM6 and -
7120. IFITM1 to -3 are nearly ubiquitously expressed throughout all cell types. IFITM5 
however, is solely expressed in osteoblasts where it has a role in bone mineralization121,122. 
Members of the IFITM protein family inhibit FLUAV, HIV-1, hepatitis C virus (HCV), 
respiratory syncytial virus (RSV), severe acute respiratory syndrome (SARS) coronavirus, 
and members of the Flavi-, Filo-, Rhabdo-, Bunya-, and Reoviruses (reviewed by Bailey et 
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al.120). Regarding influenza A virus infection, IFITM3 shows the most potent antiviral 
effect123. 
2.7.5.1 IFITM3 
Next to Mx1/MxA, IFITM3 is also a major contributor to the resistance against influenza A 
virus infections123,124. Xiao and colleagues observed an additive antiviral effect when both 
proteins were coexpressed in FLUAV-infected cells66. Moreover, it was postulated that MxA 
cannot fully compensate for the loss of IFITM3 in IFN-treated cells challenged with 
influenza A virus125. A possible explanation might be the evolution of human influenza 
strains to evade the effects of MxA47,58, rendering the cell reliant on an additional antiviral 
protein/mechanism, in this case IFITM3. The importance of IFITM3 became clear when 
Everitt et al. assessed the IFITM3 alleles of patients hospitalized with seasonal or pandemic 
H1N1/09 influenza A virus infections123. They found an enrichment of a minor IFITM3 allele 
(SNP rs12252-C) with an altered splice acceptor site. This alteration may be associated with 
a splice variant of IFITM3 lacking the first 21 amino-terminal residues due to use of an 
alternative start codon. This minority variant of IFITM3 was less well expressed, and made 
cells more susceptible to influenza virus infection in vitro. However, Kim et al. recently 
observed a higher prevalence of the C-allele of the rs12252 SNP in a Korean cohort, but this 
was not coupled to a higher prevalence of severe disease and death in this cohort. This 
suggests that this SNP in the IFITM3 gene may not be a determinant of disease severity of 
FLUAV infection after all126. Nevertheless, another SNP (rs34481144) was recently 
discovered in the 5’ untranslated region of the IFITM3 gene. The A allele is correlated with 
severe influenza infections as shown in three independent cohorts. This so-called risk allele 
disrupts a CpG site which undergoes differential methylation in CD8+ T cell subsets which 
leads to reduced levels of CD8+ T cells in the airways after FLUAV infection127. 
 
IFITM3 resides in the membranes of late endosomes and lysosomes, where it prevents 
fusion between virus and host membranes. By this, it traps viruses in an environment 
which will ultimately destroy them due to its degradative properties125. Thus, IFITM3 
allows viruses to be taken up in endosomes, but inhibits the viral fusion and subsequent 
release of viral contents into the cytosol125,128,129. Since IFITM3 only resides in late 
endosomes, viruses which fuse with early endosomal membranes might be insensitive to 
IFITM3 activity125. Furthermore, recent work by Gerlach and coworkers revealed that 
influenza A viruses with a higher pH optimum for fusion are more resistant to IFITM3130. 
This is not unexpected, seeing that the pH in early endosomes is higher than the pH in late 
endosomes. In contrast, Weston et al. recently observed that IFITM3 proteins mainly reside 
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infection131. These are alphaviruses known to enter the cell cytoplasm by membrane fusion 
with early endosomes rather than late endosomes. 
 
The role of IFITM3 as an innate component of the antiviral immune response was expanded 
when Wakim et al. suggested a role for IFITM3 in the immune cell compartment99. After 
challenging mice with a sublethal dose of influenza A virus, lung-resident memory CD8+ T 
cells retained a high expression of the IFITM3 protein. Due to hypomethylation of the 
IFITM3 promoter in these cells, they selectively retain IFITM3 expression and are therefore 
better protected against infection with FLUAV and other viruses. Recently, a comparable 
observation was reported in human subjects where memory CD8+ T cells also retain IFITM3 
expression after FLUAV infection. However, this was caused by a hypermethylation of the 
IFITM3 promoter instead of a hypomethylation127. Thus, IFITM3 fulfills an important 
prophylactic function in the immune cell compartment by providing (lung resident) 
memory CD8+ T cells with greater resistance to viruses. One could be tempted to argue that 
other ISGs might have similar functions within the immune cell compartment. 
2.7.6 ISG15 
ISG15 is a ubiquitin-like protein which can be covalently attached to several target proteins 
in a process called ISGylation132. ISGylation has different effects depending on the targeted 
protein, e.g. the stability of an ISGylated protein can either be increased or decreased133,134, 
or its affinity to its target can be enhanced135. It has been shown that ISG15 is preferentially 
conjugated to newly synthesized proteins, and this might be a general, nonspecific 
mechanism of host defense. By this, ISG15 potentially has an impact on all viral proteins 
translated in IFN-stimulated cells136. This is also the case for FLUAV proteins, as observed 
for the NS1 protein137,138. According to these observations, it is not unexpected that ISG15-/- 
mice are more susceptible to FLUAV infections139,140. 
2.7.7 Viperin 
Viperin (or radical S-adenosyl methionine (SAM) domain-containing 2 (RSAD2)) is a virus 
inhibitory protein which normally resides in the endoplasmic reticulum (ER) and ER-
derived lipid droplets. Viperin inhibits an array of enveloped viruses by inhibiting the 
enzyme farnesyl diphosphate synthase (FPPS), an enzyme involved in the isoprenoid 
synthesis. The decrease in FPPS activity alters the fluidity of host cell membranes, and as 
such hampers the budding of FLUAV by perturbing the lipid rafts where FLUAV budding 
occurs141. However, in contrast with these observations, Rsad2-/- and wild type mice 
challenged with FLUAV reacted similarly regarding mortality, lung pathology, and viral 
titers142. 
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Tetherin (or bone marrow stromal antigen 2 (BST2)) also shows antiviral activity against a 
number of enveloped viruses. More specifically, tetherin inhibits virus budding. It was 
shown to inhibit budding of FLUAV virus-like particles (VLPs)143,144, but the ability to inhibit 
budding of infectious virus is rather doubtful143,145,146. In contradiction with these 
observations, the influenza NA protein antagonizes tetherin partially through an unknown 
mechanism146, which would suggest that during the evolution of FLUAV a mechanism was 
created to oppose the activity of tetherin. 
2.7.9 ZBP1 
Z-DNA binding protein 1 (ZBP1 or DNA-dependent activator of IFN regulatory factors 
(DAI)) is a common upstream regulator of the NOD-like receptor family pyrin domain 
containing 3 protein (NLRP3) inflammasome and various programmed cell death pathways 
during influenza virus infection147-149. Influenza infection triggers a type I IFN response 
which induces the production of ZBP1 in an IFNAR1-, STAT1- and IRF9-dependent 
manner147. ZBP1 then interacts with receptor-interacting serine/threonine-protein kinase 3 
(RIPK3), and this ZBP1-RIPK3 complex is responsible for the activation of the NLRP3 
inflammasome. This inflammasome is a multiprotein complex consisting of NLRP3, adaptor 
protein apoptosis-associated speck-like protein containing a CARD domain (ASC) and a 
cysteine protease called caspase-1. Inflammasome assembly activates caspase-1 which, in 
turn, will mediate processing of the proinflammatory cytokines IL-1β and IL-18. Active 
caspase-1 can also induce an inflammatory form of cell death called pyroptosis which is 
executed via its substrate gasdermin D (reviewed by Kuriakose et al.150). How ZBP1 is 
activated is still a heavily debated topic. Kuriakose and colleagues showed that ZBP1 can 
interact with the FLUAV proteins PB1 and NP, and they concluded that ZBP1 is a sensor of 
IAV proteins that can trigger both cell death and inflammatory responses during influenza 
virus infection147. In contrast, Thapa et al. reported that ZBP1 senses FLUAV RNA instead of 
FLUAV proteins148. The latter was consolidated by Maelfait et al. whose data, which were 
gathered with a different infection model, strongly suggest that ZBP1 is an RNA sensor151. 
However, Kesavardhana and coworkers recently reported that both FLUAV proteins PB1 
and NP, and the FLUAV RNA genome are interacting partners of ZBP1 during FLUAV 
infection152. Conceivably, ZBP1 mainly senses viral RNA in the vRNPs, and binds indirectly 
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Annual influenza vaccination is an effective way to prevent human influenza. Current 
vaccines are mainly focused on eliciting a strain-matched humoral immune response, 
requiring yearly updates, and do not provide protection for all vaccinated individuals. The 
past few years, the importance of cellular immunity, and especially memory T cells, in long-
lived protection against influenza virus has become clear. To overcome the shortcomings of 
current influenza vaccines, eliciting both humoral and cellular immunity is imperative. 
Today, several new vaccines such as infection-permissive and recombinant T cell inducing 
vaccines, are being developed and show promising results. These vaccines will allow us to 
stay several steps ahead of the constantly evolving influenza virus. 
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Influenza virus infection induces a profound humoral and cellular immune response in the 
host. Serum IgG antibodies that are directed to influenza virus hemagglutinin (HA) and 
neuraminidase (NA) glycoproteins correlate with protective immunity1,2. Influenza viruses 
evade this humoral response by a process named “antigenic drift”. This phenomenon is 
driven by the relatively high frequency of misincorporated nucleotides into the genomes of 
the viral progeny by the viral RNA-dependent RNA polymerase complex3. Immune pressure 
exerted by antibodies that inhibit HA or NA function can lead to the selection of viruses 
from this diverse genetic pool that can escape humoral immunity. Cellular immunity on the 
other hand is mainly directed against more conserved internal influenza viral proteins such 
as the nucleoprotein (NP)4. Within this arm of the adaptive immune system, CD8+ T cells are 
very important for virus clearance, and are able to provide heterosubtypic immunity5. The 
importance of CD8+ T cell immunity in the host control of influenza virus infection is 
illustrated by the higher incidence of mutations in the T cell epitope regions of e.g., NP 
compared to the rest of the protein, which indicates that these epitopes are under selective 
pressure6,7. 
 
Annual vaccination is considered the most effective way to prevent disease caused by 
influenza A and B virus infection8. In many countries this practice is recommended for all 
persons older than six months who do not have contraindications, and especially for elderly 
people, immunocompromised persons and children9. The virus strains that are included in 
these vaccines are recommended by an expert panel of the World Health Organization 
(WHO) that bases its predictions on influenza surveillance data (Global Influenza 
Surveillance and Response System). 
 
Most of the current licensed influenza vaccines are tri-(TIV) or quadrivalent (QIV) 
inactivated formulations that contain 15 μg each of the hemagglutinin glycoprotein of two 
influenza A strains (H1N1 and H3N2) and one or two influenza B strains (Yamagata and 
Victoria lineage). Inactivated influenza vaccines are administered by intramuscular 
injection or, less frequently, by intradermal injection. Mostly, these types of vaccines are 
derived from viruses grown in fertilized chicken eggs. However, it is worth mentioning 
Flucelvax®, which is an FDA approved TIV that is manufactured using mammalian cell 
culture technology10. Alternatively, a live-attenuated influenza vaccine (LAIV) that is 
administered intranasally is available in the USA and some European countries. This 
vaccine is licensed for use in healthy individuals aged 2–49 years9. This vaccine is produced 
by reassortment of the selected influenza virus strain with the cold-adapted A/Ann 
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nasal cavity), but very poorly at higher temperatures in the human body (such as the lower 
respiratory tract)11. In the United States, the effectiveness of LAIV in comparison to 
inactivated vaccines was quite low in subjects aged 2–17 years during influenza seasons 
2013–2014 and 2015–2016, especially against influenza A/H1N1pdm0912,13. Therefore, the 
CDC’s Advisory Committee on Immunization Practices (ACIP) decided not to recommend 
LAIV for use during the 2016–2017 influenza season14. Flublok® is a third type of human 
influenza vaccines. This vaccine is a trivalent, seasonal influenza vaccine consisting of three 
full-length recombinant hemagglutinin influenza virus proteins. The vaccine is produced in 
an insect cell line derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda. Each 
of the three HAs is expressed using a viral vector (baculovirus Autographa californica 
Nuclear Polyhedrosis Virus) that is non-pathogenic for humans. 
 
However, these vaccines do not elicit a strong heterosubtypic immune response, since the 
majority of the vaccine-induced antibodies fail to cross-react with hetero(sub)typic HA and 
NA, and if cross-reactive T cell responses are induced, these responses are much lower than 
the homologous T cell response15,16. It was shown that there were no increases in the mean 
levels of influenza A virus-reactive IFN-γ+ T cells and NK cells in adults given either LAIV or 
TIV while LAIV did have a positive effect on influenza A virus-specific IFN-γ+ CD4+ and CD8+ 
T cells in children aged 5–9 years17. Additionally, TIV treatment had a significant effect in 6-
month to 4-year-old children on the level of influenza A virus-reactive T cells; LAIV was not 
evaluated in this age group. This indicates that the efficacy of inducing a cellular immune 
response of currently used vaccines is highly dependent on age, type of vaccine, and 
prevaccination levels of immune reactivity to influenza A virus17. In young children, who 
are often immunologically naïve to influenza virus, inactivated vaccines may even hamper 
the induction of cell-mediated immunity that would be otherwise induced by natural 
(disease causing) infections18. Hence, the big challenge in influenza vaccine development 
remains the induction of broadly neutralizing antibodies and long-lasting heterosubtypic 
cellular immune responses. 
3.2 Immune response to influenza virus infection 
3.2.1 Innate immunity 
3.2.1.1 Extracellular barriers to overcome 
Before it can infect respiratory epithelial cells, the influenza virus has to cross or 
circumvent two main barriers. The first barrier is the mucus layer that lines the respiratory 
tract. This layer forms a physical barrier consisting of a mixture of cells, cellular debris and 
polypeptides, held together by macromolecular constituents called mucins. Mucins are a 
family of glycoproteins that are secreted or remain membrane associated. They are heavily 
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glycosylated, and the terminal sialic acid residues of these glycans are linked to galactose. It 
has been shown that upon viral infection of the respiratory tract, the production of mucus 
in the epithelial surfaces of the respiratory tract increases19,20. To cross this mucus layer, 
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The second barrier consists of proteins that bind to specific carbohydrate structures, so-
called lectins. In the lung, the two main lectins involved in anti-influenza activity are 
surfactant proteins A (SP-A) and D (SP-D). These lectins hamper influenza virus infection by 
different mechanisms. SP-A is sialylated and therefore acts as a decoy receptor for influenza 
virus (γ-inhibition)22, while SP-D binds mannose-rich oligosaccharides on influenza virus 
HA and NA proteins (β-inhibition) (Figure 3.1)23. 
3.2.1.2 Sensing of influenza virus infection 
Once influenza virions have crossed the mucin- and lectin-rich layer that lines the 
respiratory tract, they reach respiratory epithelial cells. After recognition of the sialic acid-
containing host cell receptors by the HA glycoprotein, endocytosis of the influenza virus is 
triggered and the virion particle ends up in the early endosomes. The passage in the 
endosomes allows entry of protons and at a later stage potassium ions into the virions 
which primes them for genome delivery. Matrix protein 2 (M2) fulfills an important 
function in this process24. The interior pH of the endosome becomes acidic, which induces a 
conformational change in the HA protein. This leads to the insertion of the fusion peptide of 
HA into the host membrane, and formation of a fusion pore. This pore allows the release of 
the genomic RNA segments of the influenza virus into the cytosol25. 
 
The two major pattern recognition receptors (PRRs) that are responsible for the 
cytoplasmic sensing of influenza virus infection are retinoic acid inducible gene-I (RIG-I) 
and NOD-like receptor family pyrin domain containing 3 (NLRP3) protein (Figure 3.1)26,27. 
Figure 3.1 Innate immunity against influenza virus infection. (a) The first barrier that the influenza virus 
has to overcome, is the mucus layer that lines the respiratory tract. To cross this barrier, influenza viruses rely 
on the enzymatic activity of the neuraminidase glycoprotein; (b) The second barrier consists of carbohydrate-
binding proteins called lectins. Surfactant proteins A (SP-A) and D (SP-D) are the main two lectins involved in 
anti-influenza activity. SP-A acts as a decoy receptor for influenza virus, and SP-D binds to oligosaccharides on 
influenza hemagglutinin (HA) and neuraminidase (NA) proteins; (c) Once influenza virions have reached 
respiratory epithelial cells they recognize sialic acid-containing host cell receptors by the HA glycoprotein. This 
is followed by endocytosis of the influenza virus and the virion particle ends up in the early endosomes. After 
acidification of the endosome and subsequent membrane fusion, the genomic RNA segments of the influenza 
virus are released into the cytosol. The two major PRRs that are responsible for the cytoplasmic sensing of 
influenza virus infection are retinoic acid inducible gene-I (RIG-I) and NOD-like receptor family pyrin domain 
containing 3 (NLRP3) protein. Activation of RIG-I—by interaction with 5′ triphosphorylated RNA (5′ ppp-
RNA)—results in the production of proinflammatory cytokines and type I interferons (IFNs), which in turn 
induce the expression of interferon-stimulated genes (ISGs). NLRP3 is a part of the NLRP3 inflammasome, which 
becomes activated by the proton gating activity of influenza A virus M2. An additional way to activate the NLRP3 
inflammasome is through the interferon-stimulated gene Z-DNA binding protein 1 (ZBP1). ZBP1 interacts with 
receptor-interacting serine/threonine-protein kinase 3 (RIPK3), and this ZBP1-RIPK3 complex is responsible for 
the activation of the NLRP3 inflammasome (cfr. Paragraph 2.7.9). This leads to the conversion of pro-IL-1β to IL-
1β, which is a proinflammatory cytokine that is involved in the induction of Th17 cells and the expansion of CD4+ 
T cells. Active caspase-1 can also induce an inflammatory form of cell death called pyroptosis. 
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Activation of RIG-I by interaction with 5′ triphosphorylated RNA, results in the production 
of proinflammatory cytokines and type I interferons (IFNs), which in turn induce the 
expression of interferon-stimulated genes (ISGs) via the JAK/STAT signaling pathway28. 
One of the most important antiviral ISGs is the myxovirus (Mx) gene, which encodes the MxA 
and Mx1 protein in human and mouse, respectively. Mx proteins are dynamin-like GTPases 
with strong and broad antiviral activity29. Type I IFNs also modulate the adaptive immune 
response: they form a bridge between innate and adaptive immunity by stimulating 
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cells30. NLRP3 is a part of the NLRP3 inflammasome, which becomes activated by the 
proton gating activity of influenza A virus M231. This leads to the activation of caspase-1 and 
conversion of pro-IL-1β to IL-1β, which is a proinflammatory cytokine that is involved in 
the induction of T helper 17 cells and the expansion of CD4+ T cells32,33. 
3.2.1.3 Alveolar macrophages 
Alveolar macrophages (AMs) reside in the alveolar lumen and are considered the first 
immune cell type to encounter respiratory pathogens. When activated, AMs phagocytose 
virus particles and (apoptotic) infected cells, and consequently limit viral spread34,35. 
Activated alveolar macrophages also produce nitric oxide synthase 2 (NOS2) and tumor 
necrosis factor (TNF), by which they also contribute to lung pathology upon influenza virus 
infection (Figure 3.2)36,37. In addition, AMs regulate the adaptive immune responses. 
Depletion of AMs prior to influenza virus infection increases the primary cytotoxic T cell 
response in mice38. In pigs, conversely, depletion of AMs prior to influenza virus infection 
reduces the antibody titers and the number of virus-specific cytotoxic T cells. This effect 
was probably caused by an alteration of the expression pattern of inflammatory cytokines, 
since pro-inflammatory cytokines TNF and IFNγ are downregulated in the lung in contrast 
to the anti-inflammatory cytokine IL-10, which is upregulated in these animals after AM-
depletion and subsequent influenza virus infection34. The downregulation of pro-
inflammatory cytokines is also observed in mice infected with a reassorted H1N1 virus 
containing the 1918 Spanish flu HA and NA after AM-depletion35. AMs are very important 
for certain adaptive immune responses against influenza viruses. For instance, our group 
previously showed that AMs are essential for protection by anti-M2e IgG39. 
 
 
Figure 3.2 Adaptive immunity against influenza virus infection. (a) Alveolar macrophages (AMs) reside in 
the alveolar lumen and are considered the first immune cell type to encounter respiratory pathogens. 
Activated AMs produce nitric oxide synthase 2 (NOS2) and tumor necrosis factor (TNF), by which they also 
contribute to lung pathology upon influenza virus infection; (b) Dendritic cells (DCs) are professional antigen-
presenting cells (APCs). The conventional DCs (cDCs), which are located underneath the airway epithelium 
barrier and above the basal membrane, continuously monitor the airway lumen with their dendrites. Once the 
cDCs acquired viral antigen, they migrate to the draining lymph nodes (DLNs) via a CCL19 and CCL21 
chemokine gradient along the afferent lymphatic system. In the LNs, DCs present processed antigen to naïve T 
cells. The DC degrades viral proteins, and the resulting peptides (antigens) are presented by MHC class I or II 
proteins for specific CD8+ and CD4+ T cells respectively. The T cells that are specific for the antigen become 
activated and expand clonally. The newly activated T cells begin to acquire effector functions, and migrate 
from the LNs to the site of infection; (c) CD8+ T cells can kill infected respiratory epithelial cells, and, by this, 
clear the virus from the lungs. This is done by exocytosis of granules that contain perforins and granzymes. 
CD4+ T cells on the other hand mainly provide help to other immune cells, and regulate the immune response 
by producing a vast array of cytokines. 
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3.2.1.4 Dendritic cells 
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) which form an 
important link between the innate and adaptive immune systems. DCs can be considered 
the sentinels of the vertebrate immune system at body surfaces. In the lung, DCs perform 
multiple tasks, such as recognition and acquisition of antigens derived from pathogens and 
allergens, antigen transportation to the draining lymph nodes and induction of CD4+ and 
CD8+ T cell immunity40. The conventional DCs (cDCs) are located underneath the airway 
epithelium barrier and above the basal membrane. They continuously monitor the airway 
lumen with their dendrites, which they can extend into the airway lumen through the tight 
junctions of the epithelial cell layer41. During an infection, DCs will initiate the adaptive 
immune response by presenting viral antigens to B and T lymphocytes in the draining 
lymph nodes (DLNs)42,43. 
3.2.1.5 Natural killer cells 
Natural killer cells (NKs) are cytotoxic effector cells of the innate immune system. They can 
lyse influenza virus-infected cells following direct or indirect recognition of such target 
cells. The natural propensity of the cytotoxicity receptors NKp44 and NKp46 to recognize 
HA on the surface of infected cells contributes to a direct elimination of such cells44,45. 
Indirect recognition and subsequent lysis of infected cells by NKs is mediated by immune 
complexes at the surface of IgG-opsonized influenza virus-infected cells in a process called 
antibody-dependent cell cytotoxicity (ADCC)46. 
3.2.2 Adaptive immunity 
3.2.2.1 Activation of antigen-presenting cells 
DCs can be considered the most important APCs in the lungs. In the steady state lung, 
several distinct DC subsets are present. These subsets differ in phenotype, anatomic 
location, and function. The CD103+ and the CD11bhi DC subsets, located intraepithelial and 
submucosal/interstitial, respectively, are the main DC populations in the lungs and are 
collectively often referred to as cDCs47. 
 
After activation, respiratory cDCs have to acquire antigen derived from influenza virus for 
delivery to the DLN. The acquisition of antigen by DCs occurs via several mechanisms 
(Figure 3.2). The most likely way is by direct infection of the DCs, but different DC subsets 
differ in susceptibility to influenza virus infection48. Such an infection is probably abortive, 
so DCs fail to release infectious virions, but acquire sufficient amounts of viral antigens that 
are processed and uploaded into their MHC-I and -II molecules49. Another mechanism for 
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infected cells that harbor viral antigen. Lastly, antigen-acquisition can also occur through a 
membrane nibbling process, called trogocytosis50-52. 
3.2.2.2 Antigen presentation 
Once the cDCs acquired viral antigen, they migrate to the draining lymph nodes via the 
afferent lymphatic system. This migration occurs along a CCL19 and CCL21 chemokine 
gradient, and is dependent on expression of the chemokine receptor CCR753. Although there 
are other APCs present in the DLN (such as plasmacytoid DCs, monocyte-derived DCs and 
macrophages), cDCs serve as the primary APCs for naïve T cells54. CD103+ DCs are the most 
potent APCs for the activation of cytotoxic T lymphocytes (CTLs) after influenza virus 
infection. These DCs can engulf influenza virus infected cells, and process and present virus 
antigen from these cells to CTLs, a process that is known as cross-presentation. CD103+ DCs 
acquire an antiviral state, which is induced by type I IFN signaling and characterized by the 
elevated mRNA-levels of IFN-inducible genes such as ISG 15, OAS1a, Mx1, Ifitm1, Ifitm3 and 
PKR55. CD103+ DCs represent the first wave of migration and antigen presentation to CTLs. 
Afterwards, influenza virus antigen is replenished by blood-derived CD11bhi DCs that 
migrate to DLNs from the lung56,57. This is thought to serve as a form of amplification loop 
for the generation of CTLs. Both CD103+ and CD11bhi DCs also activate naïve CD4+ T cells 
with equal efficiency58. 
 
Naïve T cells circulate between blood and lymph nodes, where they remain for 12–24 h 
before returning to the blood and visiting the next lymph node. In the LNs, DCs present 
processed antigen to these naïve T cells. The DC degrades viral proteins, and the resulting 
peptides (antigens) are presented by MHC class I or II proteins. MHC class I/antigen 
complexes are presented on the cell membrane for recognition by specific CD8+ cytotoxic T 
cells. MHC class II presentation of the antigen on the cell membrane is recognized by CD4+ T 
helper (Th) cells. The T cells that are specific for the antigen—i.e., the T cells with a 
matching T cell receptor (TCR)—become activated and expand clonally. This expansion is 
extensive, as one naïve T cell can give rise to tens of thousands of progeny T cells59. The 
freshly activated T cells begin to acquire effector functions, such as the ability to produce 
effector cytokines. For activated CD4+ T cells, the cytokine environment is very important to 
differentiate into different effector Th cell types60. 
3.2.2.3 Lymphocyte migration to the infected lung 
In order to migrate from the LNs to peripheral tissues, activated T cells change the 
expression profile of homing molecules. Mature naïve T cells express lymphoid homing 
receptors CD62L and CCR7, which are necessary for migration to secondary LNs61,62. Once 
these T cells are activated after a DC encounter, they migrate to the site of infection. In 
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order to get out of the LNs, downregulation of CD62L and CCR7, and upregulation of other 
receptors is necessary. It has already been shown that different T cell subsets express their 
own specific chemokine receptor repertoire after activation, which allows them to be 
recruited to different peripheral tissues63. Recruitment of activated T cells to the infected 
lung occurs via nonspecific and specific routes. CD11a, which is a subunit of the integrin 
lymphocyte function-associated antigen-1 (LFA-1), is responsible for the nonspecific 
recruitment of activated T cells into the lungs, because this protein is upregulated in 
activated T cells, and its ligand ICAM-1 (Intercellular adhesion molecule-1) is expressed in 
peripheral tissues64. Specific recruitment of activated T cells is more complicated and less 
well understood. Mikhak and colleagues observed that lung DCs are responsible for the 
upregulation of chemokine receptor CCR4 on effector T cells, which allows for selective 
recruitment into the infected lung, where CCL2, CCL3, CCL5, CCL17 and CCL22, the ligands 
of CCR4, are produced65. However, it seems that this is not the case for CD8+ T cells, or at 
least that other mechanisms cannot be excluded. For this T cell population multiple 
recruitment mechanisms are implied to get the cells to the lung interstitium. Galkina and 
colleagues showed that migration of effector CD8+ T cells is promoted by expression of the 
chemokine CCL5 in the lung interstitium66. Slütter et al. on the other hand, have indicated 
that expression of CXCR3 on antigen-specific memory CD8+ T cells, from vaccinated mice, is 
critical for their migration to the airways67. Then again, Lim and coworkers recently 
reported the importance of the chemokine CXCL12 which is mainly produced by 
neutrophils, for virus-specific recruitment of CD8+ T cells and antiviral effector functions68. 
3.2.2.4 Viral clearance 
Once influenza-specific effector T cells have entered the respiratory tract, there is a 
significant impact on viral titers through the expression of cytokines (IFNγ, TNF, IL-4 and 
IL-10) and direct lysis of infected cells. CD8+ cytotoxic T cells mainly contribute to viral 
clearance through the cytotoxic elimination of influenza virus-infected respiratory 
epithelial cells. Such elimination is possible by two mechanisms, i.e. the release of perforins 
and granzymes by the activated T cell or the engagement of tumor necrosis factor (TNF) 
family members on the surface of target cells with their ligands. Both mechanisms result in 
apoptosis of the target cell69. Influenza-specific CD4+ Th cells act directly and indirectly on 
the viral clearance process. Primarily they act indirectly by producing cytokines and helping 
B cells and CD8+ T cells70-72. Th cells can also directly eliminate infected cells, but this 
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3.3 T cell response to influenza virus infection 
3.3.1 Primary T cell response: Deflowering the T cells 
Once infected with influenza virus, the epithelial cells start producing inflammatory 
cytokines. The first cytokines are IFNα, TNF, IL-1α and IL-1β, followed by IL-6, IL-8, 
monocyte chemoattractant proteins (MCPs), and macrophage inflammatory proteins 
(MIPs). Several of these cytokines have a chemotactic function, and thus attract innate 
immune effectors and antigen presenting cells to the site of infection. DCs that got recruited 
this way, take up viral particles and influenza-derived antigens. This triggers DC activation, 
maturation and migration to the draining LNs. 
3.3.1.1 CD4+ T cell primary responses 
Once naïve CD4+ T cells have matured, they traffic from the thymus to the secondary 
lymphoid tissues. Here the influenza-specific CD4+ T cells interact with mature DCs who 
carry viral antigens, and get activated. The activated T cells start proliferating and acquire 
effector functions. Activated CD4+ T cells differentiate to different subsets (Th1, Th2, Th17, 
Tfh, Treg), which can be characterized by their own distinct cytokine pattern. This 
differentiation is primarily promoted by the cytokine environment in which they are 
formed74. T helper (Th) 1 cells mainly produce IFNγ, TNF and IL-2. In contrast, Th2 cells do 
not produce IFNγ, but they do produce large amounts of IL-4, IL-5 and IL-13. The main 
function of Th1 cells is enhancing the pro-inflammatory cellular immunity75,76, while Th2 
cells promote non-inflammatory immune responses and can induce the production of most 
classes of antibodies, mainly IgG1 and IgE77. Influenza virus infection generates both a Th1 
response, where CD4+ T cells produce IFNγ, TNF and IL-271,78, as well as a Th2 response, 
which helps formation of a robust antibody response79. However, following influenza virus 
infection, the CD4+ T cell response is biased toward a Th1 effector response80. 
 
Next to Th1 and Th2 cells, there is a third major CD4+ T cell subpopulation called Th17 
cells81. These cells are characterized by the production of IL-17 and IL-2282. They play an 
important role in the protection against opportunistic bacterial pathogens, such as is seen 
after influenza virus infection. Influenza A virus, however, employs mechanisms that inhibit 
a strong Th17 response, leading to an increased susceptibility to secondary bacterial 
infections83. The direct role of Th17 cells in the immune response against influenza virus is 
not totally clear yet, with studies pointing to both a possible beneficial or detrimental effect 
of a Th17 response. On the one hand, it has been shown that IL-17 can protect mice against 
a lethal infection with influenza A/Puerto Rico/8/34 (H1N1) and A/Alaska/6/77 (H3N2), 
and that it has a critical role in recruiting B cells to the pulmonary site of infection. 
Additionally, the IL-17 response contributes to a better survival percentage after a lethal 
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influenza A/Puerto Rico/8/34 infection84,85. However, other studies indicate that IL-17 and 
the Th17 response may contribute to severe pulmonary immunopathology after influenza 
virus infection81,86, and pre-induction of the Th17 immune response results in an 
exacerbation of lung pathology after influenza virus infection87. However, only the latter 
study by Gopal and coworkers investigated the direct in vivo effect of Th17 cells on lung 
pathology in an influenza virus infection model. The two former studies investigate the 
effect of IL-17 during influenza virus infection, but use a different infection model85,86. The 
remaining studies make use of in vitro differentiated CD4+ and/or CD8+ T cells which 
produce IL-17, but cannot be compared because of the difference in research question and 
models used81,84. 
 
A fourth CD4+ T cell subset comprises the regulatory T cells (Tregs), which contribute to 
homeostasis of the immune system and tolerance to self-antigens. This subset on itself can 
be further subdivided into two groups, natural Tregs (nTregs) that are generated in the 
thymus by MHC-II-dependent T cell receptor (TCR) interactions88, and induced Tregs 
(iTregs) which are generated in the periphery during an immune response89. Influenza 
virus infection generally triggers a robust Treg response, where iTregs suppress antigen-
specific CD4+ and CD8+ T cell proliferation and cytokine production in an antigen-
dependent matter90. 
 
The last CD4+ T cell subset discussed here is made up by the follicular helper T cells (Tfh). 
These cells are paramount in the formation and function of germinal centers, which are 
located in secondary lymphoid organs, and are the primary sites of B cell affinity 
maturation91. Here, the Tfhs play a pivotal role in providing help signals to B cells, which are 
essential for their survival and proliferation. After somatic hypermutation, the highest 
affinity B cells are selected by Tfhs for another round of proliferation and mutation92,93. 
Most human vaccines work on basis of long term protective antibody responses, so Tfhs are 
probably mediators of development of protective immunity by vaccines. In fact, it has 
already been shown that Tfhs are a limiting factor for generating antibody responses after 
immunization94. Learning more about this CD4+ T cell subset might be essential for the 
further improvement of human vaccination. 
3.3.1.2 CD8+ T cell primary responses 
Naïve CD8+ T cells get activated in the draining lymph nodes after recognition of a viral 
epitope-MHC-I complex on an antigen presenting cell. This interaction initiates the 
differentiation of naïve CD8+ T cells into mature CTLs. CTLs then migrate to the site of 
infection, which in the case of an influenza virus infection is the infected lung95. There, their 
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the lungs. To kill infected cells, CTLs use two distinct cytotoxic mechanisms: (1) granule 
exocytosis; and (2) the engagement of tumor necrosis factor (TNF) family members with 
their respective ligands. Granule exocytosis refers to the lysosomes that are released by 
CTLs after they interacted with influenza virus antigen-derived peptides complexed with 
MHC-I on the infected cell through their T cell receptor (TCR). These granules contain the 
pore-forming protein perforin and serine proteases called granzymes. Perforin forms pores 
in the target cell membrane, which allows the pro-apoptotic granzymes to enter the cells 
and initiate programmed cell death. Cytotoxicity can also be mediated by several members 
of the TNF family, with FasL being the most important example of these family members. 
TCR engagement of peptide/MHC-I-complexes results in upregulation of FasL and its 
migration to the cell membrane of CTLs. Fas proteins are expressed on the cell membranes 
of most cell types, and these proteins get oligomerized by interacting with their ligand FasL. 
This oligomerization triggers an apoptotic cascade in the target cell, resulting in 
programmed cell death96. Another cytotoxicity-inducing TNF family member is the TNF-
related apoptosis-inducing ligand (TRAIL). TRAIL is comparable to FasL, in that interaction 
with its ligand (TRAIL-death receptor) also initiates an apoptotic pathway in the target cell. 
Evidence for its role in protection against influenza virus was reported by Brincks et al. who 
showed that TRAIL-deficiency decreases CD8+ T cell-mediated cytotoxicity, leading to more 
severe influenza virus infections97. 
3.3.2 Memory T cell response: The T cells remember 
After clearance of the primary infection in the lungs, the effector T cells go into a 
contraction phase. Herein, 90%–95% of all antigen-specific T cells undergo apoptosis. The 
small portion of cells that remains are destined to be long-living memory T cells98,99. How 
this transition takes place, and how the cell-fate of a T cell is decided, is still unclear. Several 
models have been proposed and are reviewed by Buchholz et al.100. What is known for sure, 
is that the formation and homeostasis of memory CD4+ and CD8+ T cells is dependent on IL-
7 and IL-15101-105. Upon reinfection by the same pathogen, memory T cells begin producing 
effector molecules, undergo a massive clonal expansion, and differentiate to secondary 
effector T cells in order to control the infection faster. Some key features of memory T 
cells—which makes them able to respond faster than ‘normal’ effector T cells—are a high 
proliferative potential, a multipotent state, long term survival and self-renewal in absence 
of antigen (in presence of IL-7 and IL-15)106. 
 
The past fifteen years memory T cells have been subject of many studies, which led to the 
current ”classification” of memory T cells. For a long time it was thought that memory T 
cells could be divided into two groups, the high CCR7- and CD62L-expressing central 
memory T cells (Tcm) and low CCR7- and CD62L-expressing effector memory T cells (Tem). 
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The first group of memory T cells patrols secondary lymphoid organs like naïve T cells do, 
but upon antigen-recognition they undergo a rapid and robust proliferation, differentiation 
and migration to the site of infection. The latter group recirculates between blood and non-
lymphoid tissues107. Upon antigen-recognition they rapidly execute their effector functions 
like freshly stimulated effector T cells would do107. More recently, a third memory 
population was defined: tissue-resident memory T cells (Trm), which are derived from 
precursors that entered the tissue during the immune effector phase and remained in this 
tissue108,109. Instead of CCR7 and CD62L, Trm-specific markers are the glycoprotein CD69 
and the integrin CD103110-112, although the expression of the latter is more predominant on 
CD8+ Trm cells than on CD4+ Trm cells108. CD4+ Trm cells are better associated with 
expression of CD69 and CD11a109,113. 
3.3.2.1 CD4+ memory T cells 
CD4+ memory T cells have long been studied less intensely than CD8+ memory T cells. The 
main reason for this is that CD4+ memory T cells do not expand as exuberantly as CD8+ 
memory T cells, and consequently are not present in large numbers after re-exposure to 
antigen114. For respiratory viruses, CD4+ Trm cells seem to be important for optimal 
protection against reinfection109,115. For influenza virus, it has been shown that CD4+ T cell 
epitopes are conserved within different subtypes of influenza virus. Interestingly, in people 
infected with seasonal influenza virus, virus-specific CD4+ T cells have been isolated which 
cross-react with emerging reassortant strains like H5N1116. Alexander and colleagues have 
shown that DNA vaccines, containing several CD4+ T cell epitopes, protected against lethal 
influenza virus infection117. Next to the circumstantial evidence, recent studies have 
elucidated a lot more about the role of CD4+ memory T cells in the immune response to 
influenza virus infection. It has been shown that CD4+ memory T cells can direct influenza 
virus clearance in absence of B cells and CD8+ T cells, however they cannot provide full 
protection118. In cooperation with other cell types, however, CD4+ memory T cells can 
provide clear protection during re-infection119-121. These findings have great significance for 
the production of universal influenza vaccines that aim at inducing long lived T cell 
responses. 
3.3.2.2 CD8+ memory T cells 
Memory CD8+ T cells, like CD4+ memory T cells, have the ability to rapidly generate effector 
functions. They also produce a burst of secondary CTLs that can rapidly contain secondary 
infections. Repetitive reactivation of the memory CD8+ T cells, either through booster 
vaccinations or successive infections, augments the effector-like properties of memory 
CD8+ T cells and the frequency of Tem cells in the resulting memory T cell pool122. The 
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detectable pre-existing antibodies to the 2009 pandemic H1N1 strain were monitored 
following the global spread of this virus. From this it was evident that people that showed 
no or minor disease symptoms had higher levels of pre-existing FLUAV-specific CD8+ Tem 
cells. This study also showed no clear correlation between disease severity and pre-existing 
memory CD4+ T cells123. This is rather striking because Wilkinson and colleagues noticed an 
inverse correlation between the presence of pre-existing CD4+ memory T cells and disease 
severity following a controlled challenge124. The reason for these different observations is 
currently unclear. 
 
CD8+ Trm cells form the frontline against secondary infection by influenza viruses in the 
lung compartment. Upon reinfection, they can immediately acquire effector functions. How 
come that these CD8+ Trm cells are not infected by influenza viruses, which, after all, merely 
require a sialic acid-containing receptor on a mammalian cell for their entry? It has been 
reported that CD8+ Trm cells that are formed after an influenza virus infection, show a 
massive upregulation of the interferon-induced transmembrane protein 3 (IFITM3)125. The 
same observation was made in CD8+ Trm cells from the brain after infection with Vesicular 
Stomatitis Virus126. IFITM3 is a potent antiviral molecule that can render resistance to 
infection with influenza virus by interfering with the fusion of the influenza virus envelope 
and the late endosome cell membrane, more specifically by blocking the formation of fusion 
pores127. All these observations make it very clear that generating memory T cells should be 
one of the most important objectives in the development of potent anti-influenza vaccines. 
3.4 Vaccines 
3.4.1 Current influenza vaccines 
Annual influenza vaccination is the most effective way to prevent influenza virus infection8, 
and is generally done with inactivated (TIV or QIV) or live-attenuated vaccines (LAIV). TIV 
induces higher titers of serum hemagglutination-inhibiting (HI) IgG and IgA antibodies than 
LAIV128. LAIV in its turn induces higher levels of nasal-wash IgA than TIV which mainly 
elicits IgG in the upper respiratory tract mucosa129,130. Inducing efficient cellular immune 
responses in the lung is dependent on efficient replication of the virus in the lung. TIV does 
not elicit cellular immunity because it is inactivated, and LAIV is designed in such a way that 
it only replicates in the upper respiratory tract. Therefore, both vaccines do not show much 
potential for inducing efficient cellular immune responses. However, cellular immunity was 
demonstrated in the lung after LAIV-administration in animal models131. Additionally, in 
humans, there is also an indication that LAIV elicits cellular immunity17. 
 
In the past, LAIV seemed to be superior to TIV in reducing laboratory-confirmed influenza 
in children132. Consequently, the use of LAIV was recommended in the UK, Germany, Israel, 
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Canada and Sweden for children of various ages133, and in the USA for children aged two to 
eight years134. In adults, the efficacy of LAIV is somewhat debated. In a study conducted by 
Monto et al., LAIV was 50% less efficient than TIV in the reduction of laboratory-confirmed 
influenza during the 2008–2009 influenza season135. Nichol and colleagues showed less 
efficacy in subjects between the age of 50 and 64, which led to the disapproval of LAIV for 
this age group in the USA136. Other studies show that LAIV reduces illness by 85% 
compared to TIV (subjects aged 18–41 years), and that LAIV does protect against influenza 
virus infection in adults above the age of 60 years128,137. However, as mentioned earlier, use 
of LAIV is no longer recommended for the upcoming 2016–2017 season because of its poor 
effectiveness against the H1N1 pandemic of 200912,13. 
3.4.2 T cells in heterologous protection against influenza viruses 
Current vaccines are mainly designed to elicit humoral rather than cellular immunity. The 
protective cut-off for evaluating vaccines is hence based on a hemagglutination-inhibition 
(HI) titer of 1/40 or more. This cut-off already dates from 1972, when Hobson and 
colleagues showed that a HI-titer of 1/36 corresponded with a 50% reduction of infection 
rate138. However, the 1/40 HI-titer correlate of protection is not a good cut-off for 
evaluating the vaccine-efficacy in children and elderly people139,140. Alternatively, a new 
correlate of infection should be developed, which takes into account the HI-titer and the 
influenza-specific cellular immune response. A vast amount of epidemiological studies 
supports this statement. During the 1977 influenza season, protection against homologous 
H1N1 virus infection was illustrated when H1N1 re-emerged after 20 years. Individuals 
born before 1955 had a lower influenza A/H1N1 attack rate in 1977 than people born after 
1955141. A surveillance study performed during more than 10 years in families in Cleveland 
showed that adults who were repeatedly infected with influenza virus before the pandemic 
year 1957 (H2N2), had a much lower incidence of influenza during the pandemic year142. 
Re-analysis of this study provided indirect proof that cellular immunity is involved in long-
lived protection against influenza virus infection143. Studies performed during and after the 
2009 Mexican flu pandemic showed comparable results123,144. In an experimental challenge 
study performed by McMichael et al., a direct correlation between pre-infection levels of 
CTLs and virus clearance was detected145. Similarly, in another controlled infection 
experiment, a strong protective role for memory CD4+ T cells was elucidated124. These 
studies were the starting point for the mounting evidence of the role of T cells in protection 
against influenza virus. 
3.4.3 Vaccination-induced T cell immunity: To serve and protect 
People that got infected with influenza virus in the past, have a two-part defense to 






Influenza and memory T cells | CHAPTER 3 
71 
 
antibodies that were elicited by the previous influenza virus infection. This is considered as 
neutralizing immunity, because the antibodies can directly attack the virus particles. 
However, often not all of the inoculum is neutralized or opsonized by the antibodies, which 
leaves some viral particles able to infect host cells. This is where the cellular immune 
response also kicks in. Vaccination strategies should induce both lines of the defense 
mechanism, and ideally in such a way that there is broad heterologous protection against 
subsequent influenza virus infections. As mentioned before, current inactivated vaccines do 
not elicit a strong T cell response. However, this might, in part, be overcome by the use of 
the right adjuvants. Adjuvants help to determine the type and size of the immune response 
provoked by vaccination. They can act as a depot and stabilizer for the vaccine, and 
stimulate innate immune responses, affecting the subsequent adaptive immune responses. 
The only adjuvants approved for use in humans are aluminum salts (aluminum hydroxide, 
aluminum phosphate and aluminum sulphate) and squalene-based adjuvants (AS03 and 
MF59); these adjuvants have been shown to promote induction of T cell responses146. 
Inactivated vaccines elicit neutralizing antibodies, which could impair the induction of 
cross-reactive cellular responses. This is of special concern for young children who are in 
general immunologically naïve for influenza virus18. This problem can be avoided by 
inducing infection-permissive immunity, which may still be protective, but allows virus-
induced cross-reactive immune responses. A vaccine which targets the conserved 
ectodomain of influenza virus matrix protein 2 (M2e) delivers this kind of non-neutralizing 
immunity, since anti-M2e antibodies rely on Fc receptors and innate immune components 
to provide protection39. Another promising vaccine candidate targets the influenza virus 
neuraminidase (NA) glycoprotein. Antibodies that inhibit NA-activity do not block entry of 
the virus into the host cell, so such antibodies do not provide sterilizing immunity and may 
contribute to immunity against a virus that has a similar NA type147. 
 
Last years, recombinant T cell-inducing vaccines are getting into play, the most advanced 
vaccine candidate is based on Modified Vaccinia Ankara (MVA) viruses expressing influenza 
virus NP and M1 antigens148. Individuals vaccinated with this MVA−NP+M1 show an 
increase in IFNγ-producing (cytotoxic) CD8+ T cells, and consequently an increase in 
protection against influenza virus infection149,150. Coadministration of this MVA-based 
vaccine with the seasonal TIV results in an increase of influenza strain-specific antibody 
responses and a boost of memory T cells capable of recognizing a range of influenza A 
subtypes151. 
 
FLU-v is a new vaccine candidate which consists of four peptides (three peptides derived 
from influenza A virus (FLUAV), and one peptide from influenza B virus. These peptides are 
synthetic multi-epitope peptides that were identified in silico152. The vaccine is already 
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proven to be safe and well-tolerated in phase I clinical trials153. Peripheral blood 
mononuclear cells (PBMCs) from vaccinated individuals showed more IFNγ-production in 
comparison to those of non-vaccinated individuals, but this did not lead to a decrease of 
symptoms after challenge154. 
 
The most recently reported T cell inducing vaccine candidates are FP-0.01 (FlunisynTM) and 
Multimeric-001 developed by Immune Targeting Systems Limited and BiondVax 
Pharmaceuticals ltd. respectively. The first vaccine consists of six peptides derived from 
FLUAV NP, M1, PB1 and PB2 proteins. These peptides are linked to fluorocarbon, which 
self-assembles into micelles omitting the need for adjuvants and increasing the peptides’ in 
vivo half-life155. After vaccination of healthy volunteers with FP-0.01, the frequency of IFNγ-
producing CD8+ T cells was only slightly increased. However, PBMCs isolated from these 
vaccinated individuals showed an increased IFNγ-production, in comparison to 
unvaccinated individuals, following stimulation. Multimeric-001, is composed of a large 
protein comprising nine highly conserved peptides derived from FLUAV HA, NP and M1 
proteins. PBMCs from vaccinated individuals show an increased proliferation and cytokine-
production in comparison to PBMCs from non-vaccinated individuals after stimulation with 










In order to elicit robust, long lasting, heterosubtypic immunity, there are some 
considerations to keep in mind when developing new vaccine candidates. Cross-reactive 
CD8+ CTL-mediated immunity plays an important part in controlling FLUAV infections, so it 
would be logical to focus on inducing a potent memory CD8+ T cell response. To induce such 
a strong CD8+ T cell response, efficient antigen-presentation by APCs is important. For this, 
it is interesting to target relevant DC subsets—such as CD8+ and CD103+ DCs—for maximal 
FLUAV-specific CTL-stimulation157. The important role of DCs to activate CD8+ T cells makes 
them attractive targets for vaccination. One approach to develop such so-called DC vaccines 
is by targeting antigen to PRR-activated APCs in an antibody-dependent way to achieve a 
strong initial T cell response158. Studies in animal models have demonstrated that targeting 
protein vaccines to lung dendritic cells even leads to the generation of Trm CD8+ T cells 
protective against FLUAV challenge159,160. In humans however, little is known about the 
protective potential of lung Trm cells, but they are important to consider when designing a 
novel vaccine candidate. To generate resident memory T cells by means of vaccination, one 
has to keep in mind that the number of generated memory T cells is determined by the size 
of the burst phase of the initial T cell response. Therefore, it is essential to induce an 
effector T cell population that is as large as possible. Recruiting antigen-specific CD8+ T cells 
is dependent on the presentation of antigen to the T cells, so the amount of presented 
antigen is crucial for the Trm cell population size159. In addition, the antigen-presentation at 
later time points is essential for generating a good Trm response. To achieve this, booster 
vaccines given at the correct moment might skew the Trm cell populations to higher affinity 
clones. A recent study showed that rapid boosting after vaccination with LAIV generated 
superior CD8+ T cell memory161. Research suggests that these boosters can give rise to a 
robust memory T cell response as well as enhance Tfh responses, because these cells are 
also dependent on late antigen-encounters162,163. Taking the memory T cells into account, 
this kind of vaccination strategies will generate a better antibody response and a more 
robust cellular response which is cross-reactive to new influenza strains. 
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For over 50 years researchers have been studying Mx proteins. Since the serendipitous 
discovery of the murine Mx1 gene by Jean Lindenmann1, a lot has evolved in this research 
field. Mouse Mx1 and human MxA proved to be type I and III IFN-responsive genes, the 
products of which are involved in the antiviral immune response against an array of viruses 
(Reviewed by Verhelst et al.2). Especially the antiviral effects against influenza and Thogoto 
virus have been thoroughly investigated. In in vitro systems and mouse models, Mx1 and 
MxA reduce productive infection by these viruses3-6. Theoretically, every cell type which is 
able to induce an IFN response can express Mx1 proteins. However, until now there is no 
definite proof that expression of Mx1 protects immune cells against FLUAV and THOV 
infections, nor is there anything known about the influence of Mx1 on the subsequent 
adaptive immune response. The main reason for this hiatus is that most FLUAV infection 
studies are performed with mice which do not express a functional Mx1 protein7. 
Nevertheless, there is some indirect evidence that shows that CD103+ DCs and resident 
memory CD8+ T cells are protected against FLUAV infection due to an IFN-induced antiviral 
state8,9. By deduction, one could argue that the Mx1 protein would also have a function in 
this antiviral state if the used mouse strain would express a functional Mx1 protein. 
 
To tackle this problem, we first set up a mouse model wherein we could restrict the Mx1 
expression in immune cells. Since most immune cells are of hematopoietic origin, we opted 
to generate bone marrow chimeras by reciprocal transfer of bone marrow cells between 
mice with a functional or non-functional Mx1 gene. Using this model, the first and second 
aim of the thesis were to investigate the effect of Mx1 in a FLUAV (first aim) and a THOV 
(second aim) infection model when primarily expressed by bone marrow-derived cells or 
stromal cells. 
 
Altenburg and colleagues reported on the construction of recombinant modified vaccinia 
Ankara (rMVA)-based vaccines that drive expression of FLUAV nucleoprotein (NP) with or 
without modifications10. In that study it was apparent that mutation or removal of the 
nuclear localization signal (NLS) of NP or N-terminal fusion of ubiquitin to NP improved the 
activation of NP-specific T cell clones in vitro. Immunization of C57BL/6 mice with these 
rMVA-NP constructs elicited protection against a lethal challenge with PR8 virus, but did 
not reveal differences between the constructs. The differential effects in vitro, and the lack 
of these effects in vivo, might be explained as follows. In order to elicit a strong CD8+ T cell 
response, the amount of processed antigen should reach a certain threshold. In C57BL/6 
mice, the CD8+ T cell response is dominated by NP366-374 specific CD8+ T cells, which easily 
reaches this threshold, irrespective of the modification of NP. It is known that NP is targeted 
by mouse Mx1 and even interacts with Mx111. By this, Mx1 could be a factor that limits the 
amount of processed antigen. Therefore, as a third aim of the thesis, we wanted to compare 
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the immunogenicity of these rMVA-NP vaccines in a mouse strain which does or does not 
express a functional Mx1 protein (B6.A2G Mx1+/+ or B6.A2G Mx1-/-). 
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Carry on my wayward son 
For there’ll be peace when you are done 
Lay your weary head to rest 
Don’t you cry no more 
















































Wat je vandaag moet doen, moet je doen zoals je morgen denkt dat je het had moeten doen. 
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The antiviral myxovirus resistance 1 (Mx1) gene is an interferon-induced gene which 
encodes a GTPase that plays an important role in the defense of mammalian cells against 
influenza A and other viruses. Mx1 provides protection against a number of viral infections, 
and this protection is independent of the expression of other interferon-induced genes. 
Because of their rapid induction by interferon and their antiviral function, Mx genes are 
considered an important part of the innate immune response. The way in which the 
immune cell compartment against influenza A virus is influenced or managed by Mx 
proteins, however, has not been investigated in detail. To determine if the murine Mx1 
protein has a role in the immune cell compartment, we performed bone marrow chimera 
experiments using congenic B6.A2G Mx1+/+ and B6.A2G Mx1-/- mice, which do or do not 
express a functional Mx1 gene respectively. Bone marrow chimeric mice were challenged 
with influenza A virus PR8, and the effect of the allogeneic immune compartment within the 
Mx1+/+ or Mx1-/- background was assessed using different viral and immunological 
readouts. This model showed that the role of Mx1 protein in the stromal cells prevails in the 
protection against influenza A virus. The same chimeric model was used in conjunction with 
Thogoto virus challenge. In this model it was apparent that Mx1 proteins can play a role of 
significance in the immune compartment. 
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Worldwide, influenza virus causes three to five million severe cases of illness and an 
estimate of 250 000 to 500 000 fatal cases every year1. When people get infected with 
influenza virus, the first cells that are targeted, are the airway epithelial cells. After binding, 
endocytosis and membrane fusion, the viral ribonucleoproteins (vRNPs) are released into 
the cytoplasm. These then enter the nucleus, where transcription and replication will take 
place (reviewed by Engelhardt et al.2 and Lakadamyali et al.3). These incoming vRNPs first 
form viral mRNA (primary transcription), which is then transported to the cytosol for 
translation into proteins. The newly produced viral proteins go back to the nucleus to start 
the replication of the viral genome. The resulting progeny viral RNA molecules form vRNPs, 
and leave the nucleus, ready for packaging and budding2. 
 
Belonging to the same family of Orthomyxoviridae, Thogoto virus (THOV) is a tick-borne 
virus first isolated in the Thogoto forest near Nairobi, Kenia4. THOV is genetically related to 
influenza viruses, but in contrast to influenza virus, small rodents are a natural host of this 
virus5. Antibodies against THOV have been detected in rats, buffaloes, camels, donkeys, 
cattle, sheep and humans6. However, infections in humans are rare7. 
 
Myxovirus resistance 1 (Mx1) proteins are interferon-induced dynamin-like large GTPases 
that can inhibit a wide array of viruses such as Orthomyxoviridae, Rhabdoviridae and 
Bunyaviridae. Especially the antiviral effect on influenza A virus (FLUAV) and THOV has 
been studied elaborately (reviewed by Verhelst et al.8). The exact mechanism by which Mx1 
proteins inhibit viral infection is however still largely unknown. Murine Mx1 inhibits 
influenza A viruses by suppressing primary transcription of viral genes in the nucleus9. 
Previously, we showed that murine Mx1 interacts with the polymerase basic 2 (PB2) 
protein and nucleoprotein (NP) in vRNPs, and disturbs their interaction10. Based on this 
study, and on the observation that human MxA proteins – like dynamins – form ring-like 
structures11-15, we hypothesized that the interaction with PB2 and NP might be mediated by 
an Mx1 oligomeric ring, which actively disrupts the PB2-NP interaction10. In addition, we 
recently demonstrated that Mx1 can not only prevent formation of vRNPs, but it can also 
disrupt existing vRNPs, which is in line with the proposed model16. 
 
Although there is a body of evidence that Mx proteins give protection in the innate immune 
response against certain viral infection, little is known about the possible role of Mx 
proteins in the different immune cell types. Previous studies which could not define a clear 
role for Mx1 in the immune cell compartment discussed only one or a few different immune 
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functional Mx1 protein17-20. In contrast, several research groups reported about the role of 
the type I IFN response in immune cells after FLUAV infection, leading to the formation of 
an antiviral state in different immune cell types, rendering them resistant against influenza 
virus infection21,22, or increasing the susceptibility of certain immune cells by an attenuated 
IFNAR-response23. Taken together, these studies raise a lot of extra questions about the role 
of the type I IFN response, and in particular the role of the Mx1 protein, in immune cells 
following a FLUAV infection. Therefore, we investigated the role of Mx1 expression in 
immune cells in an in vivo infection model using radiation chimeric mice. We show that the 
response to influenza virus infection is largely independent of the genotype of the 
hematopoietic cells, while the genotype of the stromal cells seems to determine the better 
part of the Mx1-driven protection against influenza virus. Conversely, this is not the case 
when using a Thogoto virus infection model, where we observed a role for both the 
genotype of the recipient and the donor. 
4.2 Results 
4.2.1 B6.A2G Mx1+/+ mice are resistant against infection with a high dose of 
influenza A virus 
Homozygous Mx1 positive (Mx1+/+) and Mx1 negative (Mx1-/-) B6.A2G mice were infected 
intranasally with 20 times the median lethal dose (LD50) of a mouse-adapted influenza 
A/Puerto Rico/8/34 (maPR8) lab strain. Morbidity and mortality were monitored during 
14 days post infection (dpi). The effect of virus infection is clearly seen for the Mx1-/- group, 
where severe weight loss is observed and all mice succumbed to infection by day 9 post 
infection (Figure 4.1). In contrast, all Mx1+/+ mice survived infection, and did not show 
significant weight loss. This illustrates that Mx1+/+ B6.A2G mice are highly resistant to 
influenza infections, even at high doses. 
4.2.2 Generation of bone marrow chimeras 
Most immune cells have a hematopoietic origin. Replacing bone marrow cells from mice 
that express a functional Mx1 protein (B6.A2G Mx1+/+) with those from mice which do not 
express a functional form of Mx1 (B6.A2G Mx1-/-) allows us to determine the possible role 
for the Mx1 protein in the immune cell compartment after a viral infection. For this, B6.A2G 
mice (Mx1+/+ or Mx1-/-) were lethally irradiated (10 Grey), and were reconstituted 24h later 
with syngeneic or allogeneic bone marrow cells. Experimental transfers were as follows: 
B6.A2G Mx1-/- donors into B6.A2G Mx1-/- recipients (Mx1-/-  Mx1-/-), B6.A2G Mx1-/- donors 
into B6.A2G Mx1+/+ recipients (Mx1-/-  Mx1+/+), B6.A2G Mx1+/+ donors into B6.A2G Mx1+/+ 
recipients (Mx1+/+  Mx1+/+), and B6.A2G Mx1+/+ donors into B6.A2G Mx1-/- recipients 
(Mx1+/+  Mx1-/-). A schematic overview of the different experimental groups is shown in 
Figure 4.2. 
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4.2.3 Resistance to influenza A virus infection primarily depends on the 
genotype of the recipient 
Bone marrow chimeric mice were infected with 10 LD50 of maPR8, and bodyweight and 
morbidity were monitored during six days after infection. B6.A2G Mx1-/- recipient mice 
(Mx1-/-  Mx1-/- and Mx1+/+  Mx1-/-) clearly suffer more from the consequences of the 
infection than B6.A2G Mx1+/+ recipient mice (Mx1+/+  Mx1+/+ and Mx1-/-  Mx1+/+), losing 
significantly more bodyweight after infection (Figure 4.3a). At 3 dpi, half of the mice of each 
group was sacrificed, and lung viral titers were determined. The same was done at 6 dpi for 
the second half of each group. Viral titers in the lung were about tenfold lower in B6.A2G 
Mx1+/+ recipients than in B6.A2G Mx1-/- recipients on day three after infection (Figure 4.3b). 
Three days later, at 6 dpi, a trend of lower lung viral titers was observed in the B6.A2G 
Mx1+/+ recipient groups in comparison to the B6.A2G Mx1-/- recipients. Over the course of 
Figure 4.1 Morbidity and mortality after FLUAV infection of Mx1-/- and Mx1+/+ B6.A2G mice. Mice were 
infected intranasally with 20 LD50 of maPR8. Morbidity (a) and mortality (b) were monitored during 14 days 
post infection. Data points were obtained in one single experiment and represent the average of five mice. 
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time, the B6.A2G Mx1+/+ recipients differ significantly from the B6.A2G Mx1-/- recipients 
both in morbidity and lung viral titers. 
 
Since Mx1 has been shown to inhibit primary transcription of viral genes in the nucleus9, 
we determined viral mRNA levels in the lung at three different time points by reverse 
transcriptase quantitative polymerase chain reaction (RT-qPCR). For this, several mice of 
each challenged bone marrow chimeric group were sacrificed either prior to infection (0 
dpi), or at 3, or at 6 dpi. Lungs were isolated and homogenized, and viral mRNA was 
extracted to determine the levels by RT-qPCR. Three days after infection, viral mRNA levels 
were much lower in lungs of B6.A2G Mx1+/+ recipients compared to those in lungs of 
B6.A2G Mx1-/- recipient mice (Figure 4.4a). At 6 dpi, this difference was even more 
profound. Pavlovic et al. showed that Mx1 differentially inhibits the transcription of the 
different influenza virus segments. The strongest inhibition is observed for the largest 
transcripts (PB1, PB2, and PA), but the smallest transcripts (M and NS) are barely 
inhibited9. In contrast, we noticed that the inhibiting effect of Mx1 was equally strong for 
the shorter and the longer viral segments. This effect was also seen for viral protein levels 
in the lung, as determined by western blot analysis of total lung homogenates (Figure 4.4b). 
The virus NP and M2 protein levels were both strongly affected by Mx1 activity in B6.A2G 
Mx1+/+ recipient mice. Although Mx1 was well expressed in the lungs of the Mx1+/+  Mx1-/- 
Figure 4.2 Schematic overview of the generation of the different bone marrow chimeric groups 
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group, there was no clear effect on viral infection. IFITM3, which is an IFN-induced protein, 
is already expressed well at steady state conditions. This high baseline expression makes it 
difficult to distinguish differences in expression levels between the four bone marrow 
chimera groups upon FLUAV infection. Nevertheless, it conveys the impression that IFITM3 
expression is lower in Mx1+/+ recipients, especially in the Mx1+/+  Mx1+/+ group. These 
data suggest that Mx1 expression by stromal cells has a stronger effect on FLUAV infection 
than Mx1 expression by cells with a hematopoietic origin. 
Figure 4.3 Morbidity and viral lung titers of bone marrow chimeric mice after FLUAV infection. Mice 
were infected with 10 LD50 of maPR8. (a) Body weight was monitored during 6 days after infection. Data 
points represent the average of at least six mice. Error bars represent the standard error of the mean. 
Asterisks indicate the significant difference with the Mx1-/-  Mx1-/- group over time. ***, p < 0.001. Circles 
indicate the significant difference with the Mx1+/+  Mx1-/- group over time. °°, p < 0.01; °°°, p < 0.001. (b) Half 
of the infected mice of each group were sacrificed at 3 dpi, and the other half at 6 dpi. At both time points lung 
viral titers were determined. Each data point represents the lung viral titer of a single animal. Red data points 
represent samples depicted in Figure 4.4b. Asterisks indicate the significant difference with the Mx1-/-  Mx1-
/- group. ***, p < 0.001. Circles indicate the significant difference with the Mx1+/+  Mx1-/- group. °°°, p < 0.001. 
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4.2.4 Cellular responses after influenza A virus infection differ between Mx1-/- 
and Mx1+/+ recipient mice 
Expression of a functional Mx1 protein in bone marrow-derived cells does not seem to 
contribute significantly to the resistance against FLUAV infection. Mx1 expression in the 
stromal cells, on the other hand, appears imperative for this resistance. However, nothing is 
known about the impact of Mx1 expression on the formation and shape of the immune 
response following FLUAV infection. To study this, lungs of FLUAV-infected bone marrow 
chimeric mice were isolated at three different time points (0, 3 and 6 dpi), single cell 
Figure 4.4 Viral mRNA and protein levels of bone marrow chimeric mice after FLUAV infection. Mice 
were infected with 10 LD50 of maPR8. Part of each group was sacrificed at 0, 3 or 6 dpi, lungs were isolated 
and processed to lung homogenates. (a) From these homogenates total mRNA was isolated, and this mRNA 
was used to determine viral mRNA levels by RT-qPCR. Total viral mRNA was quantified for each lung 
homogenate by RT-qPCR. Data points represent average levels of total viral mRNA relative to household 
genes. Error bars represent standard error of the mean. Asterisks indicate the significant difference with the 
Mx1-/-  Mx1-/- group. ***, p < 0.001. Circles indicate the significant difference with the Mx1+/+  Mx1-/- 
group. °°°, p < 0.001. Data are pooled from 2 independently performed experiments. (b) Lung homogenates 
were used for western blot analysis of viral proteins NP and M2, and interferon-induced cellular proteins Mx1 
and IFITM3. Actin was detected as loading control. Samples from different bone marrow chimera groups are 
numbered from 1 to 4. 1, Mx1-/-  Mx1-/-; 2, Mx1+/+  Mx1-/-; 3, Mx1-/-  Mx1+/+; 4, Mx1+/+  Mx1+/+. Data are 
representative of two similar experiments. 
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suspensions were prepared and stained for different surface markers. This allowed us to 
distinguish various immune cell types by flow cytometry (Supplementary figure S4.1). Prior 
to infection (0 dpi), the levels of all analyzed immune cell types were not significantly 
different between the four chimeric groups (Supplementary figures S4.2 and S4.3). This 
suggests that the composition of the immune compartment is comparable at steady state 
conditions irrespective of the genotype of the immune and stromal cells. 
 
During the course of infection, neutrophil levels behave quite similar in all bone marrow 
chimeric groups (Figure S4.2a and S4.3a). The Mx1-/-  Mx1-/- group shows the highest 
neutrophil influx at 3 and 6 dpi. Over time, the neutrophil level of the Mx1-/-  Mx1-/- group 
differs significantly with that of the Mx1-/-  Mx1+/+ group, which shows the lowest level of 
all at 6 dpi. In contrast to neutrophils, eosinophils get depleted over time (Figure S4.2b and 
S4.3b). This depletion over time is stronger for Mx1-/- recipients than it is for Mx1+/+ 
recipients, and is most clearly seen at 6 dpi. The lung conventional dendritic cell (cDC) 
levels are very low, which makes it difficult to draw straightforward conclusions. The level 
of cDC1s in Mx1-/-  Mx1-/- lungs differs significantly over time from the three other 
groups, probably because of the initial higher cDC1 levels at 0 dpi in this group (Figure 
S4.2c and S4.3c). However, it is noteworthy to mention that there is quite a big spread in the 
data of this group at this time point (Figure S4.3). The four bone marrow chimeric groups 
show no significant differences over time for their cDC2 levels (Figure S4.2d and S4.3d). 
 
After FLUAV infection, dendritic cells take up viral particles or virus infected cells, and 
migrate to the draining lymph nodes. There, they present this antigen and trigger an 
antigen-specific T cell response24. T cell levels were also measured at 0, 3 and 6 dpi, and 
compared between the bone marrow chimeric groups. The CD4+ T cell levels in the lungs of 
the Mx1-/-  Mx1-/- group differ significantly over time from all other groups (Figure S4.2e 
and S4.3e). This is because the CD4+ T cell levels in this group drop over time, while in the 
other groups the levels remained approximately the same. In contrast, the CD8+ T cell levels 
increase similarly over time for all chimeric groups (Figure S4.2f and S4.3f). 
 
During the course of infection the clearest divergence seen between the B6.A2G Mx1-/- and 
B6.A2G Mx1+/+ recipient mice was in the monocyte-derived dendritic cell (moDC) 
population (Figure 4.5a and 4.5c). We observed higher levels of moDCs in the lungs of 
B6.A2G Mx1-/- recipients in comparison to the lungs of B6.A2G Mx1+/+ recipient mice. 
Previously it has been shown that, upon FLUAV infection, monocytes are massively 
recruited into the lung to the site of inflammation, where they differentiate into moDCs25. 
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infection25,26. This was also observed in the lungs of the four different bone marrow 
chimera types (Figure 4.5b and 4.5d). However, the depletion of AMs over time is less 
strong for B6.A2G Mx1+/+ recipients compared to B6.A2G Mx1-/- recipient mice. This 
suggests that inflammation in the lungs of Mx1-/- recipients is more fierce than in the Mx1+/+ 
lungs after FLUAV infection. 
4.2.5 Mx1 expression in bone marrow-derived cells does not influence the 
formation of an antigen-specific CD8+ T cell response after an influenza A virus 
infection 
Since Mx1 expression in stromal cells alleviates the disease burden in mice (Figure 4.3a), it 
is tempting to argue that Mx1’s innate function, being the early containment of the virus, is 
its main role in the anti-FLUAV immune response. If the virus is inhibited early in the 
Figure 4.5 Effect of FLUAV infection on moDC and AM levels in the lung. Bone marrow chimeric mice 
were infected with 10 LD50 of maPR8, and lungs were isolated at 0, 3 and 6 dpi. These lungs were processed 
to single cell suspensions, which were stained for different surface markers. This allows us to identify 
different cell types such as monocyte-derived dendritic cells (a and c) and alveolar macrophages (b and d). 
(a and b) Data points represent the average level of at least six mice. Error bars represent standard error of 
the mean. (c and d) Each data point represents the relative amount of cells of each indicated cell type of a 
single animal. Asterisks indicate the significant difference with the Mx1-/-  Mx1-/- bone marrow chimera 
group. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Circles indicate the significant difference with the Mx1+/+  Mx1-
/- bone marrow chimera group over time. °, p < 0.05; °°, p < 0.01; °°°, p < 0.001. Data are pooled from 2 
independently performed experiments. 
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course of infection, this would suggest that there is no formation of a strong cellular 
antiviral response, since elucidating a specific T cell response requires a certain amount of 
productive infection27. We examined the total CD4+ and CD8+ T cell populations of bone 
marrow chimeras at different time points (0, 3 and 6 dpi) after maPR8 infection, but we did 
not observe a strong influx of T cells in any of the chimera groups (Supplementary Figures 
S4.2 and S4.3). Likely, the chosen time points (0, 3 and 6 dpi) are not well suited for 
detection of a T cell response because they are situated too early after infection. To address 
this issue, the specific antiviral T cell response was examined in bone marrow chimeras ten 
days after infection with maPR8. Because the sensitivity to FLUAV infection differs strongly 
between B6.A2G Mx1-/- recipient (Mx1-/-  Mx1-/-, Mx1+/+  Mx1-/-) and B6.A2G Mx1+/+ 
recipient mice (Mx1+/+  Mx1+/+, Mx1-/-  Mx1+/+), we adjusted the dose of virus to a 
sublethal level for each recipient genotype (0.5 LD50 for Mx1-/- recipients and 10 LD50 for 
Mx1+/+ recipients). Antigen-specific CD8+ T cell responses were analyzed in splenocytes, 
isolated ten days after infection. Both Mx1-/- and Mx1+/+ recipients showed an NP-specific T 
cell response (Figure 4.6). NP-specific CD8+ T cell levels were higher in the B6.A2G Mx1+/+ 
recipient mice compared to the B6.A2G Mx1-/- recipient mice (Figure 4.6), which is not 
surprising when considering the higher virus dose given to Mx1+/+ recipient mice. This 
indicates that B6.A2G Mx1+/+ recipients can mount a specific antiviral T cell response after 
FLUAV infection, and that Mx1 protein expression in stromal cells does not completely 
inhibit FLUAV infection nor the subsequent cellular immune response. Notably, the NP-
specific CD8+ T cell responses in the two Mx1-/- recipient groups were not significantly 
Figure 4.6 Antigen-specific CD8+ T cell response after FLUAV infection of bone marrow chimeric mice. 
B6.A2G Mx1-/- and B6.A2G Mx1+/+ recipient mice were infected with either 0.5 LD50 and 10 LD50 of maPR8, 
respectively. Ten days after challenge, splenocytes were prepared and restimulated ex vivo for 16 h with a 
FLUAV NP-derived peptide. After restimulation, flow cytometric analysis of IFNγ-producing CD8+ T cells was 
performed. Data are obtained in one single experiment. Statistical analysis was performed using a two-sided 






Elucidating the role of Mx1 in the immune cell compartment | CHAPTER 4 
107 
 
different from one another (Figure 4.6). The same was true for the two Mx1+/+ recipient 
groups. This suggests that expression of a functional Mx1 protein in cells with a 
hematopoietic origin does not influence, negatively or positively, the formation of a potent 
cellular antiviral response. 
4.2.6 B6.A2G Mx1+/+ bone marrow reduces THOV-associated effects in B6.A2G 
Mx1-/- recipient mice 
Based on the previous results, we observed no clear-cut effect of Mx1 expression in immune 
cells after FLUAV infection. Instead, it was apparent that expression of Mx1 in the stromal 
Figure 4.7 Morbidity and viral lung titers of bone marrow chimeric mice after THOV infection. Mice 
were infected intraperitoneally with 1000 PFU of THOV. (a) Body weights were monitored during 4 days after 
infection. Data points represent the average of eight mice. Error bars represent the standard error of the 
mean. Statistical analysis was done using a two-way ANOVA with post hoc Tukey’s HSD test. Asterisks indicate 
the significant difference with the Mx1-/-  Mx1-/- group. *, p < 0.05; **, p < 0.01; ****, p < 0.0001. Circles 
indicate the significant difference with the Mx1+/+  Mx1-/- group. °°, p < 0.01; °°°, p < 0.001; °°°°, p < 0.0001. 
Caps indicate the significant difference with the Mx1-/-  Mx1+/+ group. ^, p < 0.05; ^^^^, p < 0.0001. (b) Four 
days post infection, liver viral titers were determined. Each data point represents the liver viral titer of a 
single animal. Red data points represent samples depicted in Figure 4.8. ND = not detectable. Statistical 
analysis was performed using Kruskal-Wallis test with post hoc Dunn's multiple comparison test. Asterisks 
indicate the significant difference with the Mx1-/-  Mx1-/- group. ***, p < 0.001. Circles indicate the significant 
difference with the Mx1+/+  Mx1-/- group. °, p < 0.05. Data are pooled from 2 independently performed 
experiments. 
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cells is the main driving force for resistance against FLUAV infection. A possible explanation 
could have been that the direct innate effect of Mx1 is too strong to allow the development 
of an adequate cellular immune response in mice expressing Mx1 in their stromal cells. 
However, this possibility was debunked by the observation of a strong antigen-specific 
CD8+ T cell response in the B6.A2G Mx1+/+ recipient mice after FLUAV infection (Figure 4.6). 
Another possibility might be that the influenza virus infection model is not well suited for 
eliciting the role of Mx1 expression in immune cells. In this regard, another in vivo infection 
model was set up using the Thogoto virus (THOV), an Orthomyxovirus that is also sensitive 
to Mx1. 
 
Bone marrow chimeric mice were infected intraperitoneally with 1000 plaque forming 
units (PFU) of THOV (Sicilian SiAr 126 isolate), and body weight was monitored once daily 
for four days after infection. The effect of THOV infection on Mx1-/-  Mx1-/- and Mx1+/+  
Mx1+/+ mice was as expected in the sense that Mx1+/+  Mx1+/+ mice showed no body 
weight loss, and Mx1-/-  Mx1-/- mice lost quite some body weight and became moribund 
by day 4 post infection (Figure 4.7a). Interestingly, the Mx1-/-  Mx1+/+ and Mx1+/+  Mx1-
/- groups responded differently than in the influenza virus infection model. B6.A2G Mx1+/+ 
mice that had received Mx1-/- bone marrow (Mx1-/-  Mx1+/+) lost significantly more body 
weight than B6.A2G Mx1-/- mice that had received Mx1+/+ bone marrow (Mx1+/+  Mx1-/-), 
indicating a protective role for Mx1 expression in hematopoietic cells in this infection 
model. Surprisingly, liver viral titers do not reflect these findings. Just like the lung viral 
titers in the FLUAV infection model, the liver viral titers of both B6.A2G Mx1-/- recipient 
groups are very high (approximately 106 to 107 PFU/g), and they are significantly lower 
(below the detection limit of 102 PFU/g) for B6.A2G Mx1+/+ recipient groups at 4 dpi (Figure 
4.7b). Notably however, Mx1+/+  Mx1-/- mice showed a twofold lower average viral titer 
than the Mx1-/-  Mx1-/- group. These data suggest that Mx1 expression primarily in 
hematopoietic cells can significantly reduce the THOV-associated body weight loss in 
B6.A2G Mx1-/- recipient mice. 
 
Four days after infection, Mx1 protein expression in the liver was determined by western 
blot analysis of total liver homogenates. As expected, no Mx1 expression was observed in 
the Mx1-/-  Mx1-/- livers (Figure 4.8). In contrast, Mx1+/+  Mx1-/- mice do express Mx1 in 
their liver, however, the expression levels of the Mx1-/-  Mx1+/+ mice seem much higher. 
This is not surprising, considering that Mx1+/+  Mx1-/- mice only express Mx1 in cells from 
hematopoietic origin, and Mx1-/-  Mx1+/+ mice can express Mx1 in all their cells except 
those from hematopoietic origin. Given this, it is quite remarkable that mice from the 
Mx1+/+  Mx1+/+ group, which can express functional Mx1 protein in all of their cell types, 
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a strong interferon response in the liver, as illustrated by the undetectable ISG15 
expression in the liver homogenates from this chimeric group. In the Mx1-/-  Mx1+/+ 
group, as well as in both Mx1-/- recipient groups, we observed ISG15 expression indicating 
an adequate interferon response. This interferon response is presumably induced by the 
THOV infection. However, we only observe strong expression of THOV NP in the Mx1-/-  
Mx1-/- liver homogenates. Mx1+/+  Mx1-/- homogenates show very little to no expression 
of the THOV NP even though we measured high liver viral titers in this group. It is not 
surprising that we do not see any THOV NP expression in the livers of Mx1+/+ recipient mice 
since they also show no virus growth in the liver. 
4.2.7 B6.A2G Mx1+/+ bone marrow-derived cells can ameliorate THOV-induced 
liver pathology in B6.A2G Mx1-/- recipients 
THOV infection was previously shown to cause severe liver pathology in Mx1-/- mice, while 
Mx1+/+ mice did not show any liver pathology28. In order to examine the effect of THOV on 
liver tissue of bone marrow chimeric mice, livers of these mice were isolated four days after 
THOV infection and prepared for histological analysis. Macroscopically, the livers of the 
Mx1-/-  Mx1-/- mice appeared very different from the livers of the other chimera groups 
(Figure 4.9a). The Mx1-/-  Mx1-/- livers were very pale and friable in comparison to the 
other livers which had a normal brown-red color and firm tissue. Tissue sections were 
stained with hematoxylin and eosin (H&E). Microscopically, H&E-stained Mx1-/-  Mx1-/- 
liver tissue showed lesions characterized by focal to widespread liver cell necrosis (Figure 
4.9b). Interestingly, Mx1+/+  Mx1-/- liver tissue also showed lesions, however, these 
lesions appear to be in an earlier stage of necrosis than the lesions in Mx1-/-  Mx1-/- liver 
tissue. This is manifested as foci in the liver tissue where structure and cell architecture are 
lost, and strong immune cell influx was observed. This suggests that Mx1 expression in cells 
with hematopoietic origin can reduce or at least delay liver pathology in B6.A2G Mx1-/- 
Figure 4.8 Mx1 protein levels in livers of bone marrow chimeric mice after THOV infection. Bone 
marrow chimeric mice were infected intraperitoneally with 1000 PFU of THOV. Four days after infection 
livers were isolated and processed to liver homogenates. These liver homogenates were used for western blot 
analysis of Mx1, THOV NP, and ISG15. Actin was detected as loading control. Data are representative of two 
similar experiments. 
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recipient mice. B6.A2G Mx1+/+ recipient’s liver tissue was normal and showed no lesions 
(Figure 4.9b). 
 
Figure 4.9 Macro- and microscopic view of liver tissue of bone marrow chimeric mice after THOV 
infection. Bone marrow chimeric mice were infected intraperitoneally with 1000 PFU of THOV. Four days 
after infection livers were isolated, photographed, and prepared for histological analysis. (a) Macroscopic 
view of livers. (b) Microscopic view of liver tissue stained with hematoxylin and eosin. Arrows indicate focal 
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In order to quantify the amount of liver damage caused by THOV infection, alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) levels were determined in 
serum of THOV-infected bone marrow chimeric mice at 4 dpi. ALT and AST are enzymes 
which catalyze the transfer of α-amino groups from alanine and aspartate, respectively, to 
the α-ketogroup of ketoglutaric acid. Hereby, ALT and AST respectively generate pyruvic 
and oxalacetic acid which are important for the citric acid cycle. Both enzymes are highly 
concentrated in the liver, however, AST is also expressed in the heart, skeletal muscle, 
kidneys, brain, and in red blood cells. ALT can also be found in skeletal muscle and kidneys, 
albeit at low concentrations. Liver injury (acute or chronic) causes elevation of serum 
concentrations of ALT and AST because damaged liver cells ‘spill’ these enzymes into the 
bloodstream. Since ALT is more confined to the liver in comparison to AST, it is considered 
to be more specific for liver injury than AST29. The serum levels of both ALT and AST 
increase markedly in THOV-infected Mx1-/-  Mx1-/- mice in comparison to Mx1-/-  
Figure 4.10 ALT and AST serum levels after THOV infection. Bone marrow chimeric mice were infected 
intraperitoneally with 1000 PFU of THOV. Four days after infection blood was drawn from the mice, and 
serum was prepared. Serum concentrations of ALT (a) and AST (b) were determined. Each data point 
represents the ALT or AST serum level of a single animal. Data are obtained in one single experiment. 
Asterisks indicate the significant difference with the Mx1-/-  Mx1-/- group. *, p < 0.05; **, p < 0.01; Kruskal-
Wallis test with post hoc Dunn's multiple comparison test. 
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Mx1+/+ and Mx1+/+  Mx1+/+ mice (Figure 4.10). The Mx1+/+  Mx1-/- group shows 
intermediate levels of both enzymes indicating that liver injury is less severe in these 
animals compared to the Mx1-/-  Mx1-/- group. This is in accordance with the histological 
scoring of the liver sections, further substantiating that Mx1+/+  Mx1-/- mice are better 
protected against the effects of THOV infection than Mx1-/-  Mx1-/- mice. 
4.3 Discussion 
In the mouse model, it is well established that expression of a functional Mx1 protein can 
protect against a lethal FLUAV or THOV infection, whereas lack of a functional Mx1 protein 
leads to severe morbidity and mortality in these models. Mx1 is an interferon-stimulated 
gene, so it mainly acts as a part of the innate immune response by early inhibition of the 
virus in infected epithelial cells. However, until today the mechanism by which Mx1 
protects these animals against infection remains elusive. In theory, every cell type that can 
mount a type I or III IFN response is also able to express Mx1 protein. Does this mean that, 
in response to viral infection, every cell type expresses Mx1, or that Mx1 is needed for their 
proper functioning? In this respect, several studies have shown the importance of an IFN 
response in cell types involved in the antiviral immune response after FLUAV infection21-23. 
These studies make it tempting to hypothesize that Mx1 can also play a role in the immune 
cell compartment, or better said, in the protection of cell types which are involved in the 
antiviral immune response. However, studies that concluded that Mx1 fulfills no function in 
the immune cell compartment only focused on a certain part of this compartment17-19. To 
our knowledge, the possible role of Mx1 in immune cells has not yet been studied to the full. 
To tackle this question, we generated bone marrow chimeras, wherein Mx1-/- recipient mice 
received Mx1+/+ bone marrow, and vice versa. These animals were then used in several 
infection experiments. This would give us the chance to investigate the effect of Mx1 when 
it is primarily expressed by bone marrow-derived cells or stromal cells. However, one 
should take into consideration that some bone marrow-derived cell types, such as 
Langerhans cells30 and mesenchymal stromal cells (reviewed by Sugrue et al.31), are 
resistant to lethal total body irradiation. Consequently, these cell types will have the 
genotype of the bone marrow recipient, and not that of the bone marrow donor. Since these 
cell types are not directly involved in the immune responses which were investigated, this 
is of minor importance for the obtained results. 
 
FLUAV infection of bone marrow chimeras led to significantly more body weight loss and 
higher lung viral titers in the Mx1-/- recipients (Mx1-/-  Mx1-/- and Mx1+/+  Mx1-/-) 
compared to the Mx1+/+ recipients (Mx1-/-  Mx1+/+ and Mx1+/+  Mx1+/+). In viral mRNA 
and protein levels in the lung the same divergence was observed between Mx1-/- and Mx1+/+ 
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which only express a functional Mx1 in their cells from hematopoietic origin. This is 
probably due to a high influx of immune cells into the lung, and a strong IFN response as a 
result of the FLUAV infection. These data suggest that resistance to infection is primarily 
dependent on the genotype of the recipient, and not so much on the genotype of the donor 
bone marrow. 
 
In order to determine whether Mx1 has a direct or indirect effect on a specific immune cell 
type, we measured the levels of different cell types in the lung by flow cytometry at 
different time points prior to (0 dpi) or after infection (3 and 6 dpi). The influx of moDCs is 
nearly twofold higher in Mx1-/- than in Mx1+/+ recipients. This probably indicates that the 
inflammatory response in Mx1-/- recipients is higher than in Mx1+/+ recipients, since upon 
FLUAV infection lung inflammation causes recruitment of monocytes to the lung which then 
differentiate into moDCs25. This difference in inflammation also correlates with the 
differences seen for the expression of IFN-induced protein IFITM3. AMs and eosinophils get 
depleted, but this depletion is less strong in the Mx1+/+ recipients than is the case for the 
Mx1-/- recipients. Alveolar macrophages die after taking up infected or dying cells, and virus 
particles25,26. Eosinophils are usually not recruited to the lung after FLUAV infection32, and 
in addition, they are susceptible to this infection33, which might explain why they get 
depleted faster in mice which do not express Mx1 in their bone marrow-derived cell types. 
 
During the first six days after FLUAV infection no clear differences were seen in the T cell 
levels between all chimeric groups. We reexamined the antigen-specific T cell compartment 
at ten days post infection. Although there is a clear antigen-specific T cell response in all 
chimeric groups, we observed no significant differences between the Mx1-/-  Mx1-/- and 
the Mx1+/+  Mx1-/- groups, nor between the Mx1-/-  Mx1+/+ and the Mx1+/+  Mx1+/+ 
groups. This indicates that Mx1 expression in bone marrow-derived cells is not important 
for the formation of an efficient antigen-specific T cell response. More importantly however, 
these results show that Mx1+/+ recipients can form an adequate antigen-specific T cell 
response after FLUAV infection. 
 
Taken together, the data gathered with this FLUAV infection model do not answer the 
question if Mx1 can play a role in the immune cell compartment. Maybe this infection model 
is not the most eligible for answering this question. Therefore we substituted the FLUAV 
with another virus, i.e. THOV. The rationale for choosing this virus is threefold: THOV, like 
influenza A virus, is a member of the Orthomyxovirus family, it is also sensitive to the 
antiviral action of murine Mx128, and small rodents are natural hosts of this virus5. 
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Bone marrow chimeras were infected intraperitoneally with a high dose of THOV. 
Morbidity was somewhat different than seen in the FLUAV infection model in that the 
Mx1+/+  Mx1-/- group shows less body weight loss than the Mx1-/-  Mx1+/+ group. 
Remarkably, liver viral titers at 4 dpi were very high for all the Mx1-/- recipients, and below 
the detection limit for Mx1+/+ recipients. This is contradictory to the morbidity data where 
Mx1+/+  Mx1-/- mice seem to lose less body weight after infection than the mice from the 
Mx1-/-  Mx1+/+ group. 
 
When examining Mx1 expression in the liver, we noticed that the Mx1-/-  Mx1+/+ group 
showed very high Mx1 protein levels. The Mx1 protein levels are much lower in the Mx1+/+ 
 Mx1-/- and the Mx1+/+  Mx1+/+ groups. Especially the latter is remarkable, because in 
the FLUAV infection model we also observed a level of Mx1 expression in the Mx1+/+  
Mx1+/+ group comparable to that in the Mx1-/-  Mx1+/+ group. This discrepancy is likely 
caused by the lack of an IFN response in the livers of Mx1+/+  Mx1+/+ mice, which is 
demonstrated by the lack of ISG15 expression in this group. Presumably, the IFN response 
is triggered by a productive THOV infection in the liver. A high level of ISG15 expression is 
seen for the Mx1-/-  Mx1-/- group, which also shows  high levels of THOV NP expression. In 
the Mx1+/+  Mx1-/- group we observed little to no THOV NP expression which is surprising 
seeing that mice from this group showed high liver viral titers. In this Mx1+/+  Mx1-/- 
group the highest ISG15 expression is seen in the animals which show some THOV NP 
expression. Conversely, the Mx1-/-  Mx1+/+ group, which showed a high Mx1 expression, 
also shows ISG15 expression, but no THOV NP expression at all. In contrast, the Mx1+/+  
Mx1+/+ group also shows no THOV NP expression in the liver, but also no ISG15 and very 
little Mx1 expression. 
 
So far, the data obtained with the THOV infection model are quite puzzling. In order to find 
an explanation for the seemingly discrepant data, we examined the liver tissue of THOV-
infected bone marrow chimeras on a macro- and microscopic level. On microscopic scale, 
both Mx1-/-  Mx1-/- and Mx1+/+  Mx1-/- liver tissue showed lesions. As a more objective 
measure for liver damage, we measured the serum levels of two enzymes, ALT and AST. The 
obtained data reflected the results of the histological analysis of the liver tissue. Taken 
together, these results suggest that the expression of a functional Mx1 protein in 
hematopoietic-derived cells cannot protect against productive THOV infection in Mx1-/- 
recipients, but it can delay its progression. 
 
Recently, Kochs et al. postulated that THOV has a clear tropism for CD11b+ cells with a clear 
myeloid/macrophage phenotype (double positive for surface markers CD11b and F4/80) in 
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hypothesis about the role of Mx1 in this THOV infection model. Seeing that THOV shows a 
tropism for myeloid cells in the peritoneum, it is conceivable that – when these myeloid 
cells express Mx1 – they are (partially) protected against THOV infection. If these cells do 
get infected by THOV, they probably transport the virus to the liver (Georg Kochs, personal 
communication). This is a credible theory seeing that Ghosn et al. identified a population of 
large peritoneal macrophages (LPMs) which seem to have a similar phenotype as the 
CD11b+ myeloid cells described by Kochs et al.34,35. It has been shown that these LPMs 
migrate to the omentum – a fat tissue that connects the abdominal organs – upon 
inflammation36, which is in agreement with the disappearance of the CD11b+ myeloid cell 
population from the peritoneal cavity after THOV infection34. By migrating to the omentum, 
the LPMs are also able to reach the liver of infected mice. Here, the virus could infect 
hepatocytes, unless these hepatocytes express a functional Mx1 protein. Viral replication 
would be blocked in the hepatocytes which would explain why Mx1+/+  Mx1+/+ mice show 
no detectable virus titers, since they express Mx1 both in their stromal and their myeloid 
cells. Mx1-/-  Mx1-/- mice show no resistance against THOV, possibly because they do not 
express Mx1 in any cell type. In Mx1+/+  Mx1-/- mice, which only express Mx1 in their 
myeloid cells, we observed high viral titers and necrotic cell lesions in the liver, indicating 
that THOV can still reach the liver. However, THOV NP expression in the liver was low to 
nonexistent. It is plausible that myeloid cells are only partially protected against THOV 
infection, or that the viral inoculum (1000 PFU) is too high for the Mx1+/+ myeloid cells. 
However, the obtained results indicate that Mx1 expression in myeloid cells can delay the 
progression of THOV infection. Mx1-/-  Mx1+/+ mice showed no detectable liver viral titers 
and no liver injury. If THOV could reach the liver tissue via THOV-susceptible Mx1-/- 
myeloid cells, the virus would get inhibited by the presence of a functional Mx1 protein in 
the hepatocytes. However, this does not explain the stronger weight loss and higher Mx1 
protein levels for these mice in comparison with the Mx1+/+  Mx1-/- and Mx1+/+  Mx1+/+ 
groups. Conceivably, since THOV can still reach the liver quite easily in Mx1-/-  Mx1+/+ 
mice, an inflammatory response will be triggered. This is demonstrated by the ISG15 
expression in the livers of Mx1-/-  Mx1+/+ mice. This response can cause the production of 
inflammatory cytokines37,38, and probably is the reason for the high Mx1 expression and 
more severe weight loss in the Mx1-/-  Mx1+/+ group. 
 
In conclusion, to confer resistance against Mx1-susceptible viruses which do not have a 
tropism for myeloid cells, like influenza A/Puerto Rico/8/34, Mx1 expression is only 
important in the stromal cells. However, for resistance against Mx1-susceptible viruses that 
infect myeloid cells, like THOV which has a tropism for CD11b+ myeloid cells, Mx1 
expression in bone marrow-derived cells is of major importance. Nevertheless, Mx1 
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expression in stromal cells remains crucial for resistance, also against viruses with a 
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4.4 Materials and methods 
Ethics statement. All animal experiments described in this study were conducted 
according to the national (Belgian Law 14/08/1986 and 22/12/2003, Belgian Royal Decree 
06/04/2010) and European legislation (EU Directives 2010/63/EU, 86/609/EEC). All 
experiments on mice and animal protocols were approved by the ethics committee of Ghent 
University (permit numbers LA1400091 and EC2015-027). 
 
Mice. Mice were bred in-house under Specific Pathogen Free (SPF) conditions. Mice were 
housed in individually ventilated cages, in a temperature-controlled environment with 12h 
light/dark cycles, with food and water ad libitum. B6.A2G Mx1 (Mx1+/+) mice carrying a 
functional A2G Mx1 allele (first described by Horisberger et al.39) were kindly provided by 
Peter Stäheli (University of Freiburg, Germany). Congenic B6.A2G Mx1 (Mx1-/-) carrying the 
defective C57BL/6J Mx1 allele were generated in our laboratory by crossing B6.A2G Mx1 
(Mx1+/+) with C57BL/6J (Mx1-/-) mice, and subsequent crossing of the heterozygous 
offspring. 
 
Bone marrow chimera mice. B6.A2G-Mx1 congenic mice were bred in-house under 
Specific Pathogen Free (SPF) conditions. Starting one week before until three weeks after 
irradiation, mice were given water containing 0.2% neomycin ad libitum. Mice were given 
lethal total body irradiation (10 Grey) with an X-Rad 320 Biological Irradiator (Precision X-
Ray (PXi), North Brandford, Connecticut, USA), and 24h later they were reconstituted with 
syngeneic or allogeneic bone marrow cells (8-10 x 106) that were harvested from femurs of 
age- and sex-matched mice. Experimental transfers were as follows: B6.A2G Mx1-/- donors 
into B6.A2G Mx1-/- recipients (Mx1-/-  Mx1-/-), B6.A2G Mx1-/- donors into B6.A2G Mx1+/+ 
recipients (Mx1-/-  Mx1+/+), B6.A2G Mx1+/+ donors into B6.A2G Mx1+/+ recipients (Mx1+/+ 
 Mx1+/+), and B6.A2G Mx1+/+ donors into B6.A2G Mx1-/- recipients (Mx1+/+  Mx1-/-). 
Animals were allowed to reconstitute for eight weeks. 
 
Virus challenge. Mice were challenged with 10 LD50 (approximately 170 PFU) of mouse 
adapted (ma) influenza A/Puerto Rico/8/34 (PR8) (H1N1) or with 103 PFU Thogoto virus 
SiAr 126 (THOV) (Kindly provided by Georg Kochs (University of Freiburg, Germany)). The 
challenge dose was administered intranasal in a volume of 50 µl (maPR8) or 
intraperitoneally in a volume of 100 µl (THOV) to mice anesthetized with a mixture of 
ketamine (10 mg/kg) and xylazine (60 mg/kg). Morbidity was monitored during six 
(maPR8) or four (THOV) days post infection. Loss of 25% of bodyweight was used as a 
humane endpoint for euthanizing moribund mice. 
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Determination of influenza lung virus titers. Several mice of each group were killed at 
different time points (0, 3, and 6 days post infection (dpi)) by intraperitoneal injection of 
pentobarbital (125 µg/g). The mouse lungs were removed aseptically, and the left lobe was 
snap-frozen in liquid nitrogen until further processing. Lung extracts were made by 
homogenizing the lungs in PBS using metal beads. Cell debris was cleared by centrifugation 
for 10 min at 400g and 4°C. Cleared lung homogenates were stored at -80°C. Influenza virus 
titers were determined in triplicate by plaque titration on MDCK cells (300 000 cells per 
well in a 12-well plate). Monolayers were infected for 1h with 500 µl of serial 1:10 dilutions 
of the lung homogenates in serum-free DMEM medium supplemented with penicillin and 
streptomycin. Following inoculation, the supernatant was replaced by medium containing 2 
µg/ml trypsin and 0.6% avicel RC-851 (FMC Biopolymers). Two days after infection, cells 
were fixed with 4% paraformaldehyde, and permeabilized with PBS containing 0.2% Triton 
X-100. Plaques were stained using a mouse monoclonal antibody against the ectodomain of 
the influenza M2 protein (mAb6540), and an HRP-conjugated anti-mouse IgG antibody 
(Sheep anti-mouse IgG HRP, GE Healthcare, UK). Plaques were then visualized by using 
TrueBlue peroxidase substrate (Seracare, Gaithersburg, MD, USA). 
 
Determination of Thogoto liver virus titers. Mice were killed by cervical dislocation, the 
liver was removed aseptically, and one of the lobes was used for histochemistry. Of the 
remaining tissue, extracts were made by homogenizing the livers in PBS using metal beads. 
Cell debris was cleared by centrifugation for 10 min at 400g and 4°C. Cleared liver extracts 
were stored at -80°C. Thogoto virus titers were determined in duplicate by titration on Vero 
cells. Monolayers (300 000 cells in a 6-well plate) were infected for 1h with 1 ml of serial 
1:10 dilutions of the liver homogenates in DMEM medium supplemented with 2% fetal calf 
serum and 20 mM HEPES pH 7.3. Following inoculation, the supernatant was replaced by 
medium containing 0.6% avicel RC-951 (FMC Biopolymers). Four days after infection, cells 
were fixed with 4% paraformaldehyde. The cell monolayers were stained with a crystal 
violet solution (1% crystal violet + 1% methanol + 20% ethanol) for approximately 15 
minutes at room temperature. The crystal violet solution was removed, and monolayers 
were washed with water. 
 
Histopathological examination of livers. Livers of bone marrow chimeric mice (n = 4 per 
group) were excised at 4 dpi. After fixation in 4% paraformaldehyde (PFA) and embedding 
in paraffin, livers were sectioned at 5 µm and stained with hematoxylin and eosin for 
histological evaluation. Images were obtained with an Axioscan.Z1 slide scanner (Zeiss, 
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ALT/AST assay. Blood was taken via retro-orbital bleeding after sedation of the mice with 
pentobarbital (125 µg/g). To prepare serum, samples were let to clot overnight at 4°C. The 
next day, samples were centrifuged at 14000 rpm for 3 minutes and obtained serum 
samples were stored at -20°C. Levels of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were measured using a Hitachi kit and apparatus in the Clinical 
Biology Laboratory of Ghent University Hospital. 
 
Flow cytometry. Several mice of each group were killed at different time points (0, 3, and 6 
dpi) by intraperitoneal injection of pentobarbital (125 µg/g). The mouse lungs and 
mediastinal lymph nodes were removed aseptically; only the right lobes of the lung were 
used for flow cytometric analysis. Lung single cell suspensions were generated using 70 µm 
nylon cell strainers (Falcon, Corning, NY, USA). The immune cell composition of these 
tissues was then determined by analyzing the surface expression of different lineage 
markers. Briefly, high-affinity Fc receptors (FcRs) were blocked by incubation with purified 
anti-mouse CD16/CD32 (Fc Block, BD Pharmingen, 553142, 1/500) for 30 min at 4°C. 
Subsequently the cells were stained with an antibody panel designed to specifically analyze 
the T cell composition or with a broader panel for 1h at 4°C in the dark. For the T cell panel, 
cells were stained with a fixable viability stain (eBioscience Fixable Viability Dye eFluor 
506, ThermoFischer, 65-0866-14, 1/1000), CD3e-PE (eBioscience, ThermoFisher, 12-0031-
81, 1/300), CD4-PE-Cy5 (BD Pharmingen, 561836, 1/300), MHCII-PerCP-Cy5.5 (BioLegend, 
107625, 1/500), CD8a-PE-Cy7 (eBioscience, ThermoFisher, 25-0081-81, 1/300), and CD45-
AF700 (eBioscience, ThermoFisher, 56-0451-82, 1/300). For the broader panel, cells were 
stained with a fixable viability stain (eBioscience Fixable Viability Dye eFluor 450, 
ThermoFischer, 65-0863-14, 1/1000), XCR1-BV510 (BioLegend, 148218, 1/400), CD11b-
BV605 (BD Horizon, 563015, 1/500), CD64-BV711 (BioLegend, 139311, 1/100), SiglecF-PE 
(BD Pharmingen, 552126, 1/1000), CD172a-Biotin (eBioscience, ThermoFischer, 13-1721-
82, 1/100), Streptavidin-PE-CF594 (BD Horizon, 562284, 1/1000), CD3-PE-Cy5 
(eBioscience, ThermoFischer, 15-0031-82, 1/200), CD19-PE-Cy5 (eBioscience, 15-0193-83, 
1/200), CD11c-PE-Cy7 (eBioscience, ThermoFischer, 25-0114-82, 1/800), MHCII-APC-
eFluor780 (eBioscience, ThermoFisher, 47-5321-82, 1/1500), and CD45-AF700 
(eBioscience, ThermoFisher, 56-0451-82, 1/300). After staining, samples were analyzed on 
an LSRFortessa flow cytometer (BD Biosciences, San Jose, CA, USA), and analyzed using 
FlowJo X (Treestar) software. 
 
Intracellular cytokine staining (ICS) and flow cytometry after ex vivo restimulation. 
Ten days after FLUAV infection, spleens were isolated aseptically and splenocytes were 
prepared. After lysis of RBCs with NH4Cl solution, 5 x 105 splenocytes were plated in 1 ml of 
culture medium (RPMI-1640 medium supplemented with 10% fetal calf serum, 2 mM L-
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glutamine, 0.4 mM Na-pyruvate, nonessential amino acids, 100 U/ml penicillin, and 0.1 
mg/ml streptomycin.) supplemented with NP366-374 ASNENMETM peptide (Genscript, 
RP20267-5) at 4 µg/ml. After 6h of peptide restimulation, 1 µl Golgiplug (brefeldin A, BD, 
Erembodegem, Belgium) was added to 1 ml culture medium for measurement of cytokine 
production by ICS. The Cytofix/Cytoperm kit (BD) was used according to the 
manufacturer’s protocol. Briefly, 16h after addition of Golgiplug, cells were stained with a 
Live/Dead marker (eBioscience Fixable Viability Dye eFluor 450, 65-0866-14, 
ThermoFisher, 1/1000), and with fluorochrome labeled antibodies against MHCII (MHCII-
eFluor450, 48-5321-82, ThermoFischer, 1/500), CD3 (CD3-AF488, 557666, BD 
Pharmingen, 1/250), CD4 (CD4-PE-Cy5, BD Pharmingen, 561836, 1/300) and CD8 (CD8-PE-
Cy7, 25-0081-81, ThermoFischer, 1/300). Cells were then fixed/permeabilized using the 
Cytofix/Cytoperm kit (BD), and stained for IFNγ (IFNγ-APC, BD Pharmingen, 554413, 
1/100). Cells were then analyzed by using an LSR Fortessa (BD) with FlowJoX software 
(Treestar, Ashland, Orlando). 
 
Real-time quantitative PCR (RT-qPCR). Cleared lung homogenates obtained from 
infected mice, as described for the determination of influenza lung virus titers, were stored 
at -80°C. RNA isolation was done with the High Pure RNA Isolation Kit (11828665001, 
Roche) as indicated by the manufacturer. Total mRNA was converted to cDNA by RT-PCR 
using oligo-dT reaction (Transcriptor First Strand cDNA Synthesis Kit, 04897030001, 
Roche). Ten nanogram of cDNA was used for each reaction, and triplicate reactions were 
setup in 384-well plates. qPCR reactions based on SYBR green detection, were performed 
using a LightCycler equipment (Roche). qPCR-data were analyzed using the qbase+ 
software packet (Biogazelle, Zwijnaarde, Belgium). 
 
List of primers used in this study: 5’-GGGAAGAACACCGATCTTGA-3’; M1/2 reverse: 5’-
CGGTGAGCGTGAACACAAAT-3’; NA forward: 5’-CATCTCTTTGTCCCATCCGT-3’; NA reverse: 
5’-GTCCTGCATTCCAAGTGAGA-3’; HA forward: 5’-GAGGAGCTGAGGGAGCAAT-3’; HA 
reverse: 5’-GCCGTTACTCCGTTTGTGTT-3’; PB1 forward: 5’-CCTCCTTACAGCCATGGGA-3’; 
PB1 reverse: 5’-GTGCTCCAGTTTCGGTGTTT-3’; PB2 forward: 5’-
GGATCAGACCGAGTGATGGT-3’; PB2 reverse: 5’-CCATGCTTTAGCCTTTCGACT-3’; PA 
forward: 5’-CATCAATGAGCAAGGCGAGT-3’; PA reverse: 5’-GCCCCTGTAGTGTTGCAAAT-3’; 
NP forward: 5’-CAGCCTAATCAGACCAAATG-3’; NP reverse: 5’-TACCTGCTTCTCAGTTCAAG-
3’; NS1 forward: 5’-TTCACCATTGCCTTCTCTTC-3’; NS1 reverse: 5’-
CCCATTCTCATTACTGCTTC-3’; HPRT1 forward: 5’-AGTGTTGGATACAGGCCAGAC-3’; HPRT1 
reverse: 5’-CGTGATTCAAATCCCTGAAGT-3’; UBC forward: 5’-
AGGTCAAACAGGAAGACAGACGTA-3’; UBC reverse: 5’-TCACACCCAAGAACAAGCACA-3’; 
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CGAAGGTGGAAGAGTGGGAG-3’; TBP forward: 5’-TCTACCGTGAATCTTGGCTGTAAA-3’; TBP 
reverse: 5’-TTCTCATGATGACTGCAGCAAA-3’; RPL13A forward: 5’-
CCTGCTGCTCTCAAGGTT-3’; RPL13A reverse: 5’-TGGTTGTCACTGCCTGGTACTT-3’; actin 
forward: 5’-GCTTCTAGGCGGACTGTTACTGA-3’; actin reverse: 5’-
GCCATGCCAATGTTGTCTCTTAT-3’. 
 
Antibodies used in western blot analysis. A polyclonal antiserum against mouse Mx1 was 
generated by immunizing New Zealand White rabbits three times subcutaneously with 100 
µg of the synthetic, high-performance liquid chromatography-purified peptide 
CKKFLKRRLLRLDEARQKLAKFSD (C terminus of the Mx1 protein) combined with the 
water-in-oil adjuvant Montanide ISA-720 (SEPPIC SA, Paris, France). The serum IgG fraction 
was enriched by 50% ammonium sulphate precipitation followed by affinity 
chromatography with a protein A column (GE Healthcare). M2e-specific monoclonal 
antibody was produced in our laboratory. Briefly, hybridomas that produce M2e-specific 
monoclonal antibodies were isolated described (Cho et al., 2015, J Virol). After subcloning, 
these hybridoma cultures were scaled up and monoclonal antibodies were purified from 
the culture supernatant with a protein A column (GE Healthcare). Polyclonal anti-influenza 
virus RNP antibody, A/Scotland/840/74 (H3N2), (antiserum, goat), NR-3133 was obtained 
from the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, 
NIH. Rabbit polyclonal anti-mouse IFITM3 antibody was obtained from Abcam (ab15592). 
Monoclonal anti-actin antibody (mouse) was purchased from MP Biomedicals (08691001). 
Polyclonal anti-Thogoto virus NP antibody, (antiserum, rabbit), was kindly provided by 
Georg Kochs (University of Freiburg, Germany). Monoclonal anti-ISG15 antibody (mouse) 
was obtained from Santa Cruz Biotechnology Inc. (sc-166755). 
 
Statistical analysis. The obtained data were analyzed using Graphpad Prism 7 or Genstat 
software. Methods used in Genstat are described below. Statistical tests performed in 
Graphpad Prism 7 software are mentioned in figure legends. In Figure 4.7a we used a two-
way ANOVA test with post hoc Tukey’s HSD test. This test is used to compare multiple 
groups when multiple variables are at play. Parametric tests did not apply for Figures 4.6, 
4.7b, 4.10 and S4.3 according to the D’Agostino-Pearson omnibus normality test due to the 
small number of samples. Therefore, the non-parametric alternatives were used. In Figure 
4.6 a two-sided Mann-Whitney U test was used, this is the non-parametric alternative for a 
two-sided T test. In Figures 4.7b, 4.10 and S4.3 we used the Kruskal-Wallis test (the non-
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Relative body weight data analysis 
Relative body weight data was analyzed as repeated measurements using the residual 
maximum likelihood (REML) approach as implemented in Genstat v18 (Payne, 2015). 
Briefly, a linear mixed model with replicate, genotype, time and genotype x time interaction 
as fixed terms, and subject.time used as residual term, was fitted to data. Times of 
measurement were set at equal intervals and an autoregressive correlation structure of 
order 1 with equal variances (i.e. homogeneity across time) was selected as best model fit in 
all cases, based on the Aikake Information Coefficient. Significances of the fixed terms and 
significances of changes in differences between genotype effects over time were assessed 
by an F-test. 
 
Analysis of virus titers 
A linear fixed model with replicate, genotype, time and genotype x time interaction was 
fitted to the data. Significances of the fixed terms and significances of changes in differences 
between genotype effects over time were assessed by an F-test.  
 
Analysis of flow cytometry data 
A linear fixed model with replicate, genotype, time and genotype x time interaction as fixed 
terms was fitted to the eosinophil, neutrophil, CD4+ T cell, CD8+ T cell, AM, moDC, cDC1 and 
cDC2 cells counts expressed as a proportion of CD45+ cells. Plots of residuals against fitted 
values indicated homogeneity of variances in all cases, excluding transformation of the data. 
Significances of the fixed terms and significances of changes in differences between 
genotype effects over time were assessed by an F-test.  
 
Analysis of RT-qPCR data 
A Generalized Linear Mixed Model (GLMM) (fixed model: poisson distribution, log link; 
random model: gamma distribution, log link) as implemented in Genstat v1841 has been 
fitted to RT-qPCR expression data of PB1, PB2, PA, NP, HA, NA, M and NS genes 
simultaneously. The linear predictor vector of the values can be written as follows: log(µ) = 
η = Xβ + Zν, where the matrix X is the design matrix for the fixed terms genotype, time and 
genotype × time, β is their vector of regression coefficients, Z is the design matrix for the 
random term (i.e. gene, replicate and gene × replicate), and ν is the corresponding vector of 
random effect having a gamma distribution. The significance of the fixed interaction term 
genotype × time was assessed by a Wald test. Significance of the regression coefficients 
were assessed by a t-test. Estimated mean values and their standard errors were obtained 
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Figure S4.1 Gating strategy of 
flow cytometry analysis. Gating 
strategy of the T cell panel (a) and 
the broader panel (b). AM = alveolar 
macrophage, moDC = monocyte-
derived dendritic cell, cDC = 
conventional dendritic cell. 
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Figure S4.2 Comparison of different cell types over time between four bone marrow chimeric groups 
after FLUAV infection. Bone marrow chimeric mice were infected with 10 LD50 of maPR8, and lungs were 
isolated at 0, 3 and 6 dpi. These lungs were processed to single cell suspensions, which were stained for 
different surface markers. This allowed us to discriminate neutrophils (a), eosinophils (b), conventional 
dendritic cells type 1 (c), conventional dendritic cells type 2 (d), CD4+ T cells (e), and CD8+ T cells (f). Data 
points represent the average level of at least six mice. Error bars represent standard error of the mean. 
Asterisks indicate the significant difference with the Mx1-/-  Mx1-/- bone marrow chimera group over time. *, 
p < 0.05; **, p < 0.01; ***, p < 0.001. Circles indicate the significant difference with the Mx1+/+  Mx1-/- bone 











Figure S4.3 Comparison of different cell types between four bone marrow chimeric groups after 
FLUAV infection. Same data as in Figure 4.5 and S2, showing the individual level of monocyte-derived DCs 
(a), alveolar macrophages (b), neutrophils (c), eosinophils (d), conventional dendritic cells type 1 (e), 
conventional dendritic cells type 2 (f), CD4+ T cells (g), and CD8+ T cells (h). Each data point represents the 
relative amount of cells of each indicated cell type of a single animal. Asterisks indicate the significant 
difference with the Mx1-/-  Mx1-/- bone marrow chimera group at the indicated time point. *, p < 0.05; **, p < 
0.01; ***, p < 0.001. Circles indicate the significant difference with the Mx1+/+  Mx1-/- bone marrow chimera 
group at the indicated time point. °, p < 0.05; °°, p < 0.01. Kruskal-Wallis test with post hoc Dunn's multiple 
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Current influenza vaccines are designed to mainly elicit strong antigen-specific humoral 
responses. This strategy proves to be very efficient when the vaccine strains match the 
circulating influenza strains. However, in case of a mismatch the vaccine efficacy is greatly 
reduced. To prevent this in the future, a lot of effort has already been put into the 
development of influenza vaccines which induce broadly protective and long-lasting 
immunity. Eliciting specific CD8+ T cells directed against the influenza A virus (FLUAV) 
nucleoprotein (NP) is a frequently used strategy to do this. Therefore, Altenburg et al. used 
recombinant modified vaccinia Ankara (rMVA) as a vaccine vector for the induction of 
FLUAV NP-specific CD8+ T cells. They introduced several modifications to NP to enhance the 
retention and degradation in the cytosol, and consequently increase antigen processing and 
presentation to improve the induction of a CD8+ T cell response. These rMVA-NP constructs 
showed promising results in vitro, but displayed no differences with the wild type NP 
construct after vaccination of C57BL/6 mice. Here, we tested the rMVA-NP constructs in the 
B6.A2G Mx1+/+ mouse strain, which expresses the Mx1 protein. This protein has a strong 
antiviral effect against FLUAV. Hence, we hypothesized that Mx1 could be an extra limiting 
factor for the different rMVA-NP constructs after vaccination. In this model, the modified 
rMVA-NP constructs would have an advantage over the wild type rMVA-NP construct. We 
showed that, although there is a trend that certain modified rMVA-NP constructs perform 
better than the wild type rMVA-NP construct, there are no significant differences between 
the different rMVA-NP constructs when used in the B6.A2G Mx1+/+ mouse strain. 
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Current influenza vaccines mainly elicit antibodies directed against the influenza HA , and 
only a limited cellular immune response1,2. For a cellular immune response to occur, host 
cells should produce viral peptides which they present on their cell surface by means of 
MHC molecules. These viral peptides are generated through processing of viral proteins by 
the proteasome located in the cytosol. These peptides are loaded onto MHC molecules 
which are transported to the cell surface, where they get recognized by T cells (MHC-I 
molecules are recognized by CD8+ T cells, and MHC-II molecules are recognized by CD4+ T 
cells)3. The bulk of FLUAV-specific CD8+ T cells recognize NP-derived epitopes4-6. 
 
Modified vaccinia Ankara (MVA) is a Vaccinia virus-derived live attenuated virus that can 
efficiently induce T cell responses. MVA has been exploited as a vaccine that could protect 
against small pox virus, and as a recombinant vaccine vector to induce an immune response 
against heterologous antigens. MVA has a number of advantages making it an ideal system 
for delivery of viral antigen7. For example, the antigen of interest is expressed in its native 
conformation, and MVA can elicit high levels of antigen-specific humoral and cellular 
immune responses. The use of a live vector allows de novo synthesis of viral proteins in the 
cytosol of antigen-presenting cells which facilitates the antigen processing and presentation 
to CD8+ T cells. The MVA-NP+M1 vaccine, which expresses the internal FLUAV proteins NP 
and M1, was designed to specifically induce virus-specific T cell responses. This vaccine was 
tested in clinical trials and showed mainly induction of CD8+ T cells8. The MVA-NP+M1 
vaccine was also able to protect against experimental infection one month after vaccination, 
and was shown to be safe for administration to elderly people9,10. 
 
Altenburg and colleagues hypothesized that the immunogenicity of NP expressed by an 
MVA vector could be increased by enhancing the cytosolic retention and degradation of NP. 
For this they modified the NLS of NP to prevent it from entering the nucleus. This was done 
in two different ways. Either two residues of the NLS were mutated into alanine residues 
(NPmut), or the NLS was completely deleted (NPΔNLS). Another way to alter the cytosolic 
degradation of NP was to fuse ubiquitin to the amino-terminus of the protein (UbqNP). This 
targets the fusion protein for degradation by the proteasome. Initial tests with recombinant 
MVA (rMVA) vectors expressing these different NP variants showed that the modifications 
had the intended effects in vitro. After infection with a low dose of the rMVA constructs, NP-
specific CD8+ T cell clones with either a low or a high functional avidity were both activated 
more efficiently by the mutated NP constructs than by the wild type NP construct. When 
infected with a high dose of the rMVA constructs, this effect was only apparent for the T cell 
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differences in activation between the different NP constructs. This indicates that under 
suboptimal conditions (limited amounts of antigen or CD8+ T cells of low functional 
avidity), modifying NP improves the CD8+ T cell response in vitro. Moreover, pulse-labeling 
experiments allowed to conclude that the NP variants expressed by the rMVA-NPΔNLS and 
rMVA-UbqNP constructs were subject to accelerated degradation of NP in infected cells. 
 
Immunization of C57BL/6 mice with these rMVA-NP constructs reduced body weight loss 
and viral replication in the lungs after a lethal challenge with influenza A/Puerto Rico/8/34 
virus, but did not reveal differences between the constructs. The differential effects in vitro, 
and the lack of these effects in vivo, led us to the following hypothesis. In order to elicit a 
strong CD8+ T cell response, the amount of processed antigen should reach a certain 
threshold. In C57BL/6 mice, this CD8+ T cell response is dominated by NP366-374-specific 
CD8+ T cells, and this antigen-threshold is readily reached after vaccination with rMVA-
NPwt11. Demonstrating the possible enhanced T cell responses against NP elicited by 
vaccination with vectored NP variants may therefore require a host in which NP-specific T 
cell responses are restricted at an additional level. We hypothesized that the type I and III 
IFN-induced Mx1 gene could represent such a restriction factor. 
 
In contrast to most inbred mouse strains such as C57BL/6, B6.A2G mice have an intact Mx1 
gene12, and the encoded protein Mx1 has a strong antiviral effect against FLUAVs13,14. 
FLUAV NP is an important target of Mx1, and Mx1 has been shown to interact with NP15. 
The NP protein is localized in the nucleus of the infected host cell in the first hours after 
infection. Since mouse Mx1 also resides in the nucleus and interacts with FLUAV NP, we 
hypothesize that Mx1 could be a factor that limits the amount of NP antigen and processed 
NP peptides that can be uploaded in the MHC-I complex. If this is the case, then the mutated 
rMVA-NP constructs could have an advantage over the rMVA-NPwt construct in the B6.A2G 
background. 
 
To test our hypothesis, we compared the outcome of a prime-boost vaccination with the 
different rMVA-NP constructs. The presence of NP-specific CD8+ T cells in the spleen and in 
cells isolated from the blood were determined post vaccination. 
5.2 Results 
Groups of five mice (males and females) were vaccinated with rMVA, rMVA-NPwt, rMVA-
NPmut, rMVA-NPΔNLS, or rMVA-UbqNP. Immunizations were performed in congenic 
B6.A2G Mx1-/- and B6.A2G Mx1+/+ mice. Mice were vaccinated twice intramuscularly with 
108 PFU rMVA in the hind legs (50 µl/leg), with a time interval of four weeks. One week 
after the second immunization, blood and spleens were isolated, and single cells were 
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prepared for intracellular cytokine staining (ICS) and enzyme-linked immunospot 
(ELISPOT) assay. To investigate NP-specific cellular responses, restimulation was done with 
4 µg/ml of the H2b-restricted A/PR8-derived NP366-374 (ASNENMETM) peptide. 
 
NP-specific CD8+ T cell responses determined in splenocytes of B6.A2G Mx1-/- mice were 
detectable after vaccination with rMVA-NPΔNLS and rMVA-UbqNP (Figure 5.1a and 
supplementary figure S5.1). In spleens of B6.A2G Mx1+/+ mice we did not detect a significant 
NP-specific CD8+ T cell response after any of the treatments (Figure 5.1b). Indeed, the high 
Figure 5.1 ICS analysis of vaccinated B6.A2G Mx1-/- and B6.A2G Mx1+/+ mice. B6.A2G Mx1-/- and B6.A2G 
Mx1+/+ mice were vaccinated twice, four weeks apart, with rMVA (negative control) or one of the four 
indicated rMVA-NP constructs. One week after the second immunization, mice were euthanized, and spleen 
and blood were isolated. Splenocytes (a and b) and PBMCs (c and d) were pulsed with the NP366–374 peptide. 
IFNγ-production by CD3+ CD8+ T cells was used as a readout for CD8+ T cell activation. Each data point 
represents the percentage of CD8+ T cells that are IFNγ+ for a single animal. Data are obtained in one single 
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NP-responses in splenocytes derived from the negative control vaccinated Mx1+/+ mice did 
not allow to conclude that the MVA-NP vaccination had worked in these mice. ICS analysis 
of peripheral blood mononuclear cells (PBMCs) did not reveal significant differences 
between the different treatments, nor between the two mouse strains (Figure 5.1c and d). 
 
ELISPOT analysis of splenocytes revealed that vaccination with rMVA-NPmut and rMVA-
NPΔNLS induced a clear and comparable NP366-374-specific recall response in B6.A2G Mx1-/- 
mice that was significantly higher than the responses found in the negative control 
Figure 5.2 ELISPOT analysis of vaccinated B6.A2G Mx1-/- and B6.A2G Mx1+/+ mice. B6.A2G Mx1-/- and 
B6.A2G Mx1+/+ mice were vaccinated twice, four weeks apart, with rMVA (negative control) or one of the four 
indicated rMVA-NP constructs. One week after the second immunization, mice were euthanized, and spleen 
and blood were isolated. Influenza-specific T lymphocyte responses were measured in splenocytes (a and b) 
and PBMCs (c and d) by IFNγ release after stimulation with NP366-374 peptide. Each data point represents the 
amount of IFNγ-producing cells (Spot Forming Cells = SFC) per million splenocytes or PBMCs for a single 
animal. Data are obtained in one single experiment. Bars indicate means. *, p < 0.05; **, p < 0.01, Kruskal-
Wallis test with Dunn's multiple comparison test as post hoc. 
Chapter 5 
CHAPTER 5 | Involvement of Mx1 in MVA-NP-induced immunogenicity 
138 
 
vaccinated group (Figure 5.2a). In B6.A2G Mx1+/+ mice, we also observed a significant 
response induced by rMVA-NPmut and rMVA-NPΔNLS, but again no significant differences 
were observed between these constructs and the wild type NP construct (Figure 5.2b). 
However, in B6.A2G Mx1+/+ mice there does seem to be a trend that the rMVA-NPΔNLS 
induces a higher induction of NP366-374-specific responses. In both mouse strains, based on 
the ELISPOT analysis, rMVA-UbqNP poorly induces an NP366-374-specific T cell response. 
Finally, in contrast to the ICS data, the ELISPOT assay performed on PBMCs largely reflects 
the data from the assay on splenocytes (Figure 5.2c and 5.2d). 
5.3 Discussion 
Our findings from B6.A2G Mx1-/- mice differ from the ones from Altenburg and colleagues in 
the sense that, based on the ICS assay, we could not detect an NP-specific CD8+ T cell 
response after vaccination with rMVA-NPwt or rMVA-NPmut. The rMVA-NPΔNLS construct 
does seem to elicit the strongest antigen-specific CD8+ T cell response, as was also seen in 
that study. However, these findings are not reflected in the ICS assay performed with 
PBMCs. This is probably due to the low amount of CD8+ T cells in the blood, and the high 
variability of the amount of IFNγ+ cells between the different mice. We also noticed elevated 
background levels for the splenocytes of B6.A2G Mx1+/+ mice in the ICS assay (Figure 5.1b 
and 5.1d). This variation was probably because of heterogeneity in the different treatment 
groups which were made up of males and females which were bred in our own animal 
facility. 
 
The ELISPOT assay seems to correlate much better with the results reported by Altenburg 
et al.. This is partly due to the higher sensitivity of this assay in comparison with the ICS 
assay. The results of our experiments do not support a role for Mx1 in the control of NP-
specific T cell responses following vaccination with NP-encoding rMVA vectors. At best, 
based on the ELISPOT analysis, in B6.A2G Mx1+/+ mice there seems to be a trend that the 
rMVA-NPΔNLS induces a higher induction of NP366-374-specific responses (Figure 5.2). 
 
We could not show a clear advantage of the modified rMVA-NP constructs in B6.A2G Mx1+/+ 
mice. The possible role of Mx1 as a factor that limits the amount of NP antigen could thus 
not be demonstrated. Perhaps intramuscular vaccination with rMVA-NP constructs does 
not induce a strong enough type I IFN response. However, it has been shown that MVA, in 
contrast to wild type vaccinia virus, does not produce viral proteins that function as 
receptor-like inhibitors of type I and type II IFNs16. Moreover, infection with MVA can be 
detected by pathogen-sensing mechanisms in the host, which results in the production of 
IFNs, cytokines and chemokines17. This suggests that Mx1 expression will likely be induced 
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for NP antigen presentation after delivery by an MVA vector. Possibly the production of NP 
is too high for Mx1 to cope with the amount of antigen. Another possibility is that the 
nuclear phase of the NP protein is too short for mouse Mx1, which resides in the nucleus, to 
efficiently hinder NP from being processed for antigen presentation. 
 
Future experiments will consist of repeating this vaccination experiment. Additional 
readouts could be the monitoring of the M1-specific T cell response after vaccination with a 
plasmid which codes for the FLUAV M1 protein. Since M1 is not targeted by Mx1, it should 
show us a baseline T cell response in both B6.A2G Mx1-/- and B6.A2G Mx1+/+ mice. Another 
possibility is to measure the specific CD8+ T cell response directed against an alternative 
epitope such as NP217-225. This epitope was shown to be subdominant to the NP366-374 
epitope18. Altenburg et al. observed that, in vitro, especially the rMVA-NPΔNLS and rMVA-
UbqNP constructs could activate low functional avidity NP-specific CD8+ T cell clones more 
efficiently than the rMVA-NPwt construct. This led to the hypothesis that under suboptimal 
conditions (when antigen amounts are limited or when CD8+ T cells are of low functional 
avidity), modifying NP improves the CD8+ T cell response11. In our experimental setup and 
hypothesis, the suboptimal condition is provided by the expression of the Mx1 protein. 
Conceivably, the effect of Mx1 is more evident on the CD8+ T cell response against a 
subdominant epitope. In addition, it would also be relevant to test these rMVA vaccines in a 
mouse strain which expresses the human MxA protein instead of the murine Mx1. This 
mouse strain expresses a functional human MxA protein in response to IFN exposure in all 
major organs19. In contrast to mouse Mx1, human MxA resides and inhibits FLUAV in the 
cytoplasm20. Since rMVA produces the NP protein in the cytoplasm, MxA can interact with 
NP at an earlier time point than mouse Mx1. One could argue that MxA could also inhibit the 
infection by MVA. However, Lorenzo et al. recently observed that vaccinia viruses are not 
susceptible to MxA21, making this mouse strain a suitable model to further test the rMVA-
NP vaccines. 
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5.4 Materials and methods 
Ethics statement. All animal experiments described in this study were conducted 
according to the national (Belgian Law 14/08/1986 and 22/12/2003, Belgian Royal Decree 
06/04/2010) and European legislation (EU Directives 2010/63/EU, 86/609/EEC). All 
experiments on mice and animal protocols were approved by the ethics committee of Ghent 
University (permit numbers LA1400091 and EC2017-001). 
 
Mice. Mice were bred in-house under Specific Pathogen Free (SPF) conditions. Mice were 
housed in individually ventilated cages, in a temperature-controlled environment with 12h 
light/dark cycles, with food and water ad libitum. Congenic B6.A2G Mx1+/+ mice carrying a 
functional A2G Mx1 allele were kindly provided by Peter Stäheli (University of Freiburg, 
Germany). Congenic B6.A2G Mx1-/- carrying the defective C57BL/6J Mx1 allele were 
generated in our laboratory by crossing B6.A2G Mx1+/+ with C57BL/6J (Mx1-/-) mice, and 
subsequent crossing of the heterozygous offspring. For these experiments, littermates were 
used. Each Group of five mice consisted of a mix of either three males and two females or 
vice versa. 
 
Vaccination. Recombinant MVA constructs were kindly provided by Guus Rimmelzwaan 
(Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands). Mice (n = 5/group) 
were vaccinated twice, under mild isoflurane anesthesia, intramuscularly with 108 PFU 
rMVA in the hind legs (50 µl/leg), with a time interval of four weeks. 
 
IFNγ enzyme-linked immunospot assay (ELISPOT). IFNγ enzyme-linked immunospot 
plates from U-Cytech Biosciences (Utrecht, The Netherlands) were used according to the 
manufacturer’s protocol. Briefly, 96-well immuno-plates were coated with sterile 
monoclonal anti-IFNγ antibodies and blocked with blocking buffer. One week after the 
second immunization, the spleens and blood of five mice per group were isolated 
aseptically and splenocytes/PBMCs were prepared. After lysis of RBCs with NH4Cl solution, 
3 × 105 splenocytes/PBMCs were plated in 100 µl of culture medium supplemented with 
NP366-374 ASNENMETM peptide at 4 µg/ml. After 16h of peptide restimulation, plates were 
washed with enzyme-linked immunosorbent assay wash buffer and IFNγ trapped on the 
plates was detected by a biotinylated polyclonal anti-IFNγ antiserum. GABA-conjugated 
streptavidin in combination with silver stain reagent resulted in the formation of black 
silver spots at places where immune cells secreted IFNγ during peptide-restimulation. The 
spots were counted using an Eli-Expert ELISPOT reader and the Eli.Analyse software 
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Intracellular cytokine staining (ICS) and flow cytometry after ex vivo restimulation. 
One week after the second immunization, spleens and blood of five mice per group were 
isolated aseptically and splenocytes/PBMCs were prepared. After lysis of RBCs with NH4Cl 
solution, 5 x 105 splenocytes/PBMCs were plated in 1 ml of culture medium (RPMI-1640 
medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 0.4 mM Na-pyruvate, 
nonessential amino acids, 100 U/ml penicillin, and 0.1 mg/ml streptomycin) supplemented 
with restimulation peptide (described above) at a concentration of 4 µg/ml. After 6h of 
peptide restimulation, 1 µl Golgiplug (brefeldin A, BD, Erembodegem, Belgium) was added 
to 1 ml culture medium for measurement of cytokine production by ICS. The 
Cytofix/Cytoperm kit (BD) was used according to the manufacturer’s protocol. Briefly, 10 
hours after addition of Golgiplug, cells were stained with a Live/Dead marker (eBioscience 
Fixable Viability Dye eFluor 450, 65-0866-14, ThermoFisher, 1/1000), and fluorochrome 
labeled antibodies against CD45 (CD45-AF700, 56-0451-82, ThermoFischer, 1/300), MHCII 
(MHCII-eFluor450, 48-5321-82, ThermoFischer, 1/500), CD3 (CD3-AF488, 557666, BD 
Pharmingen, 1/250) and CD8 (CD8-PE-Cy7, 25-0081-81, ThermoFischer, 1/300). Cells 
were then fixed/permeabilized using the Cytofix/Cytoperm kit (BD), and stained for IFNγ 
(IFNγ-APC, BD Pharmingen, 554413, 1/100). Cells were then analyzed on an LSR II flow 
cytometer (BD) with FlowJoX software (Treestar, Ashland, Orlando). 
 
Statistical analysis. Parametric tests did not apply for ICS or ELISPOT samples according 
to the D’Agostino-Pearson omnibus normality test due to the small number of samples. 
Therefore, the Kruskal-Wallis test with Dunn’s correction was used. 
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The role of Mx1 in the antiviral immune cell compartment 
Mx proteins have been elaborately studied during the past 50 years. A lot of data have been 
produced concerning the innate function and the working mechanism of Mx proteins, 
mainly for human MxA and murine Mx1 proteins. Our lab also contributed to this very 
challenging puzzle by demonstrating that mouse Mx1 can interact with FLUAV NP and PB2, 
and can prevent these proteins from interacting with each other1. Moreover, we have 
shown that mouse Mx1 might actively disrupt existing FLUAV vRNP molecules2. However, 
little is known about the role of Mx1 in the immune cell compartment. This is mainly 
because most inbred mouse strains used in immunological studies do not express a 
functional Mx1 protein3. The few studies which were performed with Mx1+/+ mice 
concluded that Mx1 has no role in immune cells that confer resistance against FLUAV 
infection4-6. Nonetheless, several other studies provided indirect evidence which shows that 
certain immune cell types are better protected against a FLUAV infection than others due to 
an IFN-induced antiviral state7,8. The clarification of the role of Mx1 in immune cells after a 
viral infection was the main issue addressed in this thesis. 
 
The initial goal of this project was to find out if there is a function for the antiviral Mx1 
protein in the immune cell compartment. Better said, is Mx1 capable of protecting certain 
immune cell types which are involved in the immune response against a FLUAV infection? 
For this, we generated bone marrow chimeras using B6.A2G Mx1-/- mice which do not 
express a functional Mx1 protein, and B6.A2G Mx1+/+ mice which do express a functional 
Mx1 protein. After a potentially lethal FLUAV infection we did not observe any major effects 
of Mx1 expression in bone marrow-derived cells. Multiple readouts (body weight, lung viral 
titers, viral mRNA levels and protein levels) pointed out that the main determinant of 
resistance is Mx1 expression in the stromal cells. This divergence between Mx1-/- and 
Mx1+/+ recipients was also clear in the levels of eosinophils, moDCs and AMs measured in 
the lungs after infection. This entails that Mx1 expression in the stromal cells of the 
recipient mice determines the resistance against or the susceptibility for a lethal FLUAV 
infection irrespective of Mx1 expression in the bone marrow-derived cell compartment. 
 
Following this, we examined the antigen-specific immune response in bone marrow 
chimeras after a sublethal FLUAV infection. Ten days after infection we observed the 
formation of a robust antigen-specific immune response irrespective of the genotype of the 
bone marrow-derived cells or recipient. This indicated that Mx1 expression in the bone 
marrow-derived cells does not play a role of significance in the formation of a primary 
antigen-specific immune response against FLUAV. In addition, this result also suggested 
that Mx1 expression in stromal cells does not impair the formation of an antigen-specific 
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immune response against FLUAV. Thus, we can conclude that the expression of a functional 
Mx1 protein in bone marrow-derived cells is of less importance for resistance against a 
FLUAV infection than Mx1 expression in the stromal cells, and that Mx1 does not impede 
the formation of a cellular immune response. 
 
Like Mx proteins, IFITM3 is also the product of an ISG that has been shown to have a strong 
antiviral function against FLUAV9,10. Our results show that FLUAV-infected animals which 
do not express Mx1 succumb to the consequences of the infection, even when they express 
high levels of IFITM3. This suggests that IFITM3 alone cannot cope with a possible lethal 
FLUAV infection. We have shown that expression of Mx1 protein in the stromal cells can 
protect mice from succumbing to FLUAV infection. To our knowledge, it has never been 
investigated in an in vivo setting whether Mx1 alone, in the absence of IFITM3, can protect 
animals against a possible lethal FLUAV infection. Thus, it is still possible that Mx1 works 
together with IFITM3 to confer resistance against FLUAV infections. In this respect, Xiao et 
al. showed an additive antiviral effect when both IFITM3 and human MxA were coexpressed 
in FLUAV-infected cells11. Moreover, it was postulated that MxA cannot fully compensate for 
the loss of IFITM3 in IFN-treated cells challenged with FLUAV12. Interestingly, fusion of MxA 
with an NLS showed that the working mechanism of MxA is similar to that of murine Mx1 in 
the nucleus13,14. Taking this into account, it is tempting to extrapolate these observations to 
murine Mx1. However, this cannot be done without caution, because murine Mx1 and 
human MxA reside in other cellular compartments (nucleus and cytoplasm respectively). 
This would imply that the antiviral interplay, if any, between IFITM3 and MxA or between 
IFITM3 and Mx1 could be completely different. 
 
In order to further elucidate the role of Mx1 in immune cells after a viral infection, we 
implemented a second viral infection model. THOV was chosen because, like FLUAV, it is 
also an Mx1-sensitive Orthomyxovirus, and small rodents are natural hosts for this 
virus15,16. Bone marrow chimeric mice were infected with a potentially lethal dose of THOV. 
Unlike the FLUAV infection model, we could readily see an effect of the bone marrow 
genotype. Mx1-/- recipient mice which received Mx1+/+ bone marrow showed less body 
weight loss, less NP expression, and less pronounced liver pathology than Mx1-/- recipient 
mice which received Mx1-/- bone marrow. The most plausible reason for this is the THOV 
tropism for peritoneal cells with a hematopoietic origin17. Nonetheless, Mx1 expression in 
the stromal cells also showed to be the most decisive factor for resistance against THOV 
infection. Apart from increased morbidity and differential Mx1 and ISG15 production, Mx1-
/-  Mx1+/+ mice showed similar results compared to Mx1+/+  Mx1+/+ mice after THOV 
infection. Both groups contained the virus equally well in the sense that the liver viral titers 
were below the detection limit. In addition, Mx1-/-  Mx1+/+ and Mx1+/+  Mx1+/+ mice 
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showed no liver pathology at microscopic level nor in the serum levels of the enzymes ALT 
or AST. 
In conclusion we can hypothesize that Mx1 can play a significant role in the protection of 
immune cells, albeit only when the infecting virus has a clear initial tropism for cell types 
with a hematopoietic origin (Figure IV.1). To completely understand the function of Mx1 in 
Figure IV.1 The role of Mx1 in the immune cell compartment: summarizing figure. Overview of the 
results obtained with bone marrow chimeras using two different virus infection models i.e. the FLUAV 
infection model (left panel) and the THOV infection model (right panel). For both infection models the 
studied organ is depicted, and the genotypes of the bone marrow donor and recipient are indicated. 
Observations concerning replication, type I IFN-response, and morbidity are described for each chimeric 
group in both models. 
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the resistance against THOV infection, this model should be further explored. For the 
experiments described in this thesis, the THOV NP and Mx1 expression, along with the 
influx of immune cells, will be examined in liver sections of the THOV-infected bone 
marrow chimeras. Viral titers in the blood serum should also be determined. A follow-up 
bone marrow chimera experiment is being set up wherein other organs – such as spleen, 
lung, kidney, and brain – will be examined at different time points (0, 1, 2 and 4 dpi) after 
THOV infection. In this experiment we will also isolate peritoneal lavage fluid, and check the 
cellular composition at different time points after infection. This experiment will learn us 
more about the infection kinetics of THOV in different organs. It will be also interesting to 
see whether or not Mx1+/+ bone marrow-derived cells can influence these kinetics. In 
another bone marrow chimera experiment we will infect the animals with a lower dose of 
THOV, and follow up the infection beyond four days after infection. This will allow us to see 
if the Mx1+/+  Mx1-/- and Mx1-/-  Mx1+/+ mice will further recover or succumb to the 
THOV infection. An additional experiment could be the intravenous (instead of 
intraperitoneal) infection of bone marrow chimeras. By this, the initial barrier imposed by 
myeloid cells in the peritoneum would be by-passed, leading to a direct infection of 
hepatocytes. Intravenous infection is also more biologically relevant since THOV is usually 
transmitted through ticks, which fasten themselves onto the skin and feed on the host’s 
blood. This experiment would further explain the role of a functional Mx1 protein in either 
the hepatocytes themselves or the peritoneal immune cells. 
 
The THOV infection model led us to hypothesize that Mx1 can play a significant role in the 
protection of immune cells, albeit only when the infecting virus has a clear initial tropism 
for cell types with a hematopoietic origin. We will test this hypothesis using influenza 
viruses. The influenza PR8 strain has been shown to be unable to infect macrophages18,19. 
The main reason for this is the lack of glycosylation sites on the head domain of its HA 
protein. Other influenza strains which do have glycosylation sites on their HA head domain 
were able to infect macrophages, albeit not productively. Reading et al. showed that, when 
injected intraperitoneally, influenza PR8 induced a less pronounced local inflammatory 
response than influenza BJx109 (an influenza virus carrying multiple glycosylation sites on 
its HA head domain)19. Inspired by the work of Reading and colleagues we will generate 
bone marrow chimeras and infect them intraperitoneally with our maPR8 strain or with 
another influenza strain which carries glycosylations on its HA head domain. If our 
hypothesis is correct, then the influenza virus which is able to infect macrophages should be 
hampered if these macrophages express Mx1. This virus would then give rise to a 
comparable inflammatory response as is the case for the maPR8 strain. 
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Triggering the adaptive immune response in B6.A2G mice 
Recently, Altenburg et al. published their work on the development of recombinant MVA 
(rMVA) vaccines which express different variants of the FLUAV NP18. Their goal was to 
improve the processing of NP by antigen-presenting cells, which could improve the NP-
specific T cells, and they tried this by mutating (rMVA-NPmut) or removing the NLS of NP 
(rMVA-NPΔNLS), or by amino-terminal fusion of ubiquitin to NP (rMVA-UbqNP). These 
modifications are meant to enhance the cytosolic retention and degradation of NP. In vitro, 
these constructs indeed improved the activation of NP-specific CD8+ T cell clones in 
comparison to the rMVA construct which expressed the wild type NP (rMVA-NPwt). In vivo, 
however, vaccination of C57BL/6 mice with these constructs showed no differences 
between the mutated constructs and the wild type NP construct. They all elicited 
comparable protection against a lethal influenza A/Puerto Rico/8/34 challenge18. As 
pointed out before, to elicit a strong CD8+ T cell response, the amount of processed antigen 
should reach a certain threshold. In C57BL/6 mice, the CD8+ T cell response is dominated 
by T cells specific for the NP366-374 epitope, which can easily reach this threshold. We 
hypothesized that this is probably the main reason why the modified NP constructs can 
seemingly not benefit from their enhanced degradation. 
 
Our goal was to test whether the mutated rMVA-NP vaccines have an advantage over the 
rMVA-NPwt vaccine in B6.A2G M1+/+ mice. This mouse strain expresses a functional Mx1 
protein, which, based on in vitro overexpression experiments, can specifically interact with 
FLUAV NP, and – because of this – has an antiviral effect against FLUAV1. This could be the 
crucial determinant in limiting the amount of antigen produced by the rMVA-NPwt 
construct. Since Mx1 resides in the nucleus, the rMVA-NP constructs which have a mutated 
NLS should already have an advantage over the wild type NP-expressing construct, because 
the wild type NP derived from the rMVA-NPwt construct has a nuclear phase early after 
infection18. This would give Mx1 the opportunity to interact with this protein and retain it 
in the nucleus, causing a delay in the antigen processing and presentation, negatively 
impacting the NP-directed immune response. 
 
To compare the different rMVA constructs, we vaccinated B6.A2G Mx1-/- and B6.A2G Mx1+/+ 
mice twice with the different constructs with a time interval of four weeks. One week after 
the second vaccination we isolated spleen and blood from these mice, and performed ICS 
and ELISPOT assays. The ICS assay on both PBMCs and splenocytes showed no obvious 
differences between the modified constructs and the rMVA-NPwt construct in B6.A2G 
Mx1+/+ animals. The same was true for the ELISPOT assay, although there was a trend that 
the rMVA-NPmut and especially the rMVA-NPΔNLS constructs show a better CD8+ T cell 
response than the rMVA-NPwt construct. A possible explanation is that the NP production 
PART IV | GENERAL CONCLUSIONS, DISCUSSION AND FUTURE PERSPECTIVES 
154 
 
by the rMVA vector is too high for Mx1 to handle the produced amount of antigen, or the 
nuclear phase of NP is too short for Mx1 to have a pronounced effect. Taken together these 
results do not provide enough evidence to conclude something about the effect of Mx1 on 
vaccination with the different rMVA constructs. Therefore it is desired to repeat this 
vaccination experiment. Additional readouts would include the analysis of the M1-specific 
CD8+ T cell response after vaccination with a FLUAV M1-expressing vector. This could 
provide us with some kind of baseline T cell response in both B6.A2G genotypes, since Mx1 
has not been shown to target the FLUAV M1 protein. Another line of investigation is the 
examination of the NP-specific CD8+ T cell response directed against an alternative 
subdominant NP epitope such as NP217-22519, something which proved instructive in 
comparing the different MVA-NP constructs in vitro18. 
 
Additionally, it would be interesting to test the different rMVA-NP vaccines in a transgenic 
mouse strain which expresses human MxA instead of mouse Mx120. MxA also interacts with 
FLUAV NP, moreover, NP has been shown to be a key determinant of FLUAV sensitivity 
against Mx1 and MxA1,21,22. Since the MxA protein resides in the cytoplasm, it is conceivable 
that it interacts with NP at an earlier time point than the murine Mx1 protein which resides 
in the nucleus. Human FLUAV strains which are descendants from the pandemic 1918 
H1N1 strain all possess a discrete surface-exposed cluster of three residues – at positions 
100, 283, and 313 – which causes these viruses to be more resistant against human MxA 
and murine Mx1 inhibition23. FLUAV NP is also a strong CD8+ T cell antigen and, additional 
to the resistance against Mx proteins, one could argue that the changed amino acids at 
positions 100, 283, and 313 could also change certain T cell epitopes. This would have an 
effect on the efficient induction of CD8+ T cells, like was seen for the NP383-391 epitope when 
a key residue in this epitope was changed24. However, we verified whether the positions in 
NP which are important for the resistance to Mx1/MxA overlap with human or mouse 
immunodominant CD8+ T cell epitopes, and this was not the case for all three positions25. 
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maSwO (Figure 8). 
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We zijn er. Vier jaar en elf dagen na de start ben ik aan ‘den arrivé’ van mijn doctoraat 
beland. Hoewel veel mensen denken dat dit een zeer individueel parcours is geweest, is er 
toch een hele waslijst aan mensen die ik moet bedanken. Het liefst van al zou ik al deze 
mensen eens goed tegen mijne gilet willen trekken en drie (of meer) kussen geven, 
voornamelijk op de wangen al kan ik andere lichaamsdelen niet uitsluiten. Het is mij echter 
duidelijk gemaakt dat dit ‘not done’ is, dus zal ik het bij de klassieke bedankingen houden. 
Ik wil mij bij deze op voorhand excuseren indien ik iemand vergeet te bedanken. Het ligt 
niet aan u, maar eerder aan de steeds talrijker wordende gaten in mijn geheugen. 
 
Allereerst wil ik mijn promotor bedanken. Xavier, het is ondertussen meer dan vijf jaar 
geleden dat ik je bureau binnen schuifelde met de vraag of ik mijn master thesis bij jou 
mocht doen. Tot mijn grote verbazing zag je dit onmiddellijk zitten, en lag er direct een 
voorstel klaar. Na het afronden van mijn thesis had ik ook het geluk om aan een doctoraat te 
mogen beginnen in jouw groep. De switch van RSV naar influenza virus, en van een meer in 
vitro project naar de keiharde wereld van in vivo experimenten was uitdagend, maar ik ben 
toch blij dat ik die sprong gemaakt heb. Jouw kritische blik bij het opstellen van de 
experimenten en het verbeteren van mijn doctoraat heeft er voor gezorgd dat dit een (al zeg 
ik het zelf) mooi doctoraat is geworden. 
 
Ik wil ook graag de leden van de jury bedanken voor het kritisch nalezen van mijn 
proefschrift, en voor jullie verhelderende opmerkingen en vragen. 
 
Dit doctoraat had natuurlijk ook niet tot stand kunnen komen zonder de hulp van mijn fijne 
collega’s. Ik wil iedereen persoonlijk bedanken voor alles wat jullie gedaan hebben voor mij 
gedurende al die jaren. Ik ga al jullie namen ‘int vet’ zetten, dan kan je gewoon je naam 
zoeken, zien wat ik over jou te zeggen heb, en dan ben je niet verplicht om al de andere 
zever te lezen die ik hier uitkraam.  
 
Team RSV, we beginnen bij jullie. Bert, bedankt voor de begeleiding bij mijn master thesis. 
Dat project liep niet altijd even vlot, maar ik weet nu wel wat voor kloterij een peptide 
opgelost krijgen, kan zijn. Bedankt voor al je input tijdens mijn doctoraat. Ik bewonder het 
nog steeds hoe je altijd enthousiast blijft, en ik hoop dat je dat enthousiasme blijft uitstralen 
in het labo. Iebe, naast het enthousiaste geweld van Bert, ben jij degene die steeds rust 
uitstraalt in het labo. Niets kan jou van stuk brengen, o had ik die rust maar in mij. Veel 
succes met je vervolgproject op jouw doctoraat! Koen, mijn ‘partner in writing’, ik heb veel 
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aan jou gehad tijdens het schrijven. Al was het maar een korte babbel over ‘Wa zijde gij nu 
aant schrijven?’. Veel succes met je publieke verdediging, en met je nieuwe project! Dorien, 
ik heb nog niet veel mensen zich met zoveel vastberadenheid weten vastbijten in hun 
doctoraat. Je vastberadenheid, competitieve geest en je mentaliteit om nooit op te geven, 
zullen er voor zorgen dat je een dijk van een doctoraat zal hebben. Nog een jaar vollen bak 
gaan, en dan is het uw beurt om af te leggen. Anna, in a couple of months it will be you turn 
to defend your PhD thesis. Good luck with finalizing the work and writing your thesis! 
Marlies, nog geen jaar in het labo en je bent al een begrip voor iedereen. Moest er een 
schaal bestaan voor ‘hard werken’ dan zou ‘Marlies’ de SI-eenheid zijn. Merci voor de hulp 
bij mijn eerste stapjes in de histologie! Jackeline, je bent nog niet zolang in het labo, dus ik 
ken je nog niet zo goed. Ik denk wel dat ik voor iedereen spreek, als ik zeg dat je echt een 
aanwinst bent voor het labo. We misten nog wat Zuid-Amerikaanse furie. Tine, in 
bouwvakkertermen zou men je een draagmuur noemen. Als jij wegvalt staat heel het labo 
op losse schroeven. Bedankt om mij steeds goedgeluimd bij te staan als ik vragen had over 
in vivo experimenten, administratie, pakketjes versturen, en zoveel meer! Anouk, de 
moederkloek van het labo. Ik weet dat je dat niet zo graag hoort, maar ik kon het niet laten. 
Voor iemand die eigenlijk nogal timide is, kan je in je enthousiasme toch soms veel decibels 
produceren.  Merci om mij steeds te helpen bij kloneringen, DNA opzuiveringen, 
producties van virussen, en vooral om gewoon te luisteren als er iets scheelde. Ioanna, 
soon you will also be defending your PhD. Good luck, and all the best for you and your 
family! Emma, thanks for always helping me with good advice. Your expertise in the 
macrophage area was much appreciated. Good luck with keeping up the Aussie-vibe in the 
lab! 
 
Kenny, Lien en Eline, ik ben vereerd dat ik samen met jullie team Mx mocht vormen. Eline, 
ik sta elke dag nog versteld dat jij nog maar een jaar bezig bent aan je doctoraat. De 
wetenschappelijke maturiteit die jij nu al uitstraalt is echt om jaloers op te zijn. Ik ben ervan 
overtuigd dat je nog veel zal ontdekken over dit onwijs coole supereiwit.  Lien, jij bent 
echt een droom om mee samen te werken. Jouw structuur en doelgerichtheid werken echt 
aanstekelijk. Ik ben er zeker van dat je het nog superver gaat brengen met jouw onderzoek! 
En last but not least, Kenny, mijn begeleider/copromotor. Steeds goedgezind en altijd 
bereid om te helpen wanneer ik weer maar eens aan je bureau stond. De UNCa’s weten nog 
niet half hoe gelukkig ze mogen zijn met iemand zoals jij. Veel geluk daar, en hopelijk ben je 
ons niet te snel vergeten. 
 
Naast de huidige leden van het labo zijn er ook een paar ‘oud-strijders’ die een grote 
bedanking verdienen. Michael, de man die mij echt heeft leren ‘flowen’. Bedankt om mij een 
maand op sleeptouw te nemen in New York, zowel in het labo als erbuiten. Jij hebt mij doen 
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inzien dat wetenschap veel meer is dan alleen maar experimenten doen aan uwen bench. 
Veel succes nog daar in the Big Apple! Judith, de peetmoeder van Mx. Jij hebt mij wegwijs 
gemaakt in wondere wereld van dit eiwit. Ik vind het nog steeds jammer dat je er niet tot 
het einde van het project kon bij zijn als mijn copromotor. Veel succes nog bij Ablynx! 
Liesbeth en Soraya, allebei stille krachten. Bedankt voor de fijne momenten in het labo! 
 
Buiten de vele uren die ik in het labo heb gezeten, waren er toch ook momenten waarop ik 
niet zat te werken. Die momenten zijn opgevrolijkt door heel wat verschillende mensen. 
Dries, Jonas, Patrick en Sam, merci voor de momenten waarop we heel wat biertjes 
genuttigd hebben, en vooral heel veel zever en onnozelheden hebben verkondigd. Onze 
maandelijkse afspraken zijn iets waar ik steeds heel hard naar uitkijk. Barbara, bedankt om 
er voor te zorgen dat ik niet van de klimmuur val, en om af en toe een boodschap subtiel op 
uw raam te hangen.  Daan en Dimi, we hebben de laatste jaren mekaar niet echt veel 
gezien, maar als we toch nog eens samenkomen dan is het precies alsof we gisteren nog 
samen op de schoolbanken zaten te vloeken op de UOVT’s van De Maerschalck. Daarnaast 
wil ik de vele muzikale vrienden die ik gemaakt heb, ook bedanken. Alle muzikanten van 
Jeugdorkest NOOTuitgang en de Thebaanse, vooral Koen, Marten, Sandra en Anja, 
bedankt voor de zeer leuke momenten die ik met jullie al heb mogen beleven. 
 
De bedankingen beginnen hier op hun einde te lopen, en jullie aandacht is 
hoogstwaarschijnlijk al serieus aan het slinken. We zijn nochtans aangekomen bij de 
belangrijkste mensen van heel dit onderdeel, mijn familie. Ik begin bij de schoonfamilie. 
Marc en Marleen, bedankt voor de fijne momenten en de kilo’s eten en liters soep die ik 
ondertussen al heb verorberd bij jullie. Pieter en Katrien, ook jullie bedankt voor de leuke 
momenten en de interesse in mijn doctoraat. Hopelijk zijn er nog veel escape rooms waar 
we samen uit kunnen geraken. Voor de volgende mensen zijn bedankingen onvoldoende. 
Eerbiediger zou zijn om nu tromgeroffel en trompetgeschal te laten horen, maar tot op 
heden is een doctoraatsthesis nog steeds een ‘stom’ medium. Mama en papa, ik weet 
eigenlijk niet goed waar te beginnen. Merci om mij de kans te geven om te studeren en om 
mij altijd bij te staan. Ik kan jullie altijd bellen als er iets scheelt, of als ik iets moet vragen. Ik 
zal proberen om in de toekomst jullie op gepaste wijze te bedanken voor jullie 
onvoorwaardelijke steun. Bart en Frauke, An en Artan, en Freek en Elke, bedankt dat ik 
elk weekend mijn gedachten eens kon verzetten met jullie. De momenten bij mama en papa 
rond de eettafel worden heel hard gekoesterd. Er is natuurlijk wel één iemand van jullie die 
ik nog eens extra moet bedanken. Freek, je hebt mij zo zot gekregen dat ik ook biochemie 
en biotechnologie ben gaan studeren. Tot op vandaag heb ik daar nog geen seconde spijt 
van. Zoals je zelf vier jaar geleden zei: Binnen 4 jaar is het jouw beurt, ik kijk er nu al naar 
uit.  Nu is het zover, en dat ging veel sneller dan ik had gedacht. Bedankt voor je interesse 
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in mijn project, en de goede raad als het wat minder vlot ging. Heike, Lucas, Levik, Roel, 
Hanne en Juna, ‘the terrible six’ van onze familie. Als er mensen zijn die met stress te 
kampen hebben, dan zouden ze een heel grote dosis van jullie moeten voorgeschreven 
krijgen. Bedankt om de meest fantastische neefjes een nichtjes te zijn! 
 
Er is nog één iemand die ik niet bedankt heb. Elien, mijn alles. Het begin van ons doctoraat 
was ook het begin van ons eigen verhaal. Jij kent mij door en door, en begrijpt mij beter dan 
wie dan ook. Sorry voor de vermoeide/geïrriteerde (beide gaan blijkbaar hand in hand bij 
mij) stresskip die ik het afgelopen jaar was. Ik heb mij soms afgevraagd we de grenzen van 
uw geduld ooit eens zouden tegenkomen. Tot op heden is dat blijkbaar nog altijd niet 
















































The future is a gift from tomorrow. 
  Author unknown 
